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Abstract 
Interferon alpha 2b (IFN-a2b) is a soluble cytokine and a member of the type I 
interferon (IFN) family of which there are fourteen members. IFN-a2b is used 
in the treatment of hairy cell leukaemia and both hepatitis B and C. IFN-a2b 
actions are mediated through specific receptor binding which initiates a series 
of signalling cascades leading to the transcription of genes carrying the 
promoters containing the interferon stimulated response element (ISRE). Due 
to these actions the IFNs as a whole are an ideal family of proteins to be 
investigated further with the possibility of the production of life saving drug 
products. Cobra Biomanufacturing have a keen interest in IFN-a2b especially 
due to its beneficial effects. This project is therefore an investigation of the 
IFN-a2b molecule from expression to final purified product. The refolding of 
the IFN-a2b was the main concern of this project due to it being the 
`bottleneck' for many protein based processes. The investigation of natively 
folded IFN-a2b led to the conclusion that IFN-a2b is a stable protein which 
remains folded under reducing conditions. The addition of guanidine-HCI or 
urea to the native protein reveals differences in the success of unfolding. 
These differences were also witnessed during the solubilisation of the IFN- 
a2b inclusion bodies. The refolding is only successful when the inclusion 
bodies have been solubilised in guanidine-HCI. Due to the differing refolding 
results gained, which depended on the denaturant used to solubilise the 
inclusion bodies, the solubilised inclusion bodies themselves were 
investigated. This revealed partial structure present in the urea solubilised 
inclusion bodies; however this was confirmed as being not native. The 
implications of this for biomanufacturing are that if the starting conditions are 
not correct even as early as the solubilisation of the inclusion bodies then the 
following process will result in incorrectly folded product. 
The work in this thesis was carried out in the Institute of Cell and Molecular 
Biosciences, University of Newcastle upon Tyne, during the period of October 
2004 - October 2007. The work is original except where acknowledged by 
reference. 
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Chapter 1 
Chapter 1 
Introduction 
1.1: Interferon 
Discovery 
Interferon (IFN) was discovered by Isaacs and Lindermann in 1957. They 
found that chick chorioallanotic membranes incubated with heat activated 
influenza virus stimulated the production of Interferon, giving fresh 
membranes resistance to infection by virus (Isaacs and Lindermann, 1957). 
The interferons were then discovered to be produced by many cells and 
tissues. Initial biochemical experiments and clinical trials were carried out 
using simply crude IFN samples from infected white blood cells (Cantell et al., 
1981). This method led to problems with blocked antibody synthesis, 
antibacterial activities and inhibited cell growth however there was no 
evidence of whether this was due to IFN itself (Pestka, 2000). IFN was 
purified to homogeneity in 1978 (Rubinstein et al., 1978; Rubinstein et al., 
1979; Stein et al., 1980; Friesen et al., 1981; Rubinstein et al., 1981). The 
IFN was produced by incubating human white blood cells with Newcastle 
virus. Purification by reverse-phase HPLC and gel filtration chromatography 
followed. The purification resulted in the discovery and separation of the 
different types of IFN. 
Multiple types of interferon 
The production of interferon and the subsequent purification allowed the many 
types of interferon to be isolated and investigated. There are now at least 10 
mammalian interferon species of which seven are found in humans. 
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Type Name 
IFN-a 
IFN-ß 
IFN-E 
IFN-K 
Type I IFN-w 
IFN-v 
IFN-4 
IFN-T 
IFN-b 
Type II IFN-y 
IFN Al (IL-28A) 
Type III IFN A2 (IL-28B) 
IFN A3 (IL-29) 
Table 1.1: The interferon. The interferons are separated into three classes 
depending on their sequence, receptor specificity, chromosomal location, 
physiochemical properties and structure. 
The interferons have now been found to be proteins consisting of a family of 
distinct polypeptides which show homology in both the amino acid sequence 
and three dimensional structure (Pfeffer et al., 1998). A new nomenclature 
was therefore devised where the species of IFN were individually named 
rather than named by their source, for example IFN-a had been named 
leukocyte IFN, IFN-ß had previously been known as fibroblast IFN and IFN-y 
was known as immune IFN. Table 1.1 details the IFN proteins. 
The interferons are divided into three separate classes, type I (IFN a/ß), type 
II (IFN y) and type III (IFN A). As well as IFN a and ß other members of the 
IFN type I family include IFN, epsilon (c) (Hardy, et al., 2004) and Kappa (K) 
(LaFleur et al., 2001), these are found in the human genome while IFN omega 
(w) (Adolf, 1987) can be found in some mammalian genomes and primate 
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genomes. IFN, tau (T) (Roberts et al., 1992) and delta (6) (LaFevre et al., 
1998) are involved in reproductive events unique to pigs. IFN-zeta (Q (Oritani 
and Tomiyama, 2004). and nu (v) are only present in rodent and feline 
genomes (Pestka et al., 2004). There is only one human IFN-ß and IFN-w, 
but a family of human IFN-a exist. The IFNs are grouped into the three 
different types due to their sequence, receptor specificity, chromosomal 
location, physiochemical properties and structure (Samarajiwa et al., 2006). 
Type I interferons 
The human type I IFNs are encoded by a multigene family clustered on 
chromosome 9. This gene consists of 13 nonallelic IFN-a genes and a single 
functional IFN-ß, E, K and w gene. With the exception of IFN-K all the type I 
IFN-a2b genes are intronless (Bogdan et al., 2004). The type I proteins have 
a closely related amino acid sequence but display different biological activities 
due to the interaction with their cell surface receptors (Samarajiwa et al., 
2006). IFN-ß acts as a dimer and only has one disulphide bond (Foster and 
Finter, 1998). IFN-ß only has 19-23 % homology to the IFN-a protein 
sequence (Weissmann and Weber, 1986). IFN-w has multiple genes 
however only one is functional and the protein is similar to the IFN-a group by 
55-60 % homology (Adolf, 1995), IFN-K by 27- 32 % to IFN-a, 34 % similarity 
to IFN-ß, 28 % to IFN-w and E. IFN-c is most similar to IFN-ß (Hardy et al., 
2004). IFN-ý sometimes named limitin, has 25-28% identity to IFN-a, 21 % 
identity to IFN-beta and 30% identity to IFN-w. IFN-ý has higher antiviral 
activity compared to the IFN-as (Kawamoto et al., 2004). IFN-b has 27 % 
homology to IFN-ß and 42 % homology to IFN-a2 (Lefevre and Boulay, 1993). 
Type II interferons 
Type II IFNs are made up solely of IFN-y. IFN-y exists as a tetramer and 
binds to a different cell receptor than the type 1 named the interferon gamma 
receptor (IFNGR) made up of two subunits IFNGR1 and IFNGR2 (Soh et al., 
1994). IFN-y is synthesised by T-cells and natural killer cells as part of the 
inflammatory response. Synthesis by T-cells is stimulated by antigens and 
stimulation by IL-2 causes production by natural killer cells (Sen and Lengyel, 
1992). 
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Type III interferons 
The type III IFNs consist of three members; IL-28A, -28B and -29 and are also 
called IFN-like cytokines. They are similar to the type I IFNs due to sequence 
and antiviral and signalling activities (Zhou et al., 2007). They activate the 
same signal transducers and activators of transcription proteins (STAT) upon 
receptor binding and induce genes that contain the IFN-stimulated response 
elements (ISRE) in the promoter. 
Interferons and their actions 
Interferons are now defined as a family of soluble cytokine proteins with 
antiviral activity that are secreted from cells in response to a variety of stimuli 
(Sen and Lengyel, 1992). As well as antiviral activity IFN-a and IFN-ß have 
antiproliferative functions on a wide variety of immunologically important cells 
such as T-cells, natural killer cells, monocytes, macrophages and dendritic 
cells therefore inducing cytotoxic effects (Ortaldo et al., 1983). These effects 
increase expression of tumour associated surface antigens and major 
histocompatibility complex (MHC) class I antigens, induce proapoptotic genes 
and proteins and repression of antiapoptotic genes and proteins (Greiner et 
a/., 1987). Exposure of cells to viruses and double-stranded RNAs, a side 
product of viral replication, primarily induces the production of IFN-a and IFN- 
ß. Low levels of IFNs can be detected in human tissue even without induction 
(Sen and Lengyel, 1992). IFNs bind to the specific cell receptors as the first 
step in their biological activity. All type I IFNs bind two cellular receptors, 
Interferon type I receptor I (IFNaR1) and Interferon type I receptor II 
(IFNaR2), binding of the three IFNs; IFN-K, IFN-c and IFN-v has not yet been 
determined. IFN-a and IFN-ß compete for the same receptor whereas IFN-y 
binds to a different receptor (Sen and Lengyel, 1992). Upon binding of the 
IFNs to their receptors multiple signal transduction pathways are initiated 
leading to the activation of many genes (Sen and Lengyel, 1992). 
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Figure 1.1: Ribbon diagram of the crystal structure of IFN-a2b and IFN-ß. The 
five alpha helicies are coloured grey and the cysteine residues are coloured red. 
IFN-o2b, PDB no. IRH2 (Radhakrishnan et al., 1996). IFN-ß, PDB no. 1AU1 
(Karpusas et al., 1997). Drawn using Rasmol. 
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Receptors 
All type I IFNs bind a cellular receptor made up of two chains, Interferon type I 
receptor I (IFNaR1) and Interferon type I receptor II (IFNaR2) (Mogensen et 
a/., 1999). IFNaR2 is the major ligand binding component of the type 1 
receptor. The binding is species specific (Sen and Lengyel, 1992) and the 
various IFNs interact with the receptor differently creating the different 
responses. IFN-a and IFN-ß compete for the same receptor whereas IFN-y 
and the type III IFNs bind to their own specific receptor (Sen and Lengyel, 
1992). Upon binding of the IFNs to their receptors multiple signal transduction 
pathways are initiated leading to the activation of many genes (Darnell et al., 
1994). 
Signal transduction 
Binding of IFN to the cell surface receptors promotes oligomerization of the 
two receptor chains; IFNaR1 and IFNaR2. The IFN receptor chains lack 
intrinsic tyrosine kinase activity, but due to the association with Janus 
Activated Kinase 1 (JAK-1) through its own tyrosine-specific kinases results in 
transphosphorylation, JAKs are only activated on ligand binding. This 
activation and transphosphorylation of JAKs causes tyrosine residues present 
on the receptor chains to become phosphorylated and become in turn docking 
sites for cytoplasmic signal transducers and activators of transcription proteins 
(STAT). Both STAT-1 and 2 are involved with IFN Type I signalling. These 
STAT proteins form heterodimers and with the association of IFN-regulatory 
factor 9 (IRF-9) leads to the translocation of the STAT dimmers to the 
nucleus. It is within the nucleus where they are able to bind to the IRSE 
stimulating expression of IFN induced genes. 
6 
Type I IFN 
TYK JAK 
STAT 1 STAT 2 '''"' 
0 
Cytoplasm 
>> 
P 
r .,.. Y.:.... .., 
.ý 
ýý ý:.: 
IRF-9 
Nucleus 
..................................... IFN 
induced 
proteins 
Figure 1.2: IFN-a signalling pathway. IFNAR1 and 2 are the two different receptor 
chains associated with IFN Type / signalling. P= phosphorylation, IRF-9 = IFN 
regulatory factor 9. Both STAT 1 and 2 are involved with Type I signalling along with 
JAK and specific tyrosine kinases (TYK). Phosphorylation of the STAT molecules 
leads to their translocation to the nucleus causing expression of IFN induced proteins 
by activation of the Interferon stimulated response element (ISRE) 
The result of the IFN induced pathway is the up regulation of IFN-a2b- 
inducible proteins for example 2'- 5'- oligoadenylate synthetase (2'- 5' OAS) or 
the RNA-dependent protein kinase (PKR). 2'- 5' OAS is the necessary 
cofactor for activation of RNase L which can in turn degrade viral mRNA and 
inhibit viral protein synthesis. PKR a protein kinase which phosphorylates and 
inactivates eIF-2 involved in viral mRNA translation and MHC class I 
expression is increased stimulating cell-mediated immunity (Meager, 2006). 
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Interferon alpha 
The human a-interferons have now been found to be encoded by a family of 
at least 14 genes. From these genes 13 proteins are expressed, IFNA1 and 
IFNA13 are exactly the same so 12 different proteins are actually expressed 
(Peskta et al., 2004). The family of IFN-a genes has 70 % homology between 
them (Samarajiwa et al., 2006). Human IFN-a is heterogeous and several 
bands exhibiting antiviral activity range in molecular weight from 15000 to 
21000 Da by SDS-PAGE (Pestka, 2000). All the IFN-a gene products are 
made up of 165-166 amino acids and they all contain two conserved 
disulphides between the cysteine (Cys) residues Cys1-Cys98 and Cys29- 
Cys138 (Wetzel, 1981). Each IFN-a subtype behaves differently through their 
antiviral and antiproliferative actions however they do share between 76% and 
99% homology at the protein level and 79 out of the 166 amino acids are 
conserved (Kontsek, 1994). The only IFN-as to be used therapeutically are 
IFN-a2a, IFN-a2b and IFN-ac and so the remaining IFN-as are said to be an 
untapped source of opportunity (Pestka, 2000). It is not known why the body 
produces so many variants. 
The increased interest in the interferons has lead to their high resolution 
protein structures. The three dimensional structures of the major type I 
interferons were solved during the mid-nineties. The tertiary structure of IFN- 
a2a was detailed by Klaus et a!., (1997) by heteronuclear nuclear magnetic 
resonance (NMR) along with human IFN-a2b by X-ray crystallography 
(Radhakkrishnan et a!., 1996) and both human and murine IFN-ß by Karpusas 
et al., (1997) and Senda eta!., (1995) respectively. 
IFN-a2b 
The only two IFN-as which are mass produced in Escherichia coli (E. coh) by 
recombinant means and used as drugs are IFN-a2b and IFN-a2a. IFN-a2a 
was the first investigated in 1981 due to its ability to shrink tumours (Gresser 
and Bourali, 1969), IFN-a2b followed closely that year. In 1996 
Radhakrishnan et al., reported the crystal structure of recombinant human 
zinc IFN-a2b by X-ray crystallography. This form of IFN-a2b unexpectedly 
existed as a dimer (Radhakrishnan et al., 1996). 
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Each monomer of IFN-a2b is composed of five a helices labelled A-E linked 
by one overhand loop (figure 1.1), the AB loop, and three short segments, the 
BC, CD and DE loops. All type I IFNs exist in this form also. The five core a- 
helices range in length from 13-24 amino acids. Each helix is straight except 
for helix B which contains a bend centered around the residue Thr-69 
(Radhakrishnan et al., 1996). The long connection between helices A and B 
(the AB loop) is usually described in three sections, AB1: residues 22-33, 
AB2: residues 34-39 and AB3: residues 40-51 (Radhakrishnan et al., 1996). 
Residues 26-29 and 30-33 within the AB loop form two turns of 310 helix. Cys- 
29 links 310 helix to helix E through a disulphide bond with Cys-138 
(Radhakrishnan et al., 1996). This 310 helix redirects the mainchain by 900 to 
run parallel to helix D where specific interactions take place with the 
sidechains of the residues present in helix D. In contrast to the AB loop the 
BC loop consists of two residues and the DE loop contains four residues. The 
largest structural difference between IFN-a and IFN-ß has been shown to be 
the AB loop, as it contains more residues in IFN-a2b than murine IFN-ß 
(Radhakrishnan et al., 1996). Based on the structure of human IFN-a2b some 
of the main aromatic residues, Phe-36, Tyr-122 and Tyr-129 are found within 
the molecular core. (Radhakrishnan et al., 1996). The active form of IFN-a2b 
has always been thought of as the monomer due to the small concentrations 
required for in vivo activity (Radhakrishnan et al., 1996). As Radhakrishnan et 
al., (1996) crystallised IFN-a2b as a zinc dimer they also reported that the 
addition of 1 mM zinc to a gel filtration column did not shift the equilibrium in 
favour of dimer. Suggestions for the unexpected dimer are that it acts as a 
storage system of the molecule or could be involved with the recruitment of 
the receptor molecules (Radhakrishnan et al., 1996). 
In 1986 IFN-a2a and IFN-a2b were approved for treatment of hairy cell 
leukaemia by the U. S. Food and Drug Administration. Subsequently IFN-ß1a 
and IFN-ß1b were approved for treatment relapsing multiple sclerosis. IFN-a 
is now used in the treatment of hairy cell leukaemia, malignant melanoma, 
follicular lymphoma, condylomata acuminata (genital warts) (Brockmeyer et 
at, 2006), AIDS-related Kaposi sarcoma (de Wit et at, 1988) and hepatitis B 
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and C (Yotsuyanagi and Koike, 2007), IFN-y for malignant osteoporosis. IFN- 
a is also given alongside other drugs for treatment of bladder (Nagabhushan 
et al., 2007) and renal cancers (Motzer et al., 2002). 
Consensus interferon and pegylation 
Consensus Interferon (C-IFN) is a genetically engineered interferon with 
unusually high biologically activity. It is obtained by scanning IFN-a subtypes 
and assigning the most frequently observed amino acids to each position 
creating a new DNA sequence termed consensus interferon (Aloton, 1983; 
Klein et al., 1988; Hu et al., 1995). 
There are two pegylated interferons available, the first is a linear PEG chain 
linked to IFN-a2b and the second consists of a branched PEG chain linked to 
IFN-a2a. These are usually administered with ribavirin (Foster, 2004). 
Pegylation of therapeutic proteins is a well established method for reducing 
protein immunogenicity and, as IFN-a2b treatment usually requires a high 
amount of injections, pegylation has proved successful in IFN-a2b treatment 
(Jabbour et al., 2007). 
IFN-a2b expression, purification and refolding 
There have been many successful attempts to express, purify and refold IFN- 
a2b to give high yields. As there are many IFNs all of which are being 
investigated there is a diverse range of methods used to purify and refold 
them, ultimately they all have the same goal; to produce as much pure IFN- 
a2b to be used in treatment of viral diseases. The method used by Srivastava 
et al., (2005) has been the most consulted throughout this project. The IFN- 
a2b is expressed in both BL21 (DE3) and DH5a E. coli cells as inclusion 
bodies under the same heat inducible promoter used during this project. The 
IFN-a2b is then refolded followed by purification by Q SepharoseTM ion 
exchange chromatography. It is common practice to refold proteins, not 
necessarily just IFN-a2b before they are purified. As the refolding and 
purification of IFN-a2b will ultimately be subject to scale-up some 
considerations should be taken into consideration along with time restraints. 
Valente et al., (2006) expressed IFN-a2b as inclusion bodies in JM109 (DE3) 
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and refolding consisted of a two step dialysis. The first removed the 
guanidine-HCI which had been used to solubilise the inclusion bodies and the 
second involved dialysis into 0.4 M urea, this was carried out over 9 days, 
whilst the biological activity was monitored. The yield was 30%, however the 
9 day refolding is not suitable for an industrial setting. Beldarrain et al., (2001) 
incorporated metal ion catalysed air oxidation using copper sulphate for the 
refold, this resulted in a 12 % yield. Swaminathan and Khanna, (1999) added 
L-arginine to the refold mixture, this mixture was left for 24-36 hours before 
dialysis to remove the L-arginine. The IFN-a2b was purified following 
refolding by affinity chromatography on a dye-ligand matrix, Green-1 A6XL 
was used. The elution takes place with increasing NaCI, resulting in a yield of 
82 %. Neves et al., 2004 mutated Cys-1 and Cys-98 into serine residues and 
expressed it as a polyhistidine-tagged protein. The disulphide Cys-1 and Cys- 
98 is not required for biological activity (Weissmann and Weber, 1986). They 
concluded that the his-tagged IFN-a2b expressed was more stable. 
As well as bacteria IFN-a2b has been expressed as a soluble protein in Pichia 
pastoris (Shi et al., 2007). The IFN-a2b was purified by Q SepharoseTM ion 
exchange, concentrated and applied to a SuperdexTM 75 gel filtration column 
giving a 64 % yield (Shi et al., 2007). A second method of expressing IFN- 
a2b as a soluble protein was as a GST-fusion protein (Rabhi-Essafi et al., 
2007). The IFN-a2b was purified by affinity chromatography, thrombin 
cleaved, followed by size exclusion chromatography. 
1.2: Protein folding 
The three-dimensional structure of a protein is determined by its amino acid 
sequence as most purified proteins can refold spontaneously in vitro after 
being unfolded (Creighton, 1990). Early work by Anfinsen (1973) on 
denaturation and renaturation of Ribonuclease A concluded that the amino 
acid sequence determined the three-dimensional structure of proteins and 
ultimately their function. The work further determined that proteins will fold 
spontaneously. 
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The folding reaction 
The folding reaction for single domain proteins is assumed to be a one step, 
two state, first order reaction, shown in equation 1.1. 
Denatured or unfolded 
Folding 
Native or folded (1.1) 
(D) Unfolding (N) 
Multi-domain proteins fold and unfold in a step-wise manner. 
The native state 
The conformations during folding are driven by the restrictions of rotation of 
the main peptide chain 4' and 0 angles and the non-covalent interactions 
such as hydrogen bonds, van der Waals, salt bridges and hydrophobic 
interactions. The peptide chain angles are hindered by the side chains of the 
adjacent molecules allowing only one specific structure to be native 
(Ramachandran et al., 1963). The non-covalent interactions allow stability of 
the protein molecule to be attained. 
Both the native and the denatured forms of proteins are stable. The native 
form is the most stable of the conformations but, not necessarily the one with 
the lowest free energy. A similarity in all water soluble proteins is the 
presence of the hydrophilic side chains on the exterior of the three 
dimensional structure and the hydrophobic side chains buried in the core 
(Perutz et al., 1965). Different folded proteins have different degrees of 
flexibility giving information about their free energy of folding and unfolding, 
the most flexibility being on the outside of the molecule relative to the inside 
(Creighton, 1990). 
The unfolded state 
The extreme unfolded state of a protein is incorrectly termed the "random coil" 
and is achieved under highly denaturing conditions such as high 
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concentrations of guanidine-HCI or urea (Tanford et al., 1967). The random 
coil is defined by Creighton (1990) as a structure in which the rotation about 
each bond of the backbone and side chains is independent of that of bonds 
anywhere in the sequence. The restriction from the covalent bonding of these 
residues will not simply disappear if the protein is unfolded however there are 
many possibilities for these different conformations to exist. The radius of 
gyration calculated for unfolded proteins by Wilkins et al., (1999) and further 
experimental evidence of proteins unfolded states do support one another 
(Ding et al., 2005). The unfolded structures of proteins denatured by 
temperature and pH are currently being investigated as they do not always 
follow random coil conformations but retain structure especially compared to 
guanidine-HCI and urea denatured proteins. 
Intermediate states 
The reaction pathway can involve intermediates with structures very similar to 
the denatured or the native state; 
DIN (1.2) 
There is not necessarily just one intermediate (I), there can be several some 
having a more native (N) structure and some having a more denatured (D) 
structure (Richards, 1992). The formation of these intermediates has allowed 
pathways of folding and unfolding to be monitored and broken down into their 
separate components (Kim and Baldwin, 1982). The rate of each reaction 
within the folding and unfolding can provide information about which are the 
rate limiting steps. 
Some intermediates exist as stable conformations suggesting that proteins 
have a third conformational state (Uversky and Ptitsyn, 1996). The 
observation of the molten globule state confirms that these intermediate 
structures do exist (Ptitsyn, 1994). Intermediates are usually termed kinetic or 
equilibrium intermediates and are a common way of studying folding 
pathways (Ptitsyn, 1994). Ptitsyn, (1994) details the formation of these 
intermediates. An initial intermediate forms within a few milliseconds of 
13 
folding which has native secondary structure and binds 8-anilino-1- 
naphthalene-sulphonate (ANS) (Semisotnov et al., 1987). The second 
intermediate forms within 1s closely followed by the native state. Even in the 
two state reaction shown in equation 1.2 intermediates can form and be 
monitored by techniques such as far and near UV circular dichroism, binding 
of ANS and intrinsic fluorescence. Even though intermediates are formed 
during folding they are not necessarily on the pathway to the native protein, 
and may require a return to the denatured state to carry on successful 
refolding (Fersht, 1999). 
During protein folding and unfolding the interactions within the protein 
molecule are broken along with energy barriers which must be overcome. If 
the activation energy of a specific energy barrier is much higher than the rest 
this step will be rate limiting and considered the transition state of the 
reaction. 
Molten globule 
Under certain conditions during folding and unfolding, proteins can have a 
structure which is neither folded nor unfolded. The dimensions of this form 
are usually larger than the folded state but smaller than the unfolded state and 
contain secondary structure similar to that of the native along with the 
hydrophobic core, however it is not as closely packed (Ptitsyn, 1987). This 
structure which occurs as an intermediate in protein refolding has been 
termed the molten globule (Ptitsyn, 1990). The molten globule has been 
described as a stable intermediate formed during secondary structure 
formation and therefore occurs during the early stages of folding (Ptitsyn, 
1990). The molten globule state has many common features; 
1. The dimensions are larger than the native state but smaller than the 
denatured state (Zerovnik and Pain, 1987). 
2. The content of secondary structure is similar to that of the native 
protein (Baum et al., 1989). 
3. Interconversions with the native state is slow but rapid with the 
unfolded state (Ptitsyn et al., 1990). 
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The term compact intermediate (Cl) is sometimes used to describe the molten 
globule (Kim and Baldwin, 1990). The molten globule state can be identified 
and analysed due to its stability. Methods such as gel filtration 
chromatography (Zerovnik and Pain, 1987) and ANS binding have been used 
to investigate the molten globule state (Semisotnov et al., 1987). 
Stability of the native state 
In a two step unfolding transition the equilibrium constant is able to be 
calculated and therefore the free energy of folding (detailed in chapter 3, 
section 3.2.4). The following equation is used; 
AG= -RTInK 
LG = Gibbs free energy, R= gas constant, T= temperature (Kelvin), K= 
equilibrium constant. 
(1.3) 
The native state is only slightly more stable than the unfolded state usually 
between 1-15 kcal/mol (Daggett and Fersht, 2000). 
Thermodynamics of protein folding 
The free energy change upon unfolding (AGfo, d) can be described in terms of 
the enthalpic and entropic contributions by the following equation. 
AG = AH - ThS (1.4) 
Where 1G = Gibbs free energy, OH = Enthalpy, T= Temperature, AS = 
Entropy. 
The enthalpy is the change in bond energies and the entropy is the change in 
randomness of a reaction. The formation of hydrophobic interactions is driven 
by a change in entropy i. e. the water molecules become ordered around the 
hydrophobic residues restricting their free motion therefore lowering the 
entropy. 
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Protein stability 
The intramolecular forces within a protein molecule keeping it stable are a 
collection of van der Waals interactions, charged interactions, polar 
interactions and hydrophobic interactions. The van der Waals interactions are 
assumed to exist within the protein molecule itself but alongside the water 
molecules also, this is similar for the polar interactions such as hydrogen 
bonds. These interactions can also exist in the unfolded state so are not 
usually considered to be of major importance to the proteins stability (Privalov, 
1992). Equally the charged groups are small in number and so must only 
compensate for a small amount of stabilisation. The remaining interaction is 
that of hydrophobic resides, usually clustered together in the core of the 
protein. It is assumed that the major factor in stabilising the protein molecule 
comes from this hydrophobic force. However based on this assumption the 
positive entropy should exceed the negative entropy of the peptide chain 
becoming ordered. An increase in entropy is however observed with 
increasing temperature which in turn denatures the protein creating disorder, 
which should indicate an increase in the hydrophobic effect, this however is 
not the case. The conclusion from this is that the stability of the protein 
molecule cannot be considered to rely on hydrophobic interactions only; there 
must be other factors involved. 
Thermal denaturation 
Heat denaturation 
As discussed, if the temperature increases then the entropy increases 
overcoming the enthalpy of the interactions holding the protein structure 
together. Temperature induced denaturation at high temperatures involves 
heat absorption and an increase in the heat capacity of the protein therefore 
an increase in the enthalpy (Privalov, 1990). The enthalpy of the unfolded 
state increases with temperature as the ordered water molecules around the 
hydrophobic residues move away, the water molecules therefore form fewer 
hydrogen bonds with each other. If the enthalpy increases with temperature 
then the entropy must also increase for disorder and with the reduced order of 
the water molecules the hydrophobic residues have more freedom. The 
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temperature and the entropy of the unfolded state must exceed the enthalpy 
(see equation 1.4) for LG to become negative favouring the reaction. 
Cold denaturation 
From equation 1.4 decreasing the temperature should create order however, 
when the protein is in its native state that is when it is assumed to be at its 
most ordered (Privalov, 1990). So why would decreasing the temperature 
improve on this? During cold denaturation the water molecules become more 
ordered leading to a decrease in entropy. The enthalpy is negative due to 
heat release. With the increase in order it is strange that cold temperatures 
lead to denaturation and so it is important to have experimental evidence that 
this is actually the case, which is difficult due to the freezing of the aqueous 
solution (Privalov, 1990). This experimental evidence is provided by 
calorimetric data confirming that cold denaturation is an exothermic process 
(Cho et al., 1982). 
1.3: Protein refolding in biotechnology 
Protein refolding of denatured proteins has become of great importance to the 
biotechnology industry. This is due to folding of a protein leading to either 
product or useless misfolded protein. The mass production of proteins in 
biotechnology does however rely on a trial-and-error method of refolding 
proteins (Tsumoto et al., 2003). 
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Figure 1.3: Flow chart illustrating the stages from expression to fully folded 
and active protein when expressed as inclusion bodies. 
Inclusion bodies 
Inclusion bodies are dense electron-refractile particles of aggregated protein 
found in the cytoplasm and the periplasmic space of E. coli (Bowden, 1991). 
The size of inclusion bodies varies between 0.17-1.3 pm and have a density 
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of -1.3 g/ml, higher than cellular components (Taylor, 1986). Expression in E. 
coli can result in the protein being produced as inclusion bodies. Inclusion 
bodies are misfolded, insoluble, polypeptide aggregates (Rudolph et al., 
1996). Large-scale production of proteins usually begins with expression in 
bacterial systems, most commonly E. coli. E. coli has become a widely used 
host in industry for the production of many therapeutic proteins. As the 
proteins are expressed in a foreign host under forced conditions the products 
are not often produced in their natural forms and inclusion bodies are the 
result. Expression of proteins in the form of inclusion bodies is usually 
deemed undesirable however it can be advantageous as the separation of the 
inclusion bodies from other cellular debris is quite easy and successful. This 
separation usually involves repeated centrifugation whilst washing the 
inclusion bodies with specific buffers. 
There are many advantages of expressing a protein as inclusion bodies. 
1. Expression levels are high, 30 % of cellular protein in some cases. 
2. Proteins are protected from proteolysis by host cell enzymes. 
3. Initial purification which does not include the risk of denaturation. 
4. Easy separation from cells and other soluble contaminants using 
techniques such as centrifugation. 
5. If the expression product is toxic to the host, the inclusion body form 
can prevent this. 
(De Bernardez Clark, 2001; Singh and Panda, 2005). 
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Figure 1.4: Electron micrograph of E. coli cells expressing inclusion bodies, 
taken from Jungbauer and Karr, (2007). The electron micrograph shows E. coli cells 
containing inclusion bodies which can be expressed in both the cytoplasm and 
periplasmic space. Bar = 200 nm. 
Once the stages of harvesting, centrifugation, solubilisation and purification 
have been developed there still remains a need to turn the protein into its 
native state to make it active. The challenge lies in that there is no universal 
method for refolding proteins (Middelberg, 2002). Protein refolding is a well 
researched academic subject and there is no shortage of detailed reviews on 
where to begin when refolding a protein (Panda, 2003; De Bernardez Clark 
2001). The confusion starts with the vast quantity of methods and 
combinations of techniques to choose from. Much of the research into 
refolding proteins involves the expression and purification of small amounts of 
protein for biophysical analysis or studies on the folding pathways of individual 
proteins. The methods used are usually made up of many unnecessary 
purification stages leading to poor yields (De Bernardez Clark, 2001). Due to 
the importance of protein refolding to industry the scale up issues must be 
acknowledged and poor yields are not an option. 
The aggregation which occurs on inclusion body formation of recombinant 
proteins is probably due to the highly oxidizing environment of the bacterial 
cell and the limiting amount of chaperones and foldases (Lorimer, 1996; 
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Panda, 2003). Growth temperature and the pH of the media can also 
stimulate inclusion body formation (Chalmers et al., 1990; Strandberg and 
Enfors, 1991). During the high level of expression the chances of exposed 
hydrophobic surfaces on the recombinant protein to come into contact with 
each other increases and the protein aggregates. 
Solubilisation 
Once inclusion bodies have been isolated the preparation for refolding begins 
immediately with solubilisation. The two most commonly used denaturing 
agents are urea and guanidine-HCI. 
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Figure 1.5: Chemical structure of urea and guanidine. The figure illustrates how 
these two commonly used denaturants have very similar chemical structures. Drawn 
using ChemWindow''"" 6. 
Urea and guanidine-HCI are considered to break the hydrogen bonds within 
the protein molecule and the water molecules either by interacting directly 
with the protein molecule or with the surrounding solute molecules. Urea is 
usually preferred as the denaturant in an industrial setting due to the corrosive 
properties of guanidine-HCI, however this is not always the most efficient as 
urea has the potential to spontaneously produce cyanate which can react with 
the protein and carbamylate the amino groups (Cejka et al., 1968). The 
disruption of protein structure by urea and guanidine-HCI is still very much 
debated. These two denaturants are similar in structure however guanidine- 
HCI is documented as the best possibly due to the high salt concentration 
present, however it can depend on the protein (Greene and Pace, 1974). 
Their effects could be displayed by binding directly or indirectly to the protein 
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molecules or by altering the environment by reacting with the water molecules 
(Bennion and Daggett, 2003). 
Denaturation should cause the complete disruption of the protein structure as 
it is difficult to refold a protein which is only partially unfolded (De Bernardez 
Clark, 2001). Detergents can also be used to denature inclusion bodies, an 
example being sodium dodecyl sulphate (SDS). However detergents can 
interfere with downstream purification stages (De Bernardez Clark, 2001) and 
it is difficult to prove the removal of detergents once the process has ended. 
Reducing agents such as dithiothreitol (DTT) and ß-mercaptoethanol may 
also be added on solubilisation as they will prevent any disulphide bond 
formation (Fischer et al., 1993). Ethylenediaminetetraacetic acid (EDTA) can 
also be added to prevent air-catalyzed oxidation of the cysteine residues 
(Singh and Panda, 2005). Inclusion bodies have been shown to solubilise in 
extremes of pH alongside low concentrations of denaturant (Patra et al., 
2000) however this can also irreversibly modify protein molecules, examples 
being deamidation and alkaline desulphuration of cysteine residues (Thatcher 
and Hitchcock, 1994). The choice of solubilisation buffer can be of great 
importance to a process due to the high cost involved of the denaturants but 
also by ensuring maximum yield throughout. 
Simple renaturation 
After solubilisation, refolding is usually carried out by removing the high 
concentrations of denaturants and the reducing agent, if any. This may be 
carried out by dilution, diafiltration or gel filtration chromatography. The 
technique used depends heavily on the protein (De Bernardez Clark, 2001). 
Additives can be added to the refolding buffers to aid refolding and decrease 
the formation of aggregates. 
individually. 
Dilution 
All these methods shall be discussed 
Dilution of the solubilised protein directly into the refold buffer is the most 
commonly used method in small-scale refolding due to its simplicity (Li et al., 
2004). If the protein is to be exposed to low denaturant concentrations the 
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initial shock can result in aggregation and so protein concentrations are an 
important factor to consider when choosing dilution, Lilie et al., (1998) and 
Jungbauer and Karr, (2007) suggest 10-100 pg/ml. Staged or pulsed dilution 
into intermediate concentrations of denaturants can also be used. 
Unfortunately staged dilution is both time and buffer consuming and therefore 
not suitable for large scale production (Li et al., 2004). Pulsed dilution 
consists of aliquots of protein being added to the renaturation buffer at 
different time intervals in order to reduce the need for large volumes. 
However pulsed dilution must be stopped once the denaturant and protein 
concentrations become critical (Lilie et al., 1998). 
Dialysis 
Dialysis exposes the protein to intermediate denaturant concentrations and 
usually involved long periods of time of exposure to these concentrations. 
This can be beneficial in the refolding as partially folded intermediates may be 
formed at these reduced denaturant concentrations. However this 
intermediate state can increase the chances of aggregation, it is very much 
protein specific (Rudolph and Lilie, 1996). Being a slow process dialysis is 
often replaced by diafiltration in industry. The principle is the same, small 
molecules pass through a membrane and the protein of interest is retained 
whilst the buffer containing the denaturant passes through the membrane. A 
new buffer is added to the retained protein resulting in buffer exchange. The 
process of dialfiltration is driven by pressure and so does not depend on the 
rate of diffusion therefore making it quicker than dialysis. 
Refolding using chromatography 
Refolding using chromatography can be a long process due to slow flow rates 
but also expensive especially if pre-packed column are used, however it is 
being investigated more as an alternative to non-chromatographic methods 
due to better quality proteins being produced (Swietnicki, 2006) 
Buffer exchange 
Chromatography has been used to successfully refold proteins especially size 
exclusion or gel filtration chromatography (or size exclusion, SEC). SEC has 
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been used due to it being a good buffer exchange system, essentially it is a 
batch dilution method which creates a bottleneck in the process and problems 
with scale-up, Lanckriet and Middelberg, (2004) investigated the possibility of 
continuous SEC chromatography to reduce the time constraints. They found 
it be more beneficial in reducing process time while still remaining a 
successful stage. 
The refolding is based on the principle that the column is pre-equilibrated in 
the refolding buffer, the sample applied in high denaturant and the protein 
eventually elutes in the refolding buffer. The column provides separation of 
the protein refolding and any aggregates due to them being separated by their 
sizes, but also provides time for the protein to refold and possibly gives the 
aggregates a second opportunity to refold (De Bernardez Clark et al., 1999). 
Change in the buffer composition can also be coupled to a change in pH. The 
application of crude samples to the gel filtration column can result in problems 
as the resin will require rigorous and harsh cleaning protocols possibly 
compromising the stability and consistency of the chromatography. 
Matrix assisted protein refolding 
A second way of ensuring the folded protein does not come into contact with 
aggregates or aggregate-prone intermediates is to attach the protein to a 
support. Examples of these being ion exchange chromatography, 
hydrophobic interaction and affinity chromatography requiring a tag or fusion 
protein capable of binding to the resin. The detachment would work with the 
chromatography conditions and allow the protein to be released from the 
resin, folded. 
Hydrophobic interaction chromatography 
Hydrophobic interaction chromatography (HIC) involves the proteins being 
loaded at high salt concentrations which coincides well with the high 
guanidine-HCI concentrations used for solubilisation. Refolding and elution 
takes place by a reduction in the salt concentration. During migration through 
the column the protein will encounter several steps of adsorption and 
desorption resulting in the formation of the intermediates which ultimately lead 
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to the native protein. Consensus IFN-a2b has been refolded successfully 
using HIC (Wang et al., 2006a). The method used a decreasing guanidine- 
HCI gradient alongside an increasing PEG gradient to elute the protein. Li et 
al., (2004) found that increasing hydrophobicity of the HIC media had a 
negative effect on the refolding, however with the incorporation of glycerol in 
the running buffer the correct refolding could be achieved. The apparent need 
for the chaperone (glycerol and PEG in these cases) could be because of the 
strong interaction of the protein with the HIC media. The chaperone can 
reduce this effect allowing the protein to refold rather than becoming 
irreversibly bound. 
Ion exchange chromatography 
Ion exchange methods of refolding proteins tend to involve a dual gradient 
elution to avoid the high concentrations of salt usually required to elute the 
protein. Li et al., (2004) successfully purified and refolded lysozyme using a 
decreasing urea gradient alongside an increasing pH gradient. Liu et al., 
(2007a) also successfully refolded and purified TGase from Streptomyces 
fradiae using ion exchange chromatography to high activity. Ion exchange 
has been coupled with expanded bed chromatography by Biazus et al., 
(2006). Expanded bed chromatography is used for more crude protein 
samples, as the name suggests as the expanded bed expands the surface 
area available to the protein molecules increases. 
Affinity chromatography 
Affinity chromatography makes use of the improved expression of some 
proteins when tagged. Immobilised metal ion affinity chromatography (IMAC) 
purifies polyhistidine-tagged proteins. The matrix is made up of divalent metal 
ions to which the polyhistidine-tag is attracted. Elution is carried out with 
increasing concentrations of imidazole or decreasing the pH. The refolding 
can be carried out while the protein is still attached as the matrices are 
compatible with high denaturant concentrations. Before elution the 
denaturant concentration can be reduced to refold the protein. The 
concentration of protein must be monitored as high protein concentrations can 
aggregate at the top of the column reducing the elution success. The tag also 
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must not interfere with the proteins refolding. Rogl et al., (1998) successfully 
refolded two polyhistidine-tag membrane proteins on a Ni-column by reducing 
the denaturant and increasing the detergent concentration. 
Pressure 
Pressure has been used to treat proteins which have a tendency to aggregate 
easily during refolding. Hydrostatic pressures of 150-200 MPa (1.5-2 kbar) 
are applied to the samples. The aggregates produced either upon 
denaturation with guanidine-HCI or urea or just simply the inclusion bodies at 
concentrations of 8.7 mg/ml results in high recovery of the native protein. 
Katoh and Katoh, (2000); Gorovits and Horowitz, (1998) investigated the 
effect of high pressure on the aggregation of the enzyme rhodonase. The 
enzyme begins to aggregate at 3.9 M urea after denaturation. An increase in 
pressure of 2 kbar resulted in a increase in refold yield. Interestingly though 
was the ability to reverse the formation of the aggregates using this high 
pressure. The formation of the aggregates was induced and monitored by 
light scattering. The pressure was applied, released and applied a second 
time. The formation of aggregation was monitored and a decrease in the light 
scattering was observed. They state that the formation of large irreversible 
aggregates cannot be improved mostly due to experimental design with too 
long incubation times under reduced pressure. High pressure has also been 
used to solubilise inclusion bodies with and without guanidine-HCI. St. John 
et al., (1999) solubilised ß-lactamase inclusion bodies incubated at 200 MPa 
(2 kbar) for 48 hours. Their results show a recovery of soluble ß-lactamase 
using just pressure however coupled with low concentrations of guanidine-HCI 
(<_ 1.2 M) the recovery of soluble ß-lactamase improved. 
Aggregation 
The protein concentration also requires careful monitoring to prevent 
aggregation (Li et al., 2004). The process of folding of a protein has been 
described as being a directed process (Levinthal, 1968) proceeding through 
intermediate states (Privalov, 1996). The intermediate structure is unstable 
and less soluble causing aggregation and misfolding (Tsumoto et al., 2003). 
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Figure 1.6: Schematic diagram of refolding of a protein molecule. U= unfolded, 
I= Intermediate, N= Native (Tsumoto et al., 2003). Formation of aggregates is the 
most common reason for low yields during protein folding, to minimise aggregation 
many different types of additives and/or chaperones can be added during the 
refolding process. 
Aggregation has been quoted as being `the single most important constraint in 
the use of prokaryotes as expression vehicles for recombinant proteins' 
(Thatcher et al., 1994). The folding buffer used must favour the formation of 
the native state while minimizing aggregation of the intermediates (Armstrong 
et al., 1999). Goldberg et al., (1991) showed that turkey egg white lysozyme 
formed aggregates that were not necessarily caused by incorrect disulphide 
bonds but non-specific interactions between the peptide chains. The rate of 
aggregation formation has been found to be second or third order whereas 
correct refolding is first order; therefore aggregation competes successfully 
with refolding (Hevehan and De Bernadez-Clark, 1997). 
Formation of disulphide bonds 
If the protein contains disulphide bonds then a controlled redox environment 
must be set up to ensure their correct formation. This redox environment can 
be set up using many additives, examples are reduced and oxidised 
glutathione (GSH/GSSH), cysteine and cystine, cysteamine and cystamine 
(De Bernardez Clark et al., 1999). Metal ions have been added to initiate 
oxidation of the cysteines using the oxygen present in the air (Ahmed et al., 
1975) due to its simplicity and cost effectiveness. 
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Additives 
Additives can be introduced into the refold to reduce chance of aggregation 
formation. A common additive is L-arginine. L-arginine reduces the 
possibility of aggregation by interacting with amino acid side chains, which is 
also a property of guanidine-HCI of which they share structural similarities 
(Arakawa et al., 2007). However Liu et al., (2007b) showed that L-arginine 
did reduce precipitation of consensus IFN but increased the formation of 
soluble oligomers. They found that increasing the L-arginine concentration 
decreased the refolding yield. Detergents are a popular choice of additive to 
refolding mixture, the choice of the detergent used such as CHAPS, SDS and 
Triton X-100 is usually down to efficiency and cost. Another technique is to 
chemically modify the protein to make it more soluble (Thatcher et al., 1994). 
A summary of all the available additives can be seen in table 1.2. 
Additive 
Recommended 
Concentration 
Reference 
Denaturants 
Guanidine-HCI : 51 M Schulenburg et al., 2007 
Urea s2M Futami et al., 2000 
L-arginine 0.4-0.8 M Liu et al., 2007b 
Salts 
Sodium chloride 0.5 M Futami et al., 2000 
Sugars 
Glycerol 20-40 % Dong et al., 2004 
Sucrose 0.4 M Sijwali et al., 2001 
Glucose 1M Divsalar et al., 2006 
Detergents and surfactants 
CHAPS 10-60 mM Wetlaufer and Xie, 1995 
Tween 0.001%-1% Wells et al., 1994 
SDS 1 mm Xu and Keiderling, 2006 
Triton X-100 10 mm Zardeneta and Horowitz, 1994 
Polyethylene glycol 0.1-0.4 g/l Wang et al., 2006a 
Alcohols 
n-pentanol 1-10 mm Wetlaufer and Xie, 1995 
n-hexanol 0.1-10 mm Wetlaufer and Xie, 1995 
Table 1.2: Commonly used additives to enhance refolding yields by reducing 
aggregation. 
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Chaperone assisted refolding 
Chaperone assisted refolding is more commonly used during small scale 
refolding; the reason for this is purely availability and cost of the chaperones 
as they are usually added at an equimolar concentration to protein (Vallejo 
and Rinas 2004). Molecular chaperones mediate the correct assembly of 
proteins without forming any part of the final structure. They do this by 
binding and stabilising the folding intermediates (Ulrich, 1996). These 
chaperones exist naturally within the cell, aiding protein folding after formation 
on the ribosome. Many of them double as heat shock proteins also, due to 
their formation when the cell is under stress in order to protect other proteins. 
An example being Hsp 70 (also called DnaK in E. coli). In vivo the unfolded 
polypeptide chain is passed to Hsp 70 which exposes its hydrophobic pocket 
enabling it to bind to exposed hydrophobic regions in the protein. Hsp70 is 
able to do this by binding ATP, once bound the hydrolysis of ATP occurs and 
the peptide is released. The folding of some proteins requires chaperonins as 
well as Hsp70. In eukaryotes the chaperonins are called TCiP consisting of 
eight Hsp60 subunits. GroEL the TCiP homolog in bacteria consists of 
fourteen subunits (Lodish et al., 2001). The refolding of maltodextrin 
glucosidase was shown to be improved by the addition of the chaperonins 
GroEL and GroES (Paul et al., 2007). They also appeared to work well in 
conjugation with other additives such as polyol osmolytes and glycerol. 
During protein folding catalysts can be added such as prolyl-peptidyl 
isomerase (PPI) which catalyses the cis/trans isomerisation of proline 
residues or protein disulphide isomerase (PDI) which forms the correct 
disulphide bonds (De Bernardez-Clark et al., 1999). These behave differently 
to the molecular chaperones as they are catalysts, therefore altering the rate 
of reaction whereas molecular chaperones do not (Ulrich, 1996). PDI is found 
in vivo during folding in the endoplasmic reticulum and promotes reshuffling of 
the incorrect disulphide bond formation (Gething and Sambrook, 1992). PPI 
activity is found in the cytosol and can be used to accelerate the isomerisation 
within proline rich proteins (Gething and Sambrook, 1992). 
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Screening kits 
As there is no universal refolding buffer (Vincentelli et al., 2004) it has become 
clear that a way of screening proteins with many different buffers would be 
more efficient and less time consuming. It has become more popular to begin 
refolding of a protein with a screening kit much like the kits used for protein 
crystalisation. These kits usually incorporate all the additives discussed 
above, Novexin Ltd and Merck have a large range of kits available. 
1.4: Investigation of protein folding 
Once folding has taken place analysis has to be carried out to ensure the 
correct conformation has been achieved. Functional assays can be of great 
importance in elucidating whether the protein has reached its optimum 
activity, important if the protein has therapeutic implications. However 
biophysical techniques can also be used to analyse the folded and unfolded 
conformations of proteins. It is easier if the both the folded and unfolded 
characteristics are known, to which the refolded can be compared however it 
is not always necessary. Luckily due to proteins being made up of chiral 
molecules, having partial double bond character and a very unique native and 
denatured 3-dimensional structure these characteristics can be exploited 
giving structural information. The two most utilised biophysical techniques 
used throughout this project are circular dichroism and fluorescence both of 
which shall be further discussed individually. 
Spectroscopy 
Electromagnetic waves are made up of two components, an electric field and 
a magnetic field; these two components oscillate at right angles to each other 
in the direction of propagation. Electromagnetic radiation is made up of many 
different types depending on the frequency, these components can be seen in 
figure 1.7 as the electromagnetic spectrum. 
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Figure 1.7: The electromagnetic spectrum. Areas used for protein structure 
investigation are the ultraviolet, visible and infrared. 
The regions of ultraviolet, visible and infrared (IR) wavelengths are commonly 
used in analysis of proteins. Electromagnetic radiation behaves as two 
separate waves; an electric and a magnetic wave at right angles to each 
other. The electric field can be polarised and this property makes it suitable to 
be used in analysis of protein molecules. 
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Figure 1.8: Schematic diagram of the electric field (E) and magnetic field (M) 
oscillating to make up linearly polarised light (A = wavelength). For circularly 
polarised light, the plane polarised light, made up of two components can change 
direction but not magnitude. 
Circular Dichroism 
In linearly polarised light the electric field is polarised in one plane, in one 
direction and only the magnitude changes (figure 1.8). For circularly polarised 
light, the plane polarised light, made up of two components can change 
direction but not magnitude. Therefore the light can rotate in a clockwise 
(right-handed) or anti-clockwise (left-handed) manner. Two linearly polarised 
beams of light are circularly polarised in either a right or left handed manner 
due to them being out of phase with each other. Circular Dichroism (CD) 
spectroscopy measures the difference in the absorption of left-handed 
compared to right-handed polarized light (Johnson, 1985). 
AA = AL - AR (t5) 
Where DA = the difference in absorbance of left and right circularly polarised 
light (IAL and ER). 
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This absorbance can be incorporated into Beers law; 
A= ccl (1.6) 
Where A= Absorbance, E= Extinction coefficient, c= Molar concentration and 
I= pathlength (cm). 
Using CD data Beers law becomes 
AA = (EL - ER)CI (1.7) 
Where AA = Absorbance, c= Extinction coefficient for right and left circularly 
polarised light, c= Molar concentration and I= Pathlength (cm). 
Therefore the molar CD is calculated using 
L£=£L'£R (1.8) 
AE = The difference in extinction coefficient of the left and right handed 
circularly polarised light, EL = Extinction coefficient of left handed polarised 
light and ¬R = Extinction coefficient of right handed polarised light. 
If the absorption of both right and left handed light was equal no difference 
would be seen, figure 1.9A. Ac is plotted against wavelength producing the 
CD spectrum. tic for far and near UV CD has the units Mol-' cm"'. In the far 
UV the concentration used is that of the amino acid residues and in the near 
UV it refers to protein molar concentration. 
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Figure 1.9: The absorption of polarised light. A. If the right and left handed 
polarized light is absorbed to the same extent then the result is plane polarised light. 
B. If the right and left handed components are absorbed to different extents then the 
result is elliptically polarised light. (Adapted from Kelly et al., 2005) 
Circularly polarised light can be used on molecules which are asymmetric 
(chiral). Amino acids all have a chiral centre due to the four different groups 
bonded to the a-carbon atom. CD can be used to measure the optical activity 
of proteins in solution (Schmid, 1997). Most common is the measurement of 
the secondary structure of the protein molecule. This is due to a-helicies, 0- 
sheets, ß-turns and random coils all producing specific signals in the far UV 
region. 
Far UV CD 
The far-UV region (170-250 nm) gives information about the peptide bond and 
is used to investigate secondary structure of protein molecules. Figure 1.10 
illustrates the various types of secondary structure which can be measured. 
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Figure 1.10: Representation of the different secondary structures and their far 
UV signals. Solid line shows a-helix, long dashed line shows ß-sheet, dotted line 
shows ß-turn, crossed dashed line shows 310-helix or poly (Pro) 11 helix and the short 
dashed line shows irregular structure (Kelly et al., 2005). 
Measurements on conventional CD machines are not usually extended below 
180 nm however with the introduction of synchrotron radiation CD (SRCD) 
more reliable and informative measurements can be made. Using this 
technique measurements at 160 nm have been achieved (Wallace, 2000). 
Near UV CD 
The near-UV region (250-320 nm) is dominated by the aromatic residues 
(260-320 nm) and disulphide bonds (260 nm). Tryptophan (Trp) shows a 
peak at 290 nm, tyrosine between 275-282 nm and phenylalanine between 
255-270 nm (Kelly et al., 2005). The near UV spectrum can give information 
about which aromatic residues are present and their environments. 
35 
Ibo 180 200 220 240 760 
Thermal stability of protein can be measured using CD by following the 
changes in the spectrum with increasing temperature. A wavelength is 
chosen at which to monitor the changes and the entire spectrum can be 
followed over a range of temperatures. It is only when the unfolding is 
reversible that this becomes a direct relation to the conformational stability of 
the protein. If the protein aggregates as it unfolds the melting temperature 
indicates the kinetics of aggregation of the protein 
Fluorescence 
Fluorescence is the absorption of a photon of radiation (from appropriate light 
source) to promote an electron from the ground state to an excited state. This 
electron returns to a lower energy state by emitting a second photon of a 
longer wavelength. This phenomenon is represented by the Jablonski 
diagram in figure 1.11. 
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Figure 1.11: Jablonski diagram. The Jablonski diagram illustrates the energy 
levels encounted when absorption and emission takes place. The first, second and 
third electronic states are represented by So, S, and S2 respectively. 
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In a singlet excited state the electron in the highest energy state is paired with 
a second electron in a lower energy state. These two electrons have opposite 
spin orientations. The consequence of the electrons returning to ground state 
is fluorescence. In a triplet state the electrons are unpaired, and are in the 
same spin orientation. Opposite spin orientation is required for return to the 
ground state. The return of the electron to the singlet ground state is 
phosphofluorescence and has a much longer lifetime of milliseconds to 
seconds whereas fluorescence has a lifetime of 10 nsec (Lakowicz, 1983). 
For fluorescence to take place the electrons have to be excited at a specific 
wavelength. This absorption of light enables the transformation of the 
electron to a higher vibrational level, either S1 or S2. The excited electron 
relaxes down the vibrational levels to the first excited state, SSO. The electron 
then returns to ground state emitted light at a longer wavelength. Non- 
radiative relaxation can also occur instead of fluorescence or intersystem 
crossing. This is a result of excited molecules transferring their energy and 
the result is heat or quenching (Lakowicz, 1983), 
Substances which display fluorescence usually possess delocalized electrons 
present in double bonds. Emission spectra vary widely and are dependent on 
many factors such as chemical structure of the fluorophore and the 
environment in which the fluorophore is present (Lakowicz, 1983). 
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Figure 1.12: The chemical structures of tyrosine, phenylalanine and 
tryptophan. All three influence the protein absorption of light and the fluorescence 
emission due to their aromatic groups, drawn using ChemWindow'. 6. 
Proteins that contain aromatic amino acids (figure 1.12) can be used to assay 
intrinsic fluorescence (Middelberg, 2002). Protein fluorescence is generally 
excited at 280 nm or longer wavelengths. The absorption at 280 nm is due to 
the two amino acids, tyrosine and tryptophan. Above 295 nm the absorption 
and subsequent fluorescence is due to solely tryptophan and so tryptophan 
fluorescence can be selectively monitored. Phenylalanine has a weak 
absorption at 250 nm. The emission maximum for tyrosine in water occurs at 
303 nm and is relatively insensitive to solvent polarity. However, tryptophan 
whose emission maximum in water is 348 nm is highly sensitive to solvent 
polarity (Lakowicz, 1983). 
In proteins that contain all three aromatic amino acids the observed 
fluorescence is usually due to the tryptophan residues as the emission is 
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usually greater than for tyrosine and phenylalanine. There is also energy 
transfer between the three residues. As tyrosine and tryptophan absorb at. 
280 nm, the wavelength at which phenylalanine emits fluorescence, the 
fluorescence emitted by phenylalanine is quenched. In a folded protein the 
residues may be closer together therefore increasing the level of energy 
transfer. As the protein unfolds the residues may move apart and the 
emission from the quenched residues can be seen. In proteins that contain 
only tryptophan and tyrosine the fluorescence from tyrosine is not usually 
seen due to energy transfer, however on unfolding the residues move apart 
and energy transfer becomes less efficient (Schmid, 1997). 
1.5: Aims 
Cobra Biomanufacturing PLC 
Cobra Biomanufacturing PLC is the industrial partner in this BBSRC CASE 
award. Cobra Biomanufacturing PLC is a contact manufacturer providing 
customers with process development, scale-up, assay development and GMP 
manufacture, services required to take biopharmaceuticals from discovery, 
through development to commercialisation. Cobra have established leading 
capabilities in the manufacture of microbially derived biopharmaceuticals, 
peptide pharmaceuticals and DNA medicines. One of the projects Cobra is 
concerned with is the expression, purification, refolding and manufacture of 
Interferon-a2b (IFN-a2b). 
Aims 
The aim of this project is to improve the refolding strategy of IFN-a2b for 
Cobra Biomanufacturing. Initially biophysical characterisation studies of the 
natively folded IFN-a2b standard provided by Cobra Biomanufacturing were 
carried out. The IFN-a2b molecule consists of a five alpha helical bundle 
containing two disulphide bonds. The techniques used for analysis of IFN- 
a2bs biophysical characteristics was a collection of those considered 
previously; both far and near UV CD and intrinsic fluorescence. The findings 
from these initial studies provided a final point of reference at which 
expressed and refolded IFN-a2b was measured against. As discussed IFN- 
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a2b has two disulphide bonds and so their influence on IFN-a2b's thermal and 
denaturant stability was also investigated. The ability of common denaturants 
to disrupt the IFN-a2b structure was analysed which subsequently influenced 
the choice of solubilisation method used on the IFN-a2b inclusion bodies. 
The expression of IFN-a2b in E. coli shall provide the material for refolding 
studies to be carried out. The IFN-a2b was expressed as inclusion bodies 
using the plasmid provided. Washing and solubilisation of the inclusion 
bodies was optimised resulting in a relatively pure inclusion body. Purification 
of the solubilised inclusion bodies was required and was investigated by 
exploiting IFN-a2b structural features. Ion exchange was unsuccessful 
however gel filtration resulted in an efficient method of purifying the solubilised 
IFN-alb. Recent literature of tried and tested methods were also consulted. 
Once soluble inclusion bodies were acquired the refolding trials took place. 
These were based on a combination of information gained from the 
biophysical characterisation studies and published literature. Once a refolding 
strategy was formed, optimisation including further purification or polishing 
steps were considered. 
Due to the unique nature of inclusion bodies and interest in denaturation of 
proteins, especially where possible structure exists, basic biophysical studies 
were carried out on the IFN-a2b solubilised inclusion bodies. Many studies of 
denatured proteins are carried out on thermally denatured peptides using 
specialised techniques such as nuclear magnetic resonance (NMR) and 
Fourier transform infrared spectroscopy (FTIR). In this study only the 
techniques readily available were utilised providing evidence of potential 
structure present in the IFN-a2b inclusion bodies however non-native, when 
treated with denaturants. 
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Chapter 2 
Chapter 2 
Methods 
All the reagents and suppliers used can be found in Appendix 1. 
2.1: General methods 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was carried out to analyse the folded IFN-a2b standard and the 
refolded samples of IFN-a2b. This technique relies on the ability of SDS to 
denature and provide the protein molecules with a large negative charge. The 
samples are placed in the wells of the gel and subjected to an electric field in 
which they are attracted to the bottom of the gel, the anode. The acrylamide 
provides a barrier of pores allowing smaller molecules to move faster than larger 
molecules therefore separating the protein mixtures by size. The higher the 
percentage acrylamide the more resolved are smaller protein molecules. 
SDS-PAGE analysis was carried out on 12 %, 15 % and 17 % acrylamide gels in 
accordance to Laemmli (1970) using the Mini Protean II Electrophoresis Cell 
(BioRad). Details of the buffers and solutions used throughout can be found in 
table 2.1 and 2.2. 
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Figure 2.1: Precision Plus ProteinTm Dual colour Standard (Bio-Rad) used for all 
SDS-PAGE analysis. 
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Lower Buffer 
1.5 M Tris-HCI 14 mM SDS pH 8.8 
Upper Buffer 
0.5 M Tris-HCI 14 mM SDS pH 6.8 
Running buffer 
0.96 M 
0.125 M Tris-HCI 
Glycine 
0.5 % (w/v) SDS 
2X Sample buffer 
0.125 M Tris-HCI 
2%(w/v) 0.01 %(w/v) 
SDS bromophenol blue 
Table 2.1: Buffer and solution composition for SDS-PAGE 
15 % (v/v) glycerol 15 mM Na2EDTA 
40% 
Water Lower APS TEMED 
Acrylamide 
(ml) buffer (ml) (NI) (NI) 
(ml) 
15 % resolving gel 
3.305 2.25 3.375 50 20 
12 % resolving gel 3.98 2.25 2.7 50 20 
17 % resolving gel 3.7 2.25 2.35 50 20 
4% Stacking gel 2.59 1 0.35 50 10 
Table 2.2: Quantities of each component used to prepare gels depending on the 
percentage acrylamide required. 
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Electrophoresis was carried out at 140 volts for approximately 1.5 h. Staining of 
the gels was carried out using a solution of 0.2 % (w/v) Coomassie brilliant blue, 
10 % (v/v) acetic acid and 10 % (v/v) isopropanol for -r 1 h. Destaining was 
carried out in 10 % (v/v) acetic acid and 10 % (v/v) isopropanol overnight. 
SimplyBlueTM SafeStain (Invitrogen) was used when a more sensitive staining 
method was required. The freshly run gels were repeatedly washed with water 3 
times and then left for 3h in -20 ml SafeStain. Destaining was carried out in 
water. All gels were then stored in water until dried between cellophane sheets. 
Isoelectric focusing 
Isoelectric focusing (IEF) is an electrophoresis technique that separates proteins 
on the basis of their isoelectric point (pl). The pl of a protein is the pH at which 
the protein has no net charge and does not move in an electric field. IEF gels 
effectively create a pH gradient so proteins separate according to their pl. A 
protein sample is loaded onto the gel and an electric charge applied, the anode is 
at the acidic end of the gradient and the cathode is at the basic end of the 
gradient. Proteins with a net positive charge on the surface will migrate to the 
cathode and negatively charged proteins will move towards the anode. When the 
protein reaches an environment where the net surface charge is zero, it will no 
longer move. At this point the protein becomes "focused" and a band is formed in 
the gel. For this application the Novex® pH 3-10 IEF Buffer Kit (Invitrogen) was 
used. 
2.2: Ion exchange 
Theory 
Ion exchange depends of the forces of attraction between a charged matrix and 
an oppositely charged protein. There are two different types, cationic (negative) 
exchange and anionic (positive) exchange. The binding of the protein can firstly 
be achieved by applying the protein to a buffered environment of a specific pH 
causing the protein to gain a net charge opposite to the matrix. Secondly the 
protein solution should be applied to the column under the same conditions. The 
binding of the protein is reversible and can be eluted by an increase in salt 
concentration, usually NaCI. The weakly bound molecules elute first and with 
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increasing the gradient of NaCl the more strongly bound molecules elute resulting 
in their separation. 
Purification of the IFN-a2b inclusion bodies 
The pl of IFN-a2b had been calculated to 6 and so anionic exchange was chosen 
initially. The column used was a1 ml HiTrap Q SepharoseTM FF column and for 
the cationic exchange a1 ml SP SepharoseTM FF column was used (G. E. 
Healthcare). The flow rate was 1 ml/min and after each run the column was 
cleaned with 1M sodium hydroxide (NaOH) followed by water. All ion exchange 
was carried out by hand using a 20 ml syringe to apply the buffer. Initially the ion 
exchange experiments were carried out at a reduced urea concentration of 4M 
however this was eventually increased to 8M urea to ensure the IFN-a2b was 
kept denatured. A PD-10 column (G. E. Healthcare) was used initially for buffer 
exchange of the guanidine-HCI solubilised samples but due to the results this 
was substituted by dialysis to ensure complete buffer exchange. The dialysis 
was carried out for 16 h at either 4 °C or room temperature. The elution was 
performed by an increasing range of NaCl concentrations. The results and all the 
conditions tried can be seen in table 4.1, chapter 4. 
Purification post refolding 
The ion exchange post successful refolding was carried out on the same 1 ml Hi 
Trap Q FF column used for the initial purification of the inclusion bodies. Instead 
of by hand an ÄKTAprimeTM system (G. E. Healthcare) was used. The flow rate 
was 1 ml/min and the load volume was 10 ml. The ion exchange was carried out 
at pH 8.0,8.4 and 8.6 from a guanidine-HCI solubilised and refolded inclusion 
bodies. The ion exchange was also carried out on the refolded samples from 
urea solubilised inclusion bodies but only at pH 8.0. The eluate was collected in 
1 ml fractions. 
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2.3: Gel filtration 
Theory 
Gel filtration (also known as size exclusion) is a method of separating molecules 
on the basis of their size. The matrix is made up of spherical particles all porous. 
The technique relies on the smaller molecules passing into the matrix and 
therefore eluting later than larger molecules which are unable to pass into the 
beads therefore eluting early. Gel filtration has advantages over other 
chromatographic methods as it does not depend on binding of the protein to the 
matrix and the conditions used can be varied to suit the protein of interest. 
SuperdexTM 75 media was chosen for this application. SuperdexTM is based on 
cross-linked agarose particles covalently bonded to dextran. This gives the 
media both chemical and physical stability, important here due to the use of high 
concentrations of urea and guanidine-HCI. SuperdexTM 75 has a fractionation 
range of 3000 to 70000 Da. 
Column packing and efficiency 
The SuperdexTM media was supplied as free resin stored in 20 % ethanol. A 
XK16 column was packed with the SuperdexTM 75 gel filtration media. The tallest 
bed height was aimed for with the available media. The packing of the column 
was carried out using water at a flowrate of 0.7 ml/min increasing to 1 ml/min to 
finish. The bed height was 11.5 cm giving a total column volume of 23 ml. To 
confirm the columns performance the number of theoretical plates and peak 
asymmetry were determined. The typical values for SuperdexTM provided by 
G. E. Healthcare are an efficiency of N >10000 and a peak asymmetry between 
0.7-1.3. 
To measure both the number of plates and the asymmetry the column was 
equilibrated with 20 mM Tris-HCI pH 8.0 until a stable baseline was reached. The 
column was then spiked with 0.5 ml (approx 2% column volume) 1M NaCl and 
the conductivity recorded until the NaCl had eluted and a stable baseline 
achieved. 
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A selection of molecular weight markers were also applied to the gel filtration 
column to ensure the efficient running of the column. These were cytochrome C 
(12.5 kDa), carbonic anhydrase (29.5 kDa), ß-amylase (200 kDa) and blue 
dextran (2000 kDa). Both the blue dextran and ß-amylase should illustrate the 
void volume of the column. All samples were loaded at a volume of 0.5 ml at an 
approximate concentration of 1 mg/ml; carbonic anhydrase was loaded at a 
concentration of approx 0.1 mg/ml due to availability. The running buffer was 20 
mM Tris-HCI, 0.15 M NaCl pH 8.0. 
Purification of the IFN-a2b inclusion bodies 
The flowrate for the purification of the inclusion bodies was 0.5 ml/min and the 
load volume was 10 ml. The column was pre-equilibrated with the specified 
running buffer and the sample not applied until a steady baseline had been 
reached. The fractions were collected as 1 ml aliquots and pooled on the basis 
of the absorbance spectrum at 280 nm (A280). After each run the column was 
washed with water, followed by 1 column volume of 0.5 M sodium hydroxide and 
washed with water a second time. The column was stored in 20 % (v/v) ethanol. 
The running buffers were the solubilisation buffers; 6M guanidine-HCI, 20 mM 
Tris-HCI pH 8.0 or 8M urea, 20 mM Tris-HCI pH 8.0, with or without 5 mM DTT. 
2.4: Protein Concentration Determination 
Measurements at 280 nm 
The total protein concentration can be calculated by how much light passes 
through the protein sample. 
A= log Io/I (2.1) 
Where A= Absorbance, lo = Incident light intensity and I= Transmitted light 
intensity. 
The Beer-Lambert law shows that the concentration of sample and the samples 
absorbance have a linear relationship. 
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Beer-Lambert law: A=E. c. l (2.2) 
Where F- = molar extinction coefficient, c= molar concentration of the absorbing 
substance and I= pathlength of the light (cm). 
All protein concentrations were determined by absorbance at 280 nm using the 
provided (by Cobra) molar extinction coefficient 19200 cm-1 mol"1. A Cary 4E UV- 
Visible absorbance spectrophotometer was used along with a pair of 1 cm path 
length Hellma quartz cuvette. 
Bicinochoninic Acid Protein Assay (BCA) 
The BCA assay is similar to the Lowry procedure (Lowry et al., 1951), as they 
both rely on the formation of a Cue' and protein complex under alkaline 
conditions followed by the reduction to Cu" from Cue+. The amount of reduction 
is proportional to the amount of protein present. The change in colour of the BCA 
with the Cu" to a purple-blue allows the change to be monitored at 560 nm. The 
BCA working reagent is made up of reagent A and reagent B. Reagent A is 
bicinchoninic acid solution pH 11.25 and Reagent B is 4% (w/v) copper (II) 
sulphate pentahydrate. The protein standard Bovine Serum Albumin (BSA) is 
provided at 1 mg/mI. The working BCA reagent is prepared by mixing reagent A 
to reagent B at a ratio of 50: 1. This solution appears green in colour and is 
added to the protein solution at a ratio of 20: 1. The samples are incubated for 30 
minutes at 37 °C followed by absorbance measurement at 560 nm. 
2.4: N-(1-pyrene)maleimide labelling of IFN-a2b solubilised inclusion 
bodies 
The solubilised inclusion bodies were labelled with N-(1-pyrene)maleimide. N-(1- 
pyrene)maleimide is non-fluorescent probe exhibiting monomer emission peaks 
at 375 nm and 395 nm when excited at -345 nm. When the pyrene molecules 
are brought into close proximity and are excited they form excited dimers 
(excimers) that emit at longer wavelengths usually around 470 nm (Sahoo et al., 
2002). 
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The samples were incubated for 2h at room temperature with a 10 X molar 
excess of Tris-HCI(2-carboxyethyl)phosphine hydrochloride (TCEP) to reduce the 
four cysteine residues in IFN-a2b. A5M molar excess of N-(1-pyrene) 
maleimide solution was added to the protein samples and incubated overnight at 
room temperature with agitation. Following incubation excess N-(1-pyrene) 
maleimide was removed by use of a PD-10 column. The eluate was collected 
and analysed by fluorescence and absorbance. The fluorescence was measured 
between 350 -600 nm after excitation at 338 nm. The absorbance was carried 
out between 250-370 nm using an extinction coefficient of 40000 M-1 cm-1 at 344 
nm (Drury and Narayanaswami, 2005). 
2.5: Circular dichroism spectroscopy 
CD was used to investigate the secondary and tertiary structure of IFN-a2b using 
wavelengths in the far UV region (250-190 nm) and the near UV region (320-250 
nm). All CD spectroscopy was carried out on a Jasco J-810 spectropolarimeter 
and all cuvettes were from Hellma. All spectra were calculated by subtraction of a 
buffer baseline followed by conversion to Ac (Mol-1 cm-'I-'). For far UV CD the 
mean residue weight (MRW) used for IFN-a2b was 116. The spectra were 
measured at a HT (V) value <600. The conditions for all CD analysis are shown 
in table 2.3. 
Far UV Near UV 
Band Width (nm) 2 2 
Response (sec) 4 4 
Measurement wavelength (nm) 250-190 320-250 
Data Pitch (nm) 0.5 0.5 
Scanning speed (nm/min) 20 20 
Temperature (°C) 20 20 
Accumulations 10 10 
Size of cuvette (cm) 0.02 1 
Table 2.3: Conditions of all far and near UV CD analysis. 
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Initial characterisation of the IFN-a2b Cobra standard 
Initial characterisation studies were carried out on purified and folded IFN-a2b. 
IFN-a2b for these studies was provided by Cobra Biomanufacturing PLC as EP 
interferon (CTL2003#1010M) in an unknown buffer at a concentration of 8.47 
mg/ml, 10 aliquots were provided. 
Circular dichroism spectroscopy of folded IFN-a2b 
IFN-a2b was diluted and dialysed into 0.2 M sodium phosphate, 100 mM sodium 
chloride pH 7.0. IFN-a2b was diluted to 0.5 mg/ml and left to dialyse for 16 h at 4 
°C. Both the far UV and near UV CD were analysed. DTT was added to the 
folded IFN-a2b at a final concentration of 5 mM and then incubated overnight with 
agitation before the far and near UV CD was measured also. 
Circular dichroism spectroscopy of denatured IFN-a2b 
The Cobra supplied IFN-a2b was diluted to 0.5 mg/ml. Two stock solutions of 8 
M urea and 6M guanidine-HCI were used to both dilute and dialyse the two IFN- 
a2b samples. The samples were incubated for 16 h at room temperature giving a 
final denaturant concentration of 5M guanidine-HCI and 7M urea. Both far-UV 
and near-UV analysis was performed on these samples. 
2.6: Thermal stability of IFN-a2b 
Thermal melt determination by loss in secondary structure 
Thermal stability of IFN-a2b was investigated at different pH values to determine 
the transition temperatures. Melting temperatures (Tm) were determined at pH 
7.0,5.0 and 9.0, using; 0.2 M phosphate, 100 mM sodium chloride pH 7.0,100 
mM citric acid pH 5.0 and 25 mM sodium borate pH 9.0. An initial far UV CD 
scan was taken of the samples at a concentration of 0.1 mg/ml in these three 
buffers to ensure the secondary structure was still intact. The thermal unfolding 
was also to be carried out at the same concentration. Thermal unfolding was 
carried out between 20-95 °C at a rate of 1 °C/min in a 0.1 cm stoppered cuvette. 
The CD signal was followed at 223 nm. The samples also had a far-UV scan 
taken every 5 °C. This experiment was also repeated with the addition of DTT to 
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a final concentration of 5 mM. Samples containing DTT were incubated at 20 °C 
overnight prior to thermal denaturation. 
Differential scanning microcalorimetry (DSC) 
Differential scanning microcalorimetry (DSC) involves the heating of a protein 
solution at a constant rate alongside a reference cell containing the same buffer 
as the protein solution. The difference in the heat energy uptake between the 
sample and the reference required to maintain an equal temperature corresponds 
to a heat capacity which can be used to determine a melting temperature (Tm). 
The DSC was performed on a Micro-Cal VP-DSC (MicroCal Europe, Milton 
Keynes, UK). The initial scan was carried out on an IFN-a2b sample of 0.5 
mg/ml followed by 0.1 mg/ml due to the precipitation encounted. Both samples 
were in the buffer 0.2 M phosphate 0.1 M NaCl pH 7.0 and were filtered and 
degassed prior to use. The scan rate was 1 °C/min 
2.7: Intrinsic fluorescence 
Intrinsic fluorescence was used to analyse IFN-a2b due to the presence of 5 
tyrosine and 2 tryptophan residues. The emission was measured between 296- 
380 nm. The excitation wavelength was 280 nm, a5 mm cuvette (Hellma) was 
used and all measurements were carried out at 20 °C. The protein concentration 
used for fluorescence analysis was 0.1 mg/ml unless otherwise stated. All 
measurements were carried out on a Varian Cary Eclipse fluorescence 
spectrophotometer. 
Alongside the maximum intensity being monitored the barycentric mean was also 
used to compare samples (Lakey et al., 1989). The Irma, is the wavelength at 
which the emission reaches its highest point. However this is not the preferred 
method of analysing fluorescence data, as Amax is sensitive to noise in the 
sample. The ABa , measures the `centre of mass' of the data giving a wavelength 
which takes into account all emissions over a chosen wavelength range. The 
ABary is calculated by equation 1.3 where A is wavelength and i is intensity. 
50 
ABary - 
Il 
Fluorescence analysis of the folded IFN-a2b 
(2.3) 
The fluorescence of the folded IFN-a2b was analysed at a total protein 
concentration of 0.1 mg/ml. To this sample 5 mM DTT was added to measure 
the effect, if any, as with the CD analysis. 
Fluorescence analysis of IFN-a2b in urea and guanidine-HCI 
The IFN-a2b was diluted to 0.1 mg/ml and dialysed into the denaturants giving 
final concentrations of 5M guanidine and 7M urea. Samples were left to dialyse 
for 16 h at room temperature. Following fluorescence analysis of the denatured 
sample DTT was then added at a final concentration of 5 mM. The fluorescence 
of this sample was measured immediately (T = 0), at T= 60 minutes, at T= 120 
minutes and after incubation overnight. 
Determination of unfolding curves for IFN-a2b using both urea and 
guanidine-HCI. 
The unfolding of IFN-a2b was investigated using intrinsic fluorescence and in the 
far UV region measured at 223 nm. The sample of IFN-a2b at 0.05 mg/ml was 
prepared with guanidine-HCI and urea added to give a range of concentrations 
from 0M to 7M (urea) and 6.5 M (guanidine-HCI). The samples were left to 
incubate with agitation overnight. The exact concentration of the stock solution of 
guanidine-HCI was determined using a Bellingham and Stanley refractometer. 
This measures the difference in refractive index between the guanidine-HCI 
buffer and water. Equation 1.4 was used to calculate the exact concentration of 
guanidine-HCI and equation 1.5 was used to determine the urea concentration. 
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Guanidine-HCI 
57.147(AN)+38.68(1N)2- 91.60(LN)3 
Urea 
117.66(ON)+29.753(ON)2 + 185.56(LN)3 
(2.4) 
(2.5) 
AN is the difference in the refractive index of the denaturant solution and water at 
the sodium D line (Pace, 1986). 
The range of concentrations for the urea samples were every 0.5 M from 0M to 7 
M. For the guanidine-HCI experiments this was used up to 6.5 M however 
around the mid point a more narrow range was measured at increments of every 
0.15 M. The samples were analysed by both far UV CD and intrinsic 
fluorescence. DTT was added at 5 mM to a second set of samples at the same 
denaturant concentration. Once the data had been collected the guanidine-HCI 
results from both the fluorescence and the CD experiments were used for the 
calculation of the conformational stability of IFN-a2b in the absence of guanidine- 
HCI, L G(H2O) and m, the dependence of AG on denaturant concentration 
this calculation a two state folding mechanism is assumed, 
ff+f=1 
ff = fraction folded 
fu = fraction unfolded 
Using the data collected 
K= (Yf - Y)/(Yf - Yu) 
For 
(2.6) 
(2.7) 
Where yF is the value of the folded protein and yu is the value of the unfolded 
protein, y is the data at that specific guanidine-HCI concentration. 
AG = -RT InK (2.8) 
R is the gas constant 1.98 cal/K/mol, T is the temperature in Kelvin 298. 
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OG = OG(H2O) -m [D] 
LG(H2O) = the y intercept 
m= the gradient of the line 
[D] = Denaturant concentration 
(2.9) 
In some cases the detergent 3-[(3-Cholamidopropyl)dimethylammonio]-1- 
propanesulfonate (CHAPS) which is a nondenaturing zwitterionic detergent was 
added at 1% (w/v) to the urea samples with DTT. This would possibly break the 
possible hydrophobic core of the IFN-a2b which may have formed due to the 
inefficient nature denaturation with urea (Pasquali et al, 1997). The far UV CD 
was measured at 1,3,5 and 7M urea. 
8-Anilino-1-naphthalenesulphonate binding 
8-Anilino-1-naphthalenesulphonate (ANS) is a fluorescent probe which has an 
affinity for the hydrophobic regions within a polypeptide chain (Stryer, 1965). 
This affinity is at its most extensive when a molten globule structure is present. 
ANS weakly binds the denatured and native structure (Semisotnov et al., 1987; 
1991). ANS is negatively charged and a non-covalent fluorescence probe which 
emits fluorescence when exposed to highly hydrophobic environments. ANS 
shifts as with tryptophan fluorescence to shorter wavelengths when in a more 
hydrophobic environment. 
NH S03H 
Figure 2.2: Chemical structure of ANS. ANS is used to investigate the hydrophobic 
nature of protein molecules. Drawn using Chemwindow® 6. 
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ANS was added to the IFN-a2b standard, the refolded IFN-a2b samples and the 
solubilised inclusion bodies. ANS was prepared by making a concentrated 
solution, allowing it to dissolve followed by filtration using a 0.2 pm filter. The 
concentration was measured using an extinction coefficient of 5000 M-'cm-1 at 
360 nm (Matulis and Lovrien, 1998). The ANS was added to the sample at a final 
concentration of 0.1 mM, the samples were well mixed and the fluorescence 
emission measured between 400-600 nm after excitation at 360 nm. 
2.8: Growth media and bacterial strains 
All expression of IFN-a2b was carried out in autoclaved Luria Bertani media (LB), 
1 Og/I tryptone, 5g/l yeast extract, 1 Og/I sodium chloride. For the initial isolation of 
the bacterial colonies bacterial agar 2g of agar was added to 100 ml of LB and 
set in Petri dishes. Both the agar and LB were supplemented with the antibiotic 
kanamycin at a final concentration of 30 pg/ml. The LB plates were kept at 4 °C 
for short term storage. 
The strains used for the initial expression of IFN-a2b were BL21 (DE3), JM105 
and DH5a. 
Strain Genotype Reference 
BL21 E. coli BF dem ompT hsdS(rB mB-) gal 
(Studier et al., 1990) 
(DE3) A(DE3) 
thi rpsL endA scs815 hspR4 4(lac- 
JM105 (Yanischperron et al., 1985) 
proAB) [F' tarD36 proAB laclgZZM15] 
F"80dlacZOM 15 A(/acZYA-argF) U 169 
DH5a 
recAl endAl hsdR17(rk , mk+) phoA 
(Woodcock et al., 1989) 
supE44 thi-1 gyrA96 re/Al 
Table 2.4: The genotype of the bacterial strains used for the initial expression of 
IFN-a2b. 
54 
Plasmid 
The plasmid shown in figure 2.3 was provided by Cobra Biomanufacturing PLC 
and used throughout for all IFN-a2b expressions. The plasmid provided consisted 
of the DNA sequence for expression IFN-a2b. The expression was under the 
temperature control of the lambda c1857 repressor. 
Pst 1 (4766) 
Xho I (4606) 
Sma 1 (4334) 
kan 
Pvu I (4210) 
Hind III (4o86) 
Pst 1 (3526) 
Hind III (3012) 
Pst I (3008) 
, 
"; all (2998) 4011 
Pst I (2972) 
Hind III (2786) 
pMBI on 
pSL-A2bkan(+) 
4769 bp 
I 
Interferon alpha 2b 
EcoR 1 (2491) 
Pst 1 (1129) 
Hind III (1583) 
Hind III (1708) 
lambda c1857 repressor 0 J* 
lambda PR 
lambda PL 
Figure 2.3: Plasmid provided by Cobra Biomanufacturing used for the expression 
of IFN-a2b. The plasmid map shows that the expression of IFN-a2b is under control of 
the lambda c1857 repressor and has resistance to the antibiotic kanamycin (kan). 
Transformation of competent BL21 (DE3), DH5a and JM105 cells with pSL- 
A2b(Kan)+ 
The vector pSL-A2bkan(+) containing the IFN-a2b insert (2 pl) was added to 200 
pl of thawed competent cells of all three strains; BL21 (DE3), DH5a and JM105. 
Samples were incubated on ice for 30 minutes before a heat shock at 42 °C for 2 
minutes allowing cell permeabilisation. All three strains were immediately 
incubated on ice for a further 5 minutes. Following this was the addition of 500 pl 
of sterile LB to the cells and incubation at 37 °C for 1 h. The transformants were 
IacO3 
lacOl 
Hind III (1113) 
doom 
Sph 1(1123) 
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then plated out onto LB agar supplemented with kanamycin and incubated 
overnight at 37 °C. 
2.9: Expression 
All expression was carried out in E. coli strains with induction by increased 
temperature from 30 °C to 43 °C. 
Small scale expression of IFN-a2b in BL21, DH5a and JM105 
LB media tubes (5 ml) containing kanamycin at a final concentration of 30 pg/ml 
were inoculated with a single colony for the agar plate. The culture was 
incubated overnight at 30 °C repressing the lambda promoter. 250 ml flasks 
containing 50 ml LB (containing kanamycin) were inoculated by the addition of 1 
ml of the 5 ml overnight culture. The 50 ml cultures were left to grow at 30 °C 
until the optical density at 600 nm (OD600) of the culture reached 0.6-0.7. Once 
the culture reached the appropriate density the flasks containing each strain were 
transferred to a pre-heated incubator at 43 °C. Flasks of each strain were left at 
30 °C to act as controls. The flasks at 43 °C and 30 °C were sampled every h 
and the OD600 measured, these samples were also set aside for subsequent SDS 
polyacrylamide gel electrophoresis (SDS-PAGE) analysis. Thermal induction 
was allowed to proceed at 43 °C for 5 h. The expression was carried out in these 
three strains to find a suitable system for future expressions. BL21 (DE3) was 
chosen. 
Large scale expression of IFN-a2b using BL21 (DE3). 
The strain chosen for future IFN-a2b expression was BL21 (DE3). The 
expression was scaled up to 500 ml cultures to begin treatment of the inclusion 
bodies. The transformation was carried out as above. The overnight 30 °C 
culture was scaled up from 5 ml to 50 ml. From this overnight 50 ml culture 5 ml 
was added to 500 ml of sterile LB. This larger culture was grown at 30 °C until 
and OD600 of 0.6 and then the temperature increased to 43 °C. After a steady 
OD600 reading of 2 had been reached the culture was centrifuged at 7025 xg 
(average speed) for 30 minutes at 4 °C using a Beckman Avanti J-25 centrifuge 
(rotor JAI 0). The pellets were kept frozen at -20 °C. 
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10 I fermentation of IFN-a2b 
Due to the success of the IFN-a2b expression a large scale preparation was set 
up to increase yields. The fermenter vessel (Bioflow 3000 Batch/continuous 
Bioreactor, New Brunswick Scientific Edison, N. J. USA) was appropriately 
washed and sterilised by autoclaving. 10 I of LB was added to the fermenter 
vessel and autoclaved for a second time. Sigma antifoam 287 was added to the 
media to prevent excessive foaming of the culture whilst growing. To inoculate 
the culture 250 ml of overnight culture grown at 30 °C was added to the 
fermenter. Samples were taken every 30 minutes and the absorbance measured 
until an OD60o of 0.6 was reached, the temperature of the fermenter was then 
increased to 43 °C and the culture grown until a steady OD60o was reached. 
Samples were still taken every 30 minutes. The culture was harvested as 
detailed in section 2.10. 
2.10: Harvesting of the IFN-a2b inclusion bodies 
The cells from the expression were resuspended in 20 mM Tris-HCI pH 8.0 
followed by sonication on ice. The inclusion bodies were subjected to repeated 
washing and centrifugation with 20 mM Tris-HCI and 1% Triton X-100. Figure 
2.4 illustrates the individual steps in the treatment of the inclusion bodies. 
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Resuspend Cell Pellets in 20 mM Tris-HCI pH 8.0 
Sonication 
Centrifuge Supernatant 16556 xg for 1h at 4 °C 
Resuspend Pellet in 20 mM Tris-HCI 1% Triton pH 8.0 
Homogenise Pellet for 30 minutes at 37 °C 
Centrifuge at 4709 xg for 1h at 4 °C 
Resuspend Pellet 20 mM Tris-HCI 1% Triton pH 8.0 
Homogenise Pellet for 30 minutes at 37 °C 
Centrifuge at 4709 xg for 45 minutes at 4 °C 
Resuspend Pellet in 20 mM Tris-HCI 1% Triton pH 8.0 
Homogenise Pellet for 30 minutes at 37 °C 
Centrifuge at 4709 xg for 30 minutes at 4 °C 
Solubilisation of the pellet in either 6M guanidine-HCI, 
20 mM Tris-HCI 
pH 8.0 or 8M urea, 20 mM Tris-HCI pH 8.0 
Leave to solubilise overnight at room temperature 
Centrifuge at 106255 xg for 1.5 h at 4 °C 
Store solubilised IFN-a2b at -20 °C 
Figure 2.4: Flowchart illustrating the treatment of the inclusion bodies before 
solubilisation. Centrifugation speeds are an average value. 
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The cell pellet was suspended in 20 mM Tris-HCI pH 8.0. To this suspension 
protease inhibitors were added; Benzamidine (100 pg/ml), AEBSF (100 pg/ml), 
Aprotonin (0.5 jig/ml), Leupeptin (1 pg/ml) and Pepstatin A (1 pg/mi). DNase 1 
(10 pg/ml) and RNase (10 pg/ml) were also added. The cells were broken using 
Sonication (MlSonix sonicator 3000) to release the IFN-a2b inclusion bodies. 
The solution was centrifuged at 16556 xg (average speed) for 1h in Beckman 
L780 ultracentrifuge (rotor Ti70) to pellet the inclusion bodies. The supernatant 
was removed and the pellet retained. 
The inclusion body pellet was resuspended in 20 mM Tris-HCI/1 % Triton X-100 
pH 8.0. This was added to a homogeniser, stationed in a 37 °C water bath. The 
pellet was homogenised, solubilising the outer membrane proteins in the Triton 
X-100 detergent. The homogenised pellet was centrifuged for 1h at 4709 xg 
(average speed) in the ultracentrifuge (rotor Ti70). The pellet was resuspended 
and centrifuged as above, the centrifugation however was reduced to 45 minutes 
and then 30 minutes respectively. The supernatants were retained after each 
centrifugation for analysis. The washed inclusion bodies were stored at -20 °C. 
Solubilisation of the IFN-a2b inclusion bodies with 8M urea and 6M 
guanidine-HO 
1g (wet weight) of inclusion bodies was solubilised in 10 ml of denaturant. DTT 
was added wherever stated to a final concentration of 5 mM. The solutions were 
left overnight with agitation at room temperature. Centrifugation of the solubilised 
inclusion bodies was carried out at 106255 xg (average speed) for 1.5 h. The 
supernatants were diluted 1 in 10 and 0.01 g of the four pellets was resuspended 
in 100 pl of buffer for SDS-PAGE analysis. The supernatants were stored frozen 
at -20 °C. The inclusion bodies solubilised in 6M guanidine-HCI required dialysis 
into 8M urea in order to be analysed by SDS-PAGE, this was carried out at 1 ml 
in 11. 
Addition of 2M and 4M NaCl to 8M urea for solubilisation 
Solubilisation buffers were prepared of 2M and 4M NaCl with 8M urea, 20 mM 
Tris-HCI pH 8.0 solubilisation buffer. DTT was added to where stated. The 
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solubilisation of 1g of inclusion bodies was carried out overnight at room 
temperature with agitation; all following steps were as above. 
SDS-PAGE analysis of reduced and oxidised forms of IFN-a2b 
Analysis by SDS-PAGE of the samples obtained after solubilisation indicated the 
presence of a protein between the molecular weights of 37-25 kDa. As IFN-a2b 
has been found to run at a molecular weight of 15 kDa this band could signify 
dimer formation. To confirm this and discover if any further purifications steps 
were required, DTT was added at a final concentration of 50 mM. lodoacetamide 
(ICH2CO2NH2), an alkylating agent was then added to a final concentration of 5 
mM (Creighton, 1978) in order to block the cysteine residues. 
The oxidation of IFN-a2b was carried out by the addition of copper sulphate to a 
final concentration of 0.1 mM and phenanthroline at 0.5 mM to the original DTT 
reduced sample. This sample was left to incubate overnight and then analysed 
by SDS-PAGE. For this sample a non- reducing sample buffer was used at a 
ratio of 1: 1 with the sample. 
2.11: Refolding 
2.11.1: Refolding with no purification 
The refolding was to be started simply based on a dilution and dialysis method. 
The formation of the disulphide bonds was to be encouraged by the addition of 
oxidised glutathione at a final concentration of 0.1 mM. 
Refolding at 4 °C and 24 °C 
The initial refolding experiments were carried out at both 4 °C and 24 °C with 
inclusion body samples solubilised in both 8M urea and 6M guanidine-HCI. The 
refold was as follows: 
"1 in 10 dilution into 20 mM Tris, 1 mM DU pH 8.0 
"3h incubation 
9 Addition of 0.1 mM oxidised glutathione 
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"4h incubation 
Dialysis into 20 mM Tris-HCI pH 8.0 
The final samples from these four refolding experiments were analysed by far UV 
CD, fluorescence and SDS-PAGE. 
Refolding with longer oxidised glutathione incubation time from both 8M 
urea or 6M guanidine-HCI solubilised inclusion bodies 
These refolding experiments were carried out on four different samples in four 
different solubilisation buffers. The four conditions were 6M guanidine-HCI, 20 
mM Tris-HCI pH 8.0,6 M guanidine-HCI, 20 mM Tris-HCI, 1 mM DTT pH 8.0,8 M 
urea, 20 mM Tris-HCI pH 8.0 and 6M urea, 20 mM Tris-HCI, 1 mM DTT pH 8.0. 
The refold was carried out as stated above but with a 16 h incubation time with 
oxidised glutathione. 
Standard denaturation 
Freeze thaw 
The standard was diluted to 0.1 mg/ml and the fluorescence measured on 
excitation at 280 nm. This same sample was frozen overnight and the 
fluorescence under the same conditions measured. This was repeated with this 
same sample 5 times to indicated any change in fluorescence of the standard on 
freeze thawing. 
Denaturation of the standard with DTT and heat 
The standard was diluted to a concentration of 0.1 mg/ml in 6M guanidine-HCI, 
20 mM Tris-HCI pH 8.0. The sample was mixed thoroughly using a vortex and 
left at room temperature for 1 h. DTT was then added to the sample at a final 
concentration of 50 mM. This sample mixed thoroughly and left at room 
temperature for 2 h. The fluorescence was measured. Finally the sample was 
heated to 95 °C for 15 minutes. The fluorescence was measured. 
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2.11.2: Refolding after gel filtration 
Initial refolding straight in 20 mM Tris-HCI 
A sample of the guanidine-HCI solubilised inclusion bodies was dialysed straight 
into 20 mM Tris-HCI pH 8.0 at 4 °C. This was not successful previously but with 
the removal of contamination it may give a more positive result. 
Refolding after gel filtration in three steps. 
The refolding is based on a1 in 10 dilution under reducing conditions followed by 
two dialysis steps, the first under reducing conditions and the second to remove 
the DTT. 
Solubilised inclusion bodies 
Denaturants 
6M Guanidine- 6M Guanidine-HCI, 8M urea, 20 8M urea, 20 mM 6M Guanidine-HCI, 20 mM 
HCI, 20 mM Tris- 20 mM Tris-HCI, 1 mM Tris-HCI Tris-HCI, 1 mM D Tris-HCI dialysed into 8M 
HCI pH 8.0 mM DTT pH 8.0 pH 8.0 pH 8.0 urea 20 mM Tris-HCI pH 
8.0 
Er . 
-41 Gel filtration to remove contamination 
I in 10 dilution into 20 mM Tris-HCI, 1 mM DTT pH 8.0 
Dialysis into 20 mM Tris-HCI, 1 mM DTT pH 8.0 
Addition of oxidised glutathione 
0.1 mm 1 mm O mm 
Dialysis into 20 mM Tris-HCI pH 8.0 
8M Guanidine-HCI, 20 mM Tris- 
HCI, 1 mM DTT dialysed into 8M 
urea 20 mM Tns-HCI, 1 mM DU 
pH 8.0 
Figure 2.5: Flowchart to illustrate the refolding of the samples after gel filtration. 
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Following the refolds the far and near UV CD were measured along with the 
intrinsic fluorescence, ANS binding and SDS-PAGE of the final samples. 
2.12: Functional assays 
Both the antiviral and the reporter gene assays were carried out at the National 
Institute for Biological Standards and Control (NIBSC, Potters Bar, Herts, UK). 
The IFN-a2b reference standard 95/566 and all reagents were all provided by 
NIBSC. An aliquot of the Cobra Biomanufacturing reference standard was taken 
frozen on dry ice, along with the refolded samples. Each refolded sample was 
divided into two; one was kept in 20 mM Tris-HCI pH 8.0 and the second was 
dialysed into phosphate buffered saline (PBS, 137 mM NaCl, 2.7 mM KCI, 4.3 
mM Na2HPO4,1.47 mM NaH2PO4 pH 7.4). 
Antiviral assay 
The cell lines tested were 2D9 and A549 (PBS samples only). Both the Tris-HCI 
and PBS samples were tested on the 2D9 cells. The cell lines were trypsinised 
and resuspended as single cell suspensions at 5x 105 cells per ml of growth 
medium Roswell Park Memorial Institute (RPMI) 1640 (Moore and Woods, 1976) 
supplemented with penicillin and streptomycin to prevent contamination, L- 
glutamine at 300 mg/l, 6% fetal calf serum, trypsin versene, sodium pyruvate. 
The cells were seeded onto a 96 well plate and incubated for 24 h at 37 °C. 
Serial dilutions of the samples were carried out in the growth medium and then 
transferred to the plates in duplicate. The plates were incubated for 24 h at 37 
°C. Following the incubation the medium was replaced by medium containing 2 
% fetal calf serum containing encephalomyocarditis virus (EMCV). The plates 
were incubated for 24 h at 37 °C. 
Staining was carried out by washing the plates with PBS with added Ca 2+ and 
Mg 2+ and then addition of 0.05 % naphthol blue. The stain was left for 25 minutes 
and then removed. A fixative was added to the wells consisting of 10 % formalin, 
0.1 M sodium acetate and 9% acetic acid solution. This was left for 2-5 minutes 
and removed by washing with water. The plates were left to dry for 3h at 37 °C. 
The stain was eluted using 0.1 M sodium hydroxide and the plates read at 630 
nm. 
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Plate setup of the antiviral assays 
B 
C 
D 
E 
F 
G 
u 
B 
C 
D 
E 
F 
G 
u 
Plate I 
123456789 10 11 12 
CC Std Std CStd CStd Gla Gla Gib Gib G2a G2a vc 
vc cc I 
23456789 10 11 12 
Plate 2 
1 
CC G2b G2b Std Std UI UI U2 U2 UF UF uC 
vc cc 
Figure 2.6: Plate set up of the antiviral assay carried out on refolded if samples. 
CC = Cell control, cells only no IFN-a2b or virus. CV = Virus control, cells and virus only. 
The sample layout can be seen along the top row. The samples were diluted 2 fold 
towards the bottom of the plate. For abbreviations see table 2.5. 
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Starting 
Sample Abbreviation 
Concentration 
The international standard for human IFN-a2b, 95/566, 
31.25 pg/ml 
with an assigned potency of 70,000 international units Std 
(IU) per ampoule. 
Cobra Biomanufacturing provided standard 24 pg/mi CStd 
Sample solubilised in guanidine-HCI and refolded 24 pg/ml Gla 
Sample solubilised in guanidine-HCI and refolded 240 pg/ml G1 b 
Sample solubilised in guanidine-HCI and dialysed into 
33 pg/mi G2a 
urea and refolded 
solubilised in guanidine-HCI and dialysed into urea and 
330 pg/ml G2b 
refolded 
Sample solubilised in urea and refolded 5.3 ng/mi U1 
Sample solubilised in urea 1 mM DTT and refolded 8.9 ng/ml U2 
Sample solubilised in urea and attempted to be 0.39 pg/ml UF 
refolded (unfolded sample) 
Table 2.5: Concentrations of the samples used for the antiviral assay. 
Reporter gene assay 
Investigation of the protein inducing activity of the IFN-a2b. This experiment was 
only carried out on the PBS samples. The cell line used was a transfected 
(Human embryonic kidney cell line) HEK 293 cell line harbouring a secreted 
alkaline phosphatase cDNA linked to the IRES promoter. Cells were seeded in a 
96 well microtitre plate at 2x 104 cells/ml in 0.1 ml colourless Dulbecco's modified 
Eagle's medium (DMEM) growth medium, and incubated for 24 h at 37 °C. After 
incubation, serial dilutions of the IFN-a2b samples were made on a separate 
plate and then transferred onto the assay plate. These plates were then 
incubated for 48 h at 37 °C. The 0.05 ml p-nitophenyl phosphate (pNPP) 
substrate (1 mg/ml in 10% ethanolamine buffer pH 9.8) was added to the plates 
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and they were centrifuged to remove any bubbles. The plates were left for 20 
minutes and then read at 405 nm using an ELISA reader. 
A 
B 
C 
D 
E 
F 
G 
N 
B 
C 
D 
E 
F 
G 
Plate setup of the reporter gene assays 
Plate I 
123456789 10 11 12 
Std Std CStd CStd Gla G1a Gib Gib G2a G2a G2b G2b 
Control 
Plate 2 
123456789 10 11 12 
UI UI U2 U2 Std Std UF UF CStd CStd Blank Blank 
Control 
Figure 2.7: Plate set up of the reporter gene assay carried out on refolded if 
samples. The sample layout can be seen along the top row. The samples were diluted 
2 fold towards the bottom of the plate. 
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Starting 
Sample Abbreviation 
Concentration 
The international standard for human IFN-a2b, 95/566, 
with an assigned potency of 70,000 international units 0.1 ng/ml Std 
(IU) per ampoule. 
Cobra Biomanufacturing provided standard 4.8 ng/ml CStd 
Sample solubilised in guanidine-HCI and refolded 24 ng/ml G1a 
Sample solubilised in guanidine-HCI and refolded 2.4 ng/ml G1 b 
Sample solubilised in guanidine-HCI and dialysed into 
33 ng/ml G2a 
urea and refolded 
solubilised in guanidine-HCI and dialysed into urea and 3.3 ng/ml G2b 
refolded 
Sample solubilised in urea and refolded 530 ng/ml U1 
Sample solubilised in urea 1 mM DTT and refolded 890 ng/ml U2 
Sample solubilised in urea and attempted to be 3.5 pg/ml UF 
refolded (unfolded sample) 
Table 2.6: Concentrations of the samples used for the reporter gene assay. 
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Chapter 3 
Chapter 3 
Biophysical characterisation of the Cobra IFN-a2b reference 
standard 
3.1: Introduction 
In order to analyse the refolded material expressed and refolded during this 
project it was advantageous to investigate the IFN-a2b standard that Cobra 
Biomanufacturing use for their analysis. This IFN-a2b was provided by Cobra 
at a total protein concentration of 8.47 mg/ml as EP interferon 
(CTL2003#1010M). As Cobra do not have access to circular dichroism (CD) 
and fluorescence equipment it seemed appropriate that in-depth unfolding 
characterisation of the IFN-a2b standard should be carried out. This provided 
an understanding of how this molecule behaved in solution natively and non- 
natively but also provided experience using the techniques which will became 
useful tools during the further work. The far and near UV CD provided a 
fingerprint for the IFN-a2b molecule along with the intrinsic fluorescence, to 
which future refolded IFN-a2b was compared. 
Unfolding of IFN-a2b was investigated using both guanidine-HCI and urea, 
both well utilised denaturants capable of non-covalently disrupting protein 
structure (Greene and Pace, 1974). Following the methods by Pace and 
Scholtz, (1997) the free energy (LG) of unfolding was calculated providing 
information on the stability of IFN-a2b. Along with guanidine-HCI and urea 
denaturation by DTT was investigated. IFN-a2b contains two disulphide 
bonds and they may be important in the molecule's stability and crucial to 
unfolding or more importantly refolding. The unfolding using the two 
denaturants was monitored by far and near UV CD analysis but also by 
intrinsic fluorescence and 8-Anilino-1-naphthalenesulphonate (ANS) binding 
(Semisotnov et al., 1987). These are all good sensitive biophysical indicators 
of the presence of both secondary and tertiary structure. 
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The far UV CD spectra provided information on the secondary structure 
present in IFN-a2b. As IFN-a2b is made up of five alpha helices then strong 
signals at 208 and 220 nm were expected and consequently observed. The 
intrinsic fluorescence can provide information on the environments of the 
aromatic residues present in IFN-a2b particularly focusing on tryptophan and 
tyrosine, these results supported by the near UV CD analysis. As discussed 
in chapter 2, section 2.7, ANS binds to exposed hydrophobic regions of 
proteins (Stryer, 1965). This fluorescent probe confirmed any molten globule 
structure present in IFN-a2b during the unfolding. 
3.2: Results 
3.2.1: Far and near UV CD analysis of the IFN-a2b standard 
The IFN-a2b standard was analysed in the far (190-250 nm) and near (250- 
320 nm) UV region. 
Far and near UV CD of the natively folded IFN-a2b standard 
To investigate the IFN-a2b standard the protein was diluted to 0.5 mg/ml and 
dialysed overnight into 0.2 M phosphate, 0.1 M sodium chloride pH 7.0. The 
far UV measurements were carried out using a 0.02 cm pathlength 
demountable cuvette and the near UV analysis carried out in a1 cm 
pathlength low volume (150 µl) cuvette. Measurements were carried out at 20 
°C and were an average of 10 accumulations. 
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Figure 3.1: The far UV CD spectrum of natively folded IFN-a2b. The far UV CD 
of IFN-a2b shows an alpha helical structure with negative peak intensities at 222 nm 
and 208 nm. Sample concentration was 0.5 mg/ml in 0.2M phosphate, 0.1 M sodium 
chloride pH 7.0 at 20 °C, the result is an average of 10 accumulations. 
The far UV CD of the IFN-a2b standard shown in figure 3.1 is a characteristic 
alpha helical spectrum. The negative intensities seen at 208 nm and 222 nm 
are exactly what would be expected from a protein consisting of mainly alpha 
helical structure, confirming structural data found by Radhakrishnan et al., 
(1996). This spectrum shall act as a good reference for all future work. It is 
assumed that the IFN-a2b standard received from Cobra is natively folded. 
Units of 1c are M-1 cm-' 1-' . 
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Figure 3.2: The near UV CD spectrum of natively folded IFN-a2b. The near UV 
CD of IFN-a2b shows two negative signals between 280 nm and 300 nm probably 
resulting from the two tryptophan residues present. The sample concentration was 
0.5 mg/ml in 0.2M phosphate, 0.1 M sodium chloride pH 7.0 at 20 °C, the result is an 
average of 10 accumulations. 
The near UV CD analysis in figure 3.2 displays a strong signal in the near UV 
region indicative of tertiary structure. The strong signals between 280 nm and 
300 nm are characteristic of tryptophan residues being in a fixed environment 
(Kelly et al., 2005). Between 275 and 282 nm the signals are due to the five 
tyrosine residues and between 255 and 270 nm the signals are from the 
phenylalanine residues (Kelly et al., 2005). 
Guanidine-HCI and urea treated IFN-a2b analysed by far and near UV 
CD. 
This analysis involved incubating the IFN-a2b standard in high concentrations 
of both guanidine-HCI and urea. From this the unfolded state of IFN -a2b 
should be obtained. The samples were incubated in the buffers; 5M 
guanidine-HCI, 0.2 M phosphate pH 7.0 and 7M urea, 0.2 M phosphate pH 
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7.0 for 16 hours at room temperature with constant agitation. Both the far and 
near UV CD were measured. 
0 
-2 / 
-3 / 
-4 
Folded IFN-u2b std 
-5 Folded IFN-u2b incubated with 7M urea 
Folded IFN-u2b incubated with 5M guanidine-HCI 
-6 
210 220 230 240 250 
Wavelength (nm) 
Figure 3.3: Far UV CD spectrum of the IFN-a2b standard in the presence of 7M 
urea and 5M guanidine-HCI. The guanidine-HO shows complete loss of 
secondary structure whereas structure still remains in the urea sample. The intensity 
of the urea sample has decreased which may be due to a concentration difference. 
Sample concentrations were 0.5 mg/ml and the measurements were taken at 20 °C. 
Due to the absorptive properties of guanidine-HCI and urea the data collected ends 
at around 208 nm. 
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Figure 3.4: Near UV CD spectrum of the IFN-a2b standard in the presence of 7 
M urea and 5M guanidine-HCI. The guanidine-HCI shows complete loss of tertiary 
structure whereas structure still remains in the urea sample but as with the far UV the 
intensity has decreased. The sample concentrations were 0.5 mg/ml and the 
measurements were carried out at 20 °C. 
The CD studies of the folded IFN-a2b in the presence of high concentrations 
of urea and guanidine-HCI show that 7M urea is incapable of denaturing the 
IFN-a2b structure. On addition of guanidine-HCI, both the far (figure 3.3) and 
near UV (figure 3.4) CD shows the complete loss of both tertiary and 
secondary structure. This is of great importance, both to these experiments 
but also to Cobra, the IFN-a2b appears to behave differently in two very 
powerful denaturing agents but also highlights the stability of the IFN-a2b 
molecule when folded. The far UV CD data is affected by the absorptive 
properties of both guanidine-HCI and urea this results in 600 volts being 
exceeded leaving only data above 208 nm being presented. 
Far and near UV analysis of the IFN-a2b standard with DTT 
IFN-a2b has two disulphide bonds so the addition of DTT to the folded IFN- 
a2b will establish, if any, whether reduced cysteine residues have a 
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destabilising effect on the IFN-a2b molecule. DTT was added at a final 
concentration of 5 mM and the sample incubated overnight with constant 
agitation. The far and near UV CD was measured. 
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Figure 3.5: Far UV CD of IFN-a2b after addition of 5 mM DTT. The spectrum 
shows a decrease in the intensities at 208 nm and 222 nm. The helical secondary 
structure is reduced but is not entirely lost. 
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Figure 3.6: Near UV analysis of the folded IFN-a2b standard with 5 mM DTT. 
The tertiary structure signal is reduced when the disulphides are broken. 
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The addition of DTT to the folded IFN-a2b standard does have an effect on 
the protein's secondary (figure 3.5) and tertiary structure (figure 3.6). The 
results suggest that the protein remains largely folded even when the 
disulphides are broken. This implies that the disulphides are not required for 
the folded conformation of IFN-a2b, but may stabilise the native state. 
3.2.3: Intrinsic fluorescence of the IFN-a2b standard 
As well as CD analysis intrinsic fluorescence was used to analyse these 
treated IFN-a2b samples. The results from the intrinsic fluorescence will 
hopefully support the near UV results as they are both based on aromatic 
residues and their environment. Fluorescence is a very sensitive technique 
which does not require the high protein concentrations needed for CD 
analysis. 
Intrinsic fluorescence of the IFN-a2b standard on addition of DTT 
The fluorescence emission of IFN-a2b was measured after excitation at 280 
nm, thereby selecting for both tryptophan and tyrosine emission of which 
there are two and five residues respectively. The sample concentration for 
fluorescence analysis was 0.1 mg/ml measured in a5 mm cuvette at 20 °C 
and the DTT was added to a final concentration of 5 mM. Incubation times 
were recorded from immediate addition, after 1h and after overnight 
incubation (ON). 
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Figure 3.7: Intrinsic fluorescence of the folded IFN-a2b standard in the 
presence of 5 mM DTT. The fluorescence shows a small shift to the longer 
wavelengths when the DTT has been added and left to incubate overnight (ON). 
DTT added straight away (sa), DTT added and incubation for 1 hour (1h). 
Sample 
Barycentric 
mean (nm) 
IFN-a2b standard 340.02 
IFN-a2b standard + DTT sa 340.58 
IFN-a2b standard + DTT 1h 340.82 
IFN-a2b standard + DTT ON 340.96 
Table 3.1: Table of values of the barycentric mean of the IFN-a2b standard on 
addition of 5 mM DTT for increasing incubation time. There is no difference to 
the fluorescence emission on addition of DTT. Measured between 306 and 380 nm. 
The fluorescence analysis shown in figure 3.7 shows tryptophan emission. 
Tryptophan in water emits at 348 nm (Lakowicz, 1983). When subjected to 
hydrophobic environments this value shifts to the shorter wavelengths. The 
IFN-a2b folded standard, without any additives emits at 340.02 nm (calculated 
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between 306 and 380 nm, see table 3.1). This illustrates the two tryptophan 
residues in IFN-a2b are within a hydrophobic environment. Once DTT is 
added the results support the near UV analysis in figure 3.6. Both the near 
UV CD and the intrinsic fluorescence show that the tertiary structure or more 
specifically, the environment of the aromatic residues, mainly tryptophan, 
remains unchanged when the disulphides are broken. The barycentric mean 
changes by -1 nm which does not indicate unfolding of the IFN-a2b molecule 
and exposure of the two tryptophan residues to a more polar environment. 
Intrinsic fluorescence of the IFN-a2b in high concentrations of urea and 
guanidine-HCI should be carried out to help support these findings. This will 
also provide a barycentric mean for the unfolded IFN-a2b. 
Intrinsic fluorescence analysis of the IFN-a2b standard after incubation 
with guanidine-HCI and urea. 
These experiments were carried out under the same conditions as in section 
3.2. The measurements were taken on immediate addition of the denaturant 
(sa), after 1 hour and after overnight incubation (ON) with agitation. The final 
concentrations of denaturants were 5M guanidine-HCI and 7M urea. 
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Figure 3.8: Fluorescence analysis of the unfolding of the IFN-a2b, in the 
presence of guanidine-HCI. The guanidine-HCI was added to the IFN-a2b 
standard and was measured sa = straight away (black dashed line), after 1 hour (red 
line) and ON = overnight (green line). The fluorescence intensity decreases on 
immediate addition of the guanidine-HCI and further reduction in intensity is seen 
after overnight incubation. 
On addition of 5M guanidine-HCI to the IFN-a2b standard there is a decrease 
in the fluorescence intensity see figure 3.8. Once the sample has been 
incubated overnight the intensity decreases again. There is a very small shift 
to the longer wavelengths indicating that some unfolding is taking place within 
the molecule but much less than expected from the far UV and near UV CD 
data. 
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Figure 3.9: Unfolding of IFN-a2b on addition of 5M guanidine-HCI followed by 
5 mM DTT analysed by intrinsic fluorescence. The fluorescence results 
demonstrate a decrease in intensity on addition of guanidine-HCI with increasing 
incubation time with the 5 mM DTT indicating unfolding (sa = straight away, ON = 
overnight incubation). 
When DTT is added to the IFN-a2b alongside the guanidine-HCI a more 
definitive unfolding pattern is seen (figure 3.9). The fluorescence intensity 
decreases and a red shift in the emission is observed with increasing 
incubation time. 
Sample Barycentric mean (nm) 
Folded IFN-a2b 341.39 
Folded IFN-a2b +5M guanidine-HCI straight away 341.15 
Folded IFN-a2b +5M guanidine-HCI 1h 341.25 
Folded IFN-a2b +5M guanidine-HCI overnight 341.58 
Folded IFN-a2b +5M guanidine-HCI +5 mM DTT straight away 341.58 
Folded IFN-a2b +5M guanidine-HCI +5 mM DTT 1h 343.93 
Folded IFN-a2b +5M guanidine-HCI +5 mM DTT 2h 343.78 
Folded IFN-a2b +5M guanidine-HCI +5 mM DTT overnight 343.54 
Table 3.2: Barycentric means from the unfolding of IFN-a2b with guanidine- 
HCl and DTT. Increase in the Barycentric mean on addition of DTT alongside 
guanidine-HCI suggests unfolding. Measured between 306 and 380 nm. 
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The barycentric means listed in table 3.2 show very little difference in the 
fluorescence emission when guanidine-HCI is added to the IFN-a2b. This is 
surprising as the far UV shows complete loss of secondary structure on 
addition of guanidine-HCI which should lead to exposure of the aromatic 
residues. When DTT is added to the molecule a change in the fluorescence 
spectra is observed. The intensity is reduced and the barycentric mean, after 
overnight incubation shifts from 341.58 nm to 343.54 nm. The same 
experiment was carried out with 7M urea. 
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Figure 3.10: Fluorescence analysis of the unfolding of the IFN-a2b, in the 
presence of urea. The urea was added to the IFN-a2b standard and was measured 
immediately (sa), after 1 hour and left overnight (ON). The fluorescence intensity 
decreases on addition of the urea however does not further reduce with increasing 
incubation time. 
Figure 3.10 shows the fluorescence intensity of the IFN-a2b incubated with 
urea. There is a small decrease in intensity on immediate addition of urea. 
The intensity does not change after incubation for 1 hour or overnight. This 
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supports the far and near UV data of urea's inability to successfully denature 
the IFN-a2b 
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Figure 3.11: Unfolding of IFN-a2b on addition of 7M urea followed by 5 mM 
DTT analysed by intrinsic fluorescence. The fluorescence results demonstrates 
the small decrease in intensity on addition of urea, but with increasing incubation 
time with the 5 mM more unfolding takes place DTT (sa = straight away, ON = 
overnight incubation). 
Sample Barycentric mean (nm) 
Folded IFN-a2b 341.39 
Folded IFN-a2b + urea straight away 341.70 
Folded IFN-a2b + urea 1h 341.56 
Folded IFN-a2b + urea overnight 341.62 
Folded IFN-a2b + urea +DTT straight away 342.97 
Folded IFN-a2b + urea +DTT 1h 344.15 
Folded IFN-a2b + urea +DTT 2h 344.07 
Folded IFN-a2b + urea +DTT overnight 344.70 
Table 3.3: Barycentric means of the unfolding of the IFN-ar2b with urea and 
DTT. With the addition of DTT alongside the urea some unfolding is achieved due to 
the increase in barycentric mean. Measured between 306 and 380 nm. 
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The fluorescence results on addition of urea show little difference in the 
emission spectrum when urea solely is added to the IFN-a2b. On addition of 
DTT a similar relationship to that of the guanidine-HCI treated IFN-a2b is 
observed where with increasing incubation time the more unfolding takes 
place. 
The final barycentric mean (table 3.3) of the 7M urea treated IFN left 
overnight with DTT was 344.70 nm which is longer than the guanidine-HCI 
overnight incubated IFN-a2b with DTT which gives 343.54 nm. This may 
indicate that 5M guanidine-HCI is not sufficient to completely denature the 
IFN or that the incubation time may not be long enough for the guanidine-HCI 
to disrupt the IFN-a2b structure. 
3.2.4: Urea and guanidine-HCI unfolding curves for IFN-a2b 
The IFN-a2b standard was subjected to unfolding by guanidine-HCI and urea 
to gain curves of concentration dependence that can be used to calculate 
OG(H20) and m of IFN-a2b. Unfolding curves can be determined using many 
techniques. Here only intrinsic fluorescence and far UV CD were 
investigated. The method relies on calculation of equilibrium constants at a 
range of denaturant concentrations for the reaction below 
Folded (F) Unfolded (U) (3.1) 
Calculation of the equilibrium constant enables the free energy (AG) of 
unfolding at each denaturant concentration to be obtained. By 
extrapolation not only can the free energy change for unfolding in the 
absence of denaturant termed AG(H20)can be achieved but also m, the 
dependence of AG(H20)on denaturant concentration (Pace and Scholtz, 
1997). Co-operative unfolding curves consist of three regions; the pre 
transition region, the transition region and the post transition region. All 
curves were fitted in OriginTM using the Analysis: Fit Sigmoidal menu, 
which uses the Boltzmann equation for fitting: 
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y= 
Where 
Al -A, 
1 -. - F'' `-to }j' dt- 
+ A2 (3.2) 
xo = centre, dx = width, Al = initial Y value: A2 = final Y 
value: ti' +r" 
The Y value at Yo is half way between the two limiting values, therefore 
providing a mid point of unfolding. The fitting using a least squares 
procedure based on the Levenberg-Marquardt (LM) algorithm. The mid 
point shows the centre of the transitional region allowing data surrounding 
the mid point to be used to calculate the free energy of unfolding. 
Unfolding of IFN-a2b with guanidine-HCI analysed by intrinsic 
fluorescence 
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Figure 3.12: Unfolding curve of IFN-a2b with guanidine-HCI monitored by 
intrinsic fluorescence. The curve shows co-operative unfolding of the IFN-a2b 
molecule with the addition of guanidine-HCI. The transition region is used to 
calculate the free energy of unfolding and also the mid point. The mid-point was 
found to be 4.5 M. Curve fitted by OriginTM using a Boltzmann function. 
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The unfolding curve of the IFN-a2b standard can be seen in figure 3.12 where 
intrinsic fluorescence was used for the analysis. The mid point of unfolding 
was found to be 4.5 M. A refractometer was used for determination of the 
stock guanidine-HCI and urea solutions to ensure accuracy throughout these 
experiments (Pace and Scholtz, 1997). The three different regions of the 
curve are labelled illustrating a two state transition of IFN-a2b from the folded 
to the unfolded. 
To calculate tG(H2O) and m the unfolding has to be reversible. Samples 
from the experiment carried out in figure 3.12 were diluted down to specific 
guanidine-HCI concentrations and left for 16 hours and measured a second 
time. The dilution should enable the samples to begin refolding showing 
reversibility. 
Original samples Diluted samples 
Guanidine-HCI 
concentration (M) 
Barycentric 
mean (nm) 
Guanidine-HCI 
concentration 
Barycentric 
mean (nm) 
2 341 1 342 
2.5 341 1.25 342 
3 341 1.5 342 
4.1 342 2.1 342 
4.9 348 3.3 343 
5.5 348 3.7 347 
6.5 348 4.3 348 
Table 3.4: Samples in 6M guanidine-HCI diluted to ensure reversibility. The 
reduction in the barycentric mean of samples where the guanidine-HCI has been 
diluted down show reformation of structure and therefore confirmation that the 
unfolding reaction with guanidine-HCI is reversible. 
The results from the diluted samples shown in table 3.4 confirm that the 
unfolding process of IFN is reversible. The calculation of LiG(H20) and m can 
be calculated by firstly determining the equilibrium constant for a range of 
denaturant concentrations in the transition region; 
K= (YF - Y)/ (Y - Yu) (3.3) 
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Where yF is the value of the folded protein and yu is the value of the unfolded 
protein, y is the data at that specific guanidine-HCI concentration. Once K 
has been calculated this can then be incorporated into the calculation for the 
free energy; 
OG = -RT InK (3.4) 
R is the gas constant (1.98 cal/K/moI), T is the temperature in Kelvin, 298. K 
is the equilibrium constant. 
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Figure 3.13: Relationship between AG and guanidine-HCI concentration using 
intrinsic fluorescence data. This data was used to calculate dG(H2O) (y intercept) 
and m (gradient of the line). LG(H20) was found to be 13.50 kcal/mol ± 0.97 and m 
was 3.01 kcal/mol/M. 
The data from the unfolding experiment was used to calculate iG which could 
then be used to calculate 1\G(H20) and m for the folded state, see figure 3.13. 
LiG(H20) was found to be 13.50 kcal/mol ± 0.97 and m was 3.01 kcal/mol/M. 
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Unfolding of IFN-a2b with guanidine-HCI analysed by far UV CD 
The previous experiment investigated the unfolding of IFN-a2b by intrinsic 
fluorescence, in this experiment the unfolding was monitored by a decrease in 
secondary structure at 223 nm. 
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Figure 3.14: Unfolding curve of the IFN-a2b standard using an increasing 
range of guanidine-HCI concentrations followed at 223 nm. The mid point of 
unfolding was found to be 4 M. Curve fitted by OriginTM using a Boltzmann function. 
The mid point using far UV CD (figure 3.14) was found to be 4M lower than 
the midpoint of 4.6 M found using intrinsic fluorescence. This data was used 
to calculate OG(H2O) and m of unfolding as with the intrinsic fluorescence 
results. 
AG(H20) was found to be 5.90 kcal/mol ± 3.62 and m was 1.49 kcal/mol/M. 
The value for AG(H20) was found to be lower that the value for the intrinsic 
fluorescence however the data from the intrinsic fluorescence experiment are 
less noisy than that of the CD data. 
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Unfolding curves using guanidine-HCI and 5 mM DTT 
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Figure 3.15: Unfolding curve of the IFN-a2b standard using guanidine-HCI with 
1 mM DTT monitored by far UV CD. The decrease in secondary structure was 
followed at 223 nm. The mid point at 3.7 M was found to be lower than with 
guanidine-HC alone. Curve fitted by OriginTM using a Boltzmann function. 
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Figure 3.16: Unfolding curve of the IFN-a2b standard using guanidine-HCI with 
1 mM DTT monitored by intrinsic fluorescence. The mid point at 2.6 M was found 
to be lower than with guanidine-HCI alone and guanidine with 1 mM DTT followed at 
223 nm. Curve fitted by OriginTM using a Boltzmann function. 
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The unfolding curves in figures 3.15 and 3.16 show the unfolding of IFN-a2b 
in the presence of guanidine-HCI and 5 mM DTT. The curves do not give as 
well defined co-operative unfolding as the guanidine-HCI only. This is 
probably due to the destabilising effect the DTT has on the IFN-a2b structure. 
The intrinsic fluorescence gives a mid-point of 2.6 M and the CD gives a mid- 
point of 3.7 M. 
Unfolding of IFN-a2b with urea 
The initial unfolding of IFN-a2b using urea does not appear to yield unfolded 
IFN-a2b. The unfolding curves were carried out in case any co operative 
unfolding takes place. 
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Figure 3.17: Unfolding curve of the lFN-ar2b standard using urea followed at 
223 nm. The linear trend indicates little co-operative unfolding. It does show that the 
amount of secondary structure does however decrease in the presence of increasing 
urea concentrations. 
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Figure 3.18: Unfolding curve of the IFN-a2b standard using urea followed by 
fluorescence. As with the CD results some unfolding of the IFN-a2b takes place 
however it is not co-operative due to the linear relationship observed. 
The unfolding of the IFN-a2b using only urea shown in both figures 3.17 and 
3.18 show no indication of cooperative unfolding. The initial unfolding 
experiments also showed that urea alone was not capable of denaturing the 
IFN-a2b. 
Unfolding of IFN-a2b with urea and 5 mM DTT 
As the initial unfolding experiments with urea indicated no unfolding, an 
unfolding curve was obtained in the presence of DTT as that did allow some 
unfolding (figure 3.11). This experiment will show whether this unfolding is 
cooperative as with the guanidine experiments. 
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Figure 3.19: Unfolding curve of the IFN-a2b standard using urea with 1 mM 
DTT followed by far UV CD at 223 nm. The linear relation ship indicates no co- 
operative unfolding. 
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Figure 3.20: Unfolding curve of the IFN-a2b standard using urea with 1 mM 
DTT measured using intrinsic fluorescence. The use of both urea and DTT has 
little effect on the IFN-a2b again showing no co-operative unfolding. 
The unfolding of IFN with urea and DTT shown in figures 3.19 and 3.20 do not 
show any co operative unfolding. To the urea with 5 mM DTT samples3-[(3- 
Cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS); a 
detergent was added. This would hopefully penetrate the hydrophobic core of 
the IFN-a2b inducing more co-operative unfolding. 
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Figure 3.21: Unfolding of the IFN-a2b standard with urea and CHAPS. The 
CHAPS was added to disrupt the hydrophobic core of the protein to enable unfolding 
to take place by the urea. The result was the same as the previous results for urea in 
that the IFN-a2b still does not unfold co-operatively. 
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The CHAPS was added to the IFN-a2b standard to disrupt the hydrophobic 
core of the protein in order to initiate the cooperative unfolding of the IFN-a2b 
molecule. From the results shown in figure 3.21 this has not worked. The 
unfolding of the IFN-a2b at high concentrations of urea still provides a linear 
relationship. The secondary structure in the presence of CHAPS does 
however appear to be reduced. 
3.2.5: Thermal unfolding of the IFN-a2b standard 
Thermal unfolding of the IFN-a2b standard using far UV CD 
The Cobra IFN-a2b was also unfolded using temperature to gain a mid point 
of unfolding using a different method of denaturation. The IFN-a2b was 
heated up to 90 °C using the peltier in the CD machine at 1 °C/min and the 
reduction in secondary structure monitored at 223 nm. This unfolding was 
carried out a second time in the presence of 5 mM DTT. The fluorescence 
had shown that the IFN-a2b structure is still intact when the disulphides are 
broken; this experiment will illustrate how stable the molecule remains under 
reducing conditions. The thermal unfolding was initially carried out at pH 7.0 
however to investigate the stability of the IFN-a2b further pH 9.0 and 5.0 was 
analysed also. 
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Figure 3.22: Thermal unfolding curves of /FN-a2b standard monitored at 223 
nm at I °C/min at pH 7.0. The mid point of unfolding of the IFN-a2b standard is 70 
°C (black line). With the addition of DTT (red line) the mid point is 40 °C. This 
decrease in the mid point of unfolding indicates the breaking of the disulphides 
weakens the IFN-a2b structure. Curve fitted by OriginTM using a Boltzmann function. 
The unfolding of the IFN-a2b at pH 7.0 can be seen in figure 3.22. The mid 
point without DTT was found to be 70 °C and on addition of 5 mM DTT 40 °C. 
The decrease in temperature when DTT is added confirms that the reduced 
IFN-a2b is less stable. However; the shape of the curve is still sigmoidal 
suggesting that the molecule is still folded and unfolds cooperatively even 
when the disulphides are broken. The pH values of 9.0 and 5.0 were 
investigated with and without DTT and the results can be seen in figure 3.24. 
The far UV CD of the IFN at the three different pH values can be seen in 
figure 3.23, this was to ensure the secondary structure of the IFN-a2b was still 
intact. 
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Figure 3.23: Far UV CD of IFN at pH 7.0,9.0 and 5.0. The analysis shows that at 
pH 9.0 and 5.0 the secondary structure is still intact. 
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Figure 3.24: Thermal unfolding of the IFN-a2b standard at pH 5.0 and pH 9.0 
with and without DTT. The Tm for both pH values decreases on addition of DTT as 
with pH 7.0 and co-operative unfolding can still be seen. Curve fitted by OriginTM 
using a Boltzmann function. 
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The temperature at which 50 % of the molecules are unfolded can be 
calculated by two methods the first by the Jasco software and the second by 
importing the data into the statistical software Origin TM which uses a 
Boltzmann function to fit a sigmoidal curve. 
Method 
pH Origin TM Jasco 
7.0 70 70 
7.0 + DTT 40 38 
5.0 70 70 
5.0 + DTT 41 39 
9.0 68 67 
9.0 + DTT 44 49 
Table 3.5: Table of mid-points of unfolding from thermal unfolding of the IFN- 
alb with and without DTT at three pH values. The mid-points at pH 7.0,9.0 and 
5.0 are between 67-70 °C. On addition of DTT the three pH values give mid points of 
unfolding are between 38-49 T. Measured by both the Jasco CD software and 
Origin TM 
The mid-points of unfolding at the three pH values measured by two different 
methods can be seen in table 3.5. The samples without DTT all have mid- 
points around 70 °C. On addition of DTT the mid-points decrease to around 
38-49 °C. This demonstrates the stability of IFN-a2b. All show cooperative 
unfolding by the sigmoidal shaped curves. On addition of the DTT the mid- 
points decrease but again at all three pH values cooperative unfolding is 
seen. This indicates that when the disulphides are broken the alpha helical 
bundle does not unfold. This supports the CD and fluorescence data and may 
prove useful when devising a refolding protocol for IFN-a2b. 
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Figure 3.25: Illustration of the decrease in alpha helical structure of IFN-a2b on 
heating at pH 7.0. 
Figure 3.25 illustrates the unfolding of IFN-a2b during the thermal melt 
monitored at 223 nm. Every 5 °C a far UV spectrum was measured. The 
unfolding shows the decrease in the alpha helical structure and an increase in 
the ß structure also reported by Beldarrain et al. (2001) at pH 7.0 with heating 
and Luykx, et al. (2005) who observed it by the addition of increasing 
concentrations of acetonitrile. 
Thermal unfolding measured by intrinsic fluorescence 
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Figure 3.26: Thermal unfolding of IFN-a2b monitored by intrinsic fluorescence. 
The data shows co operative unfolding and gives a Tm of 68 °C. Curve fitted by 
OriginTM using a Boltzmann function. 
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The thermal unfolding followed by intrinsic fluorescence supports the previous 
thermal unfolding with a mid point being reached of 68 °C. 
0.0004 
0.0002 
0.0000 
U 
co U 
ä -0.0002 
0 
-0.0004 
-0.0006 
Temperature (°C) 
Second attempt 0.1 mg/ml 
First attempt 0.5 mg/ml 
Figure 3.27: DSC results of IFN-a2b heated to 90 °C at 0.5 mg/ml and 0.1 
mg/ml. The DSC result for 0.5 mg/ml shows precipitation of the IFN-a2b. The 
reduced concentration of 0.1 mg/ml does not allow determination of a Tm. 
The DSC results were reproducibly unsuccessful and therefore not used for 
any analysis on the stability of IFN-a2b. The results shown in figure 3.27 
show the precipitation of the IFN-a2b at temperatures above 80 °C which led 
to the decrease in total protein concentration from 0.5 mg/ml (red line) to 0.1 
mg/ml (black line), the spectra collected however did not provide good enough 
results to be used. The DSC technique was not used any further for any 
analysis of the refolded material. 
3.2.6: ANS binding of the IFN-a2b standard 
1-anilinonaphthalene-8-sulfonic acid (ANS) is a fluorescent probe capable of 
non-covalently binding to exposed hydrophobic regions on protein molecules. 
ANS is barely fluorescent when free in solution, once bound to a protein the 
fluorescence increases. In these experiments ANS was used to investigate 
the folded and unfolded forms of IFN-a2b. 
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ANS binding of native IFN-a2b with DTT 
As with the previous analysis the natively folded IFN-a2b was subjected to 
ANS binding followed by addition of DTT. The results can be seen in figure 
3.28. 
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Figure 3.28: ANS fluorescence of the folded IFN-a2b standard with and without 
DTT. Increase in the intensity and a shift to the shorter wavelengths. 
The data obtained from the IFN-a2b with and without DTT shows a large 
increase in ANS binding on addition of 5 mM DTT. This shows that the ANS 
has gained access to the hydrophobic core of the protein. The barycentric 
mean of the IFN-a2b standard was 511 nm and on addition of DTT 503 nm 
displaying a blue shift. This blue shift is indicative of ANS moving into a more 
hydrophobic environment. As with folded proteins their hydrophobic areas 
and not readily accessible to the ANS and so an emission at a longer 
wavelength is expected along with a decrease in intensity. 
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ANS binding on addition of guanidine-HCI to the IFN-a2b standard 
In this experiment guanidine-HCI to a final concentration of 5M was added to 
the IFN-a2b standard. ANS was added to this sample, the fluorescence 
measured and DTT added to a final concentration of 5 mM and the 
fluorescence measured again. 
Folded IFN-a2b 
Folded IFN-a2b +5M guanidine-HCI 
Folded IFN-alb +5M guanidine-HCI +5 mM DTT 
20 mM Tris pH 8.0 
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Figure 3.29: ANS binding of the IFN-a2b standard on addition of 5M 
guanidine-HCI followed by 5 mM DTT. The intensity decreases on addition of the 
guanidine-HCI illustrating the denaturing effects of the guanidine-HCI on the IFN-a2b 
standard. 
Sample 
Barycentric mean 
(nm) 
Folded IFN-a2b 511 
Folded IFN-a2b +5M guanidine-HCI 528 
Folded IFN-a2b +5M guanidine-HCI +5 mM DTT 518 
Table 3.6: Barycentric mean of the ANS binding of the folded IFN-a2b on 
addition of guanidine-HCI and DTT. Measured between 420 and 600 nm. 
98 
On addition of guanidine-HCI to the IFN-a2b standard the ANS fluorescence 
intensity drops and shifts to a longer wavelength (table 3.6), this illustrates 
shows the disruption of the hydrophobic core as the protein unfolds. This 
results in little ANS binding therefore a reduction in emission intensity, see 
figure 3.29. The blue shift of the guanidine-HCI sample when DTT is added is 
odd however with such a reduction in intensity unfolding has taken place and 
the barycentric mean does not shift to the same wavelength as the IFN-a2b 
standard. 
ANS binding on addition of urea to the IFN-a2b standard 
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Figure 3.30: ANS binding of the IFN-a2b standard on addition of urea. When 
Urea is added to the IFN-a2b a red shift is seen (red line) and a decrease in intensity. 
On addition of DTT (green line) the fluorescence shifts back to a shorter wavelength 
of 502 nm, the fluorescence intensity increases higher than the folded IFN-a2b (black 
dashed line). This indicates that the urea does not unfold the protein and on addition 
of DTT the hydrophobic areas of the protein are exposed and are able to bind ANS. 
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Sample 
Barycentric mean 
(nm) 
Folded IFN-a2b 511 
Folded IFN-a2b +7M urea 519 
Folded IFN-a2b +7M urea +5 mM DTT 502 
Table 3.7: Barvcentric mean of the ANS bindina o f the folded IFN-a2b o1 
addition of 7M urea followed by DTT. Measured between 420 and 600 nm. 
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The ANS results for the IFN-a2b on addition of urea are in some respects 
consistent with the guanidine-HCI results. When Urea is added to the IFN- 
a2b a red shift is seen and a decrease in intensity (figure 3.30). When DTT is 
added the fluorescence shifts back to a shorter wavelength of 502 nm (table 
3.7) which is shorter than the wavelength for the folded IFN-a2b, the 
fluorescence intensity increases higher than the folded IFN-a2b. This 
indicates that the urea does not unfold the protein and on addition of DTT the 
hydrophobic areas of the protein are exposed and can bind ANS. 
3.3: Conclusion 
The biophysical characterisation of the IFN-a2b standard provided by Cobra 
Biomanufacturing has highlighted some potentially useful properties and 
characteristics of the IFN-a2b molecule. These findings should improve the 
refolding of IFN-a2b. The strong CD features of the IFN-a2b in both the far 
and near UV regions shall be used as references during the refolding work. In 
the far UV region the IFN-a2b gives two strong signals at 208 and 220 nm 
indicating an alpha helical structure (Alder et al., 1973). In the near UV region 
there are strong tryptophan signals between 280 and 300 nm. The far and 
near UV CD results support structural data already published (Radhakrishnan 
et al., 1996). Leukocyte IFN A was investigated by CD in 1982 by Bewley et 
al., indicating both the alpha helical nature of IFN but also the near UV 
fingerprint of the IFN A molecule. 
It was clear that IFN-a2b reacted differently to the two denaturants guanidine- 
HCI and urea. Guanidine-HCI has proved to be the more efficient denaturant 
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whereas urea results in inconsistent results and unsuccessful denaturation. 
The far UV CD and intrinsic fluorescence analysis of unfolding with guanidine- 
HCI enabled the AG(H20) and m-value of unfolding to be calculated. The 
iG(H2O) is the stability of the native state of the protein in the absence of 
denaturant and the m-value is the dependence of LiG on the denaturant 
concentration. 
The values calculated were OG(H2O) = 13.50 kcal/mol ± 0.97 and m=3.01 
kcal/mol/M from the intrinsic fluorescence measurements and IXG(H20) = 5.9 
kcal/mol ± 3.6 and m=1.49 kcal/mol/M from the far UV CD measurements. 
The values for m are a measurement of the steepness of the transition 
between the native folded form and the unfolded. It would have been 
interesting to compare the values for m from the unfolding of IFN-a2b with and 
without DTT due to the lower Tm calculated. However, the results with the 
addition of DTT does not result in a two state transition required for his type of 
analysis. 
The addition of urea did not result in any denaturation according to the CD 
results. On addition of guanidine-HCI the fluorescence intensity decreased 
and the spectrum shifted to the longer wavelengths both indicators of 
unfolding. Urea showed this also but only when DTT was added alongside; 
the urea as alone was not enough. This suggested that the two disulphides 
had a stabilising effect on the IFN-a2b molecule. When DTT was added to 
both the guanidine-HCI and the urea treated samples the fluorescence did 
decrease and a red shift was observed. 
Thermal unfolding of IFN-a2b was carried out to investigate how stable the 
IFN-a2b was when subjected to increasing temperatures with and without 
DTT. The guanidine-HCI unfolding had shown a two state co-operative 
relationship when unfolding, would temperature show the same relationship? 
The results supported the guanidine-HCI unfolding. Thermal unfolding was 
measured over a range of 20 to 90 °C at 1 °C/min. The Tm at pH 7.0 was 
calculated to be 70 °C, three other pH values were investigated; pH 5.0 and 
9.0. The far UV CD suggested little effect of the pH extremes on the IFN-a2b 
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molecule. Beldarrain et al., (2001) also showed that IFN-a2b at pH 3.5 
showed little difference in structure in both the far and near UV region 
compared to pH 7.0. The Tm values at these two different pH values were 70 
°C for pH 5.0 and 68 °C for pH 9.0, calculated using Origin TM. The thermal 
unfolding was carried out at all three pH values with the addition of DTT, this 
showed co-operative unfolding but a lower Tm. The Tm values were 40 °C for 
pH 7.0 + DTT, 41 °C for pH 5.0 and 44 °C or pH 9.0 calculated using the 
software OriginTM. These results implied that IFN-a2b did not collapse on 
reduction of the two disulphide bonds, but was less stable. In addition to the 
Tm values the thermal unfolding at pH 7.0 monitored by the loss in structure in 
the far UV region was subject to far UV scans taken at specific temperatures 
to produce a figure of the decreasing structure with increasing temperature 
(figure 3.26). This figure illustrated the reduction in the alpha helical signals 
but also the formation of ß-sheets again observed by Beldarrain et al., (2001) 
at pH 7.0 with increasing temperature but also by Luykx et al., (2005) when 
concentrations equal and above 30 % acetonitrile are added to IFN-a2b. The 
thermal unfolding using the DSC was consistently unsuccessful and not used 
for any further analysis throughout this project. 
The next part of the project was to focus on the refolding of IFN-a2b from 
inclusion bodies. The first step in refolding from inclusion bodies is 
solubilisation. With the unfolding of IFN-a2b producing different results 
depending on whether guanidine-HCI or urea is used may have implications 
for this solubilisation stage. Due to the apparent stabilising effect of the 
disulphides and the ability of IFN-a2b to remain alpha helical without them 
may result in a refolding protocol where the IFN-a2b is refolded under 
reducing conditions and only during the final stages the reducing agent is 
removed forming the disulphides. 
Disulphide bonds are able to be present in the native folded form of protein 
molecules but also the unfolded state and so are not necessarily required for 
stability of the folded structure (Creighton, 1992). According to Creighton 
(1992) proteins with reduced disulphides tend to be unfolded because of the 
stabilising effect of the disulphide bond however it also depends on the 
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stability of the proteins structure as a whole. The stabilisation provided by 
disulphide bonds has been debated by two conflicting views and due to 
limited strong evidence supporting either view conclusions can only be 
reached through the experimental evidence itself. The first view from Flory 
(1956) is that the disulphide bond provides an increase in free energy of the 
denatured state by decreasing the conformational entropy. The second view 
is of Doig and Williams (1991) which suggests that it is both the entropy and 
enthalpy involved of the protein molecule and the surrounding system which 
are involved. 
Experimental evidence supporting both views has been provided from the 
investigation of the stabilising effects of disulphide bonds (Betz, 1993). The 
mutation of the cysteine residues of human lysozyme to alanine was 
investigated by Kuroki et al., (1992). The native protein containing the 
disulphide had a higher free energy than the non-crosslinked and a higher Tm 
in keeping with the IFN-a2b results found here. The introduction of a 
disulphide at different positions within the enzyme Bacillus circulans xylanase 
enabled its thermal stability to be increased (Davoodi et al., 2007). Any 
changes in the structure of the enzyme were analysed by both far and near 
UV CD and all but one mutant were identical to the wild type in the near UV 
region and all identical in the far UV region. The removal of disulphides not 
by mutation but by reduction as is the case in the IFN-a2b work may have 
negative steric effects due to large groups being bound to the cysteines and 
that this may well have the destabilising effect. 
The work carried out by Pace et al., (1988) on RNase T, showed that the 
protein remains folded and can be folded without the need for the disulphides 
to be intact. Reduction of the four cysteines present does reduce the thermal 
and urea stability of the protein but a two step unfolding curve can be 
generated. For RNase T, only one disulphide is buried within the proteins 
core and the other is solvent accessible. With IFN-a2b the disulphides are in 
regions of high mobility suggesting they are solvent accessible especially as 
the first disulphide connects the N terminus of helix E to the AB1 loop 
(Radhakrishnan et al., (1996). The second disulphide is between Cys29 on 
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the 310A helix and Cys138 within helix E. The residues forming the 310A helix 
are solvent accessible and so it is quite possible that the disulphides present 
within IFN-a2b are not buried as with RNase T, allowing the proteins to 
remain folded under reducing conditions. These proteins behave in contrast 
to proteins investigated for their disulphides properties such as Bovine 
pancreatic trypsin inhibitor (BPTI) which unfolds when all three of the 
disulphides are broken. As an intact protein BPTI is deemed a very stable 
protein with a Tm of 95 °C (Creighton and Goldenberg, 1984). This suggests, 
as discussed in chapter 1, section 1.2, page 16, that protein stability cannot 
simply be due to one force alone and that all interactions whether covalent or 
not play a part in protein stability. 
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Chapter 4 
Chapter 4 
Expression, purification and initial refolding studies 
4.1: Introduction 
This chapter details the expression and consequent harvesting of the IFN-a2b. 
Included also are initial refolding trials. The expression of the IFN-a2b was under 
the control of the temperature sensitive lambda c1857 repressor (Sussman and 
Jacob, 1962). This technique was new to this laboratory and so various E. coli 
strains were investigated to provide successful expression, this ultimately lead to 
one strain being chosen to be taken through further experiments. The IFN-a2b 
expressed resulted in inclusion bodies, this was in keeping with Cobra's previous 
data. Once the cells had been lysed by sonication, the inclusion bodies 
underwent a series of washing stages to remove contamination such as cell 
debris and nucleic acids. The solubilisation initially carried out using 8M urea 
was investigated to compare to the solubilisation using 6M guanidine-HCI. 
Valente et al., (2006) found there to be a difference in yield of IFN-a2b between 
the two denaturants. 
Purification of the solubilised inclusion bodies was attempted by both anion 
exchange chromatography after dialysis of the guanidine-HCI solubilised 
inclusion bodies into urea and gel filtration. Ion exchange has been used in the 
past to purify IFN-a2b however usually this is carried out after the refolding step 
(Beldarrain et a!., 2001; Srivastava et a!., 2005). The gel filtration involved the 
packing of a specific column and subsequent analysis ensuring column 
efficiency. The initial refolding studies provided early information of the effects of 
certain parameters on the IFN-a2b molecule such as temperature. This was 
carried out as a mixture of `trial and error' techniques revealing how the protein 
reacts to differing environmental temperatures and the effect of the different 
solubilisation denaturants. The methodology was based on work done by 
Srivastava et al. (2005) which involved a1 in 10 dilution followed by dialysis. 
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4.2: Results 
4.2.1: Expression of IFN-a2b 
A diagnostic digest using EcoR I and Sal I was carried out, this confirmed that the 
plasmid and IFN-a2b band were the correct sizes. The plasmid used for the 
expression of the IFN-a2 is presented in chapter 2, figure 2.3. Initial expression 
experiments were carried out to find a compatible strain and conditions to 
express the IFN-a2b protein. The expression of IFN-a2b was under the control of 
the temperature sensitive lambda c1857 repressor. The cells were grown to an 
optical density at 600 nm (OD600) of 0.6 at 30 °C, the temperature of the incubator 
was then increased to 43 °C to induce expression. As temperature induction had 
not been widely used in this laboratory it was decided that three E. coli strains 
should be tested initially to find out how well this type of induction method 
worked. The three E. coli strains available at the time were BL21 (DE3), DH5a 
and JM105, all three were tested. 
Small scale expression of IFN-a2b in strains BL21 (DE3), DH5a and JM105 
Expression in three different strains was carried out to find a strain capable of 
successfully expressing IFN-a2b to be used in all future experiments. This was 
initially carried out as a 50 ml culture. 
Lanes 
4678 
74 kDa `- 
50 kDa 
37 kDa 
25 kDa 
20 kDa 
15 kDa 
10 kDa 
IFN-a2b Standard 
BL21 30 °C Pellet 
BL21 30 °C SN 
BL21 43 °C Pellet 
BL21 43 °C SN 
DI-15a 30 °C Pellet 
DH5a 30 °C SN 
DH5a 43 °C Pellet 
DH5a 43 °C SN 
JM105 30 °C Pellet 
JM105 30 °C SN 
JM105 43 °C Pellet 
JM105 43 0C SN 
Figure 4.1: 12 % SDS-PAGE analysis of the 50 ml expression of IFN-a2b by the three E. 
coil strains; BL21 (DE3), DH5a and JM105. All three strains expressed IFN-cr2b (lanes 5,9 and 
13). BL21 (DE3) was chosen for future use. Lanes 3,4,7,8,11 and 12 show the flasks which 
were not induced, SN = supernatant. IFN-a2b standard loaded to 3 pg. 
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Figure 4.1 shows the expression of IFN-a2b by the strains BL21 (DE3), DH5a 
and JM105. Lanes 3,7 and 11 represent the pellets from the flasks kept at 30 
°C. They do not show expression of IFN-a2b. Lanes 5,9 and 13 are the induced 
flasks, all three strains show expression due to the large band present at the 
same molecular weight as the IFN-a2b standard in lane 2. The strain BL21 (DE3) 
was chosen for future use. Expression using the JM105 strain resulted in an 
apparently higher level of contamination (lanes 11 and 13). BL21 (DE3) grew the 
fastest out of all three strains, an OD6oonm of 0.6 being reached in 3 hours 
compared to 4 and 5 hours using DH5a and JM105 respectively. The death of 
one of the DH5a cultures (lane 7) made their reliability suspect. 
Expression of IFN-a2b in BL21 (DE3) in 0.5 I cultures 
BL21 (DE3) had been chosen as the strain to express IFN-o2b. Figure 4.2 
shows the expression of a larger culture (500 ml). Two flasks are represented to 
show the increase in IFN-u2b levels after induction over a3 hour period, the first 
flask was induced at 43 °C and the second was not. 
Lanes 
75 kDa A, 246789 10 
112 
14 
1) MWM 
50 kDa 2) IFN-a2b Standard 37 kDa 
3) Flask 1,1 h, Pellet 
25 kDa 4) Flask 1,1 h, SN 
20 kDa 5) Flask 1,2h, Pellet 
6) Flask 1,2h, SN 
15 k°a all# a 7) Flask 1,3h, Pellet 
8) Flask 1,3h, SN 
10 kDa 9) Flask 2,1 h, Pellet 
10) Flask 2,1 h, SN 
11) Flask 2,2h, Pellet 
12) Flask 2,2h, SN 
13) Flask 2,3h, Pellet 
14) Flask 2,3h, SN 
Figure 4.2: 12 % SDS-PAGE of the 0.5 1 expression in the E. coli strain BL21 
(DE3) over three hours. Lanes 3,5 and 7 show the increase in expression over the 
three hours. Lanes 9,11 and 13 are the samples taken from the flasks left at 30 °C, 
these show no expression of ! FN-a2b. IFN-a2b standard loaded to 3 pg. 
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Figure 4.2 shows the increasing expression of IFN-a2b in BL21 (DE3) over 3 
hours. This confirmed BL21 (DE3) as a reliable strain for the IFN-a2b expression 
at larger scales. 
10 1 fermentation of IFN-a2b 
A 10 1 fermentation of IFNma2b was set up as the expression worked well on the 
smaller scales. Figure 4.3 shows the OD600 readings over 5 h; the total time it 
took for the fermentation of iFN-a2b. 
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Time (h) 
Figure 4.3: Growth curve of the BL21 (DE3) strain used to express IFN-a2b in the 
10 1 fermentation. Expression was induced after 2 hours (OD600). The expression of 
the IFN-a2b was carried out for 3 hours until a constant ODWO was reached. Curve fitted 
by OriginTM using a Boltzmann function. 
The fermentation of IFN-a2b was successful and resulted in 52.46 g of wet cell 
pellet, which led to 17.95 g of washed inclusion bodies. 
4.2.3: Harvesting and solubilisation of the IFN-a2b inclusion bodies 
Harvesting of IFN-alb 
Following fermentation the cells were broken using sonication and the inclusion 
bodies subjected to many washing steps, detailed in chapter 2, section 2.10. 
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Once the inclusion bodies had been isolated they were solubilised and so 
refolding studies could begin. The initial solubilisation of the inclusion bodies with 
8M urea proved to be useful if subsequent purification was needed, however 
guanidine-HC1 proved to be the more efficient denaturant. As a consequence 
both were investigated along with their effects, if any, on the success of the 
refolding. 
Summary of inclusion body treatment 
" Resuspension of the cell pellet in 20 mM Tris-HCI pH 8.0 
9 Sonication. 
9 Centrifugation at 16556 xg (average speed) for 1h at 4 °C. 
" Resuspension of pellet in 20 mM Tris-HCI 1% Triton X-100 with 
homogenisation at 37 °C for 30 minutes. 
" Centifugation at 4709 xg (average speed) for 1.5 h at 4 °C. 
" Repeated resuspension and centrifugation twice reducing 
centrifugation time by 15 minutes each time. 
" Solubilisation of the inclusion bodies. 
" Centrifugation at 106255 xg (average speed) for 1.5 h at 4 °C. 
the 
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SDS-PAGE analysis of the inclusion body harvesting 
A 
Lanes 
2 346789 10 1. MWIVI 
50 kDaý 2. IFN-a2b standard 37 kDa 
25 kDa -ý 3. Resuspended cell pellet (20 mM Tris- 
20 kDa f HCI pH 8.0). 
'ww "'"` 
4. Sonicated sample. 
15 kDa f 5. Pellet (16556 xg centrifugation). 
6. SN. 
10 kDa -º 7. Homogenised sample (30 minutes at 
37 °C in 20 mM Tris-HCI pH 8.0). 
8. Pellet (4709 xg centrifugation). 
9. SN. 
10. Homogenised sample (30 minutes at 
37 °C in 20 mM Tris-HCI pH 8.0). 
B 
--- Lanes 12 3456789 10 
50 kDa 
37 kDa 9 1. MWM 
2. Std 
25kDa f 
3. Pellet (4709 xg 45 minutes) 
20 kDý 4. SN 
5. Homogenised sample (30 
15 kDa 9 minutes at 37 °C). 
6. Pellet (4709 xg 30 minutes) 
10 kDaf 7. SN 
8. Blank 
9. Blank 
10. Blank 
Figure 4.4: 17 % SDS-PAGE of samples taken throughout the harvesting and 
washing of the IFN-a2b inclusion bodies. A: The solubilisation of the cells and their 
sonication followed by the washing steps. B: The last two washing steps alongside the 
centrifugation. The IFN-a2b standard in lane 2 on both gels shows splitting of the 
band, this is assumed to be degradation due to the repeated freeze thawing of the IFN- 
a2b standard gel sample. All centrifugation speeds are averages. IFN-a2b standard 
loaded to 3 pg. 
The gel in figure 4.4 shows the gradual removal of higher molecular weight 
contamination and limited IFN-a2b in the soluble fractions indicating successful 
isolation of the IFN-a2b inclusion bodies. The inclusion bodies were initially 
solubilised in 8M urea, 20 mM Tris-HCI pH 8.0 due to the potential need for 
further purification. 
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Mass spectrometry 
Matrix-assisted laser desorption/ionization (MALDI) protein identification mass 
spectrometry was carried out to confirm the product from the expression was 
IFN-a2b. The results are shown in figure 4.5. 
1 11 21 31 41 
R ALLýKISLFSCL Krr<_ ,. = r. A 
51 61 71 81 91 
ETIPVLHEMI QQIFNLFSTK - FYTELYQ QLNDLEACVI 
101 111 121 131 141 
QGVGVTETPL MK KYFQRITLYL KEKKYSPCAW EVVRAEIMR 
SKE 
Figure 4.5: The amino acid sequence of IFN-a2b. The matched peptides found by 
mass spectrometry are shown in red. Mass spectrometry was carried out by Pinnacle, 
University of Newcastle upon Tyne, Nov 2005. The machine used was an ABI Voyager- 
DE TM STR BiospectrometryTm Workstation MALDI-TOF Mass Spectrometer. The 
Mowse score of 83 confirmed the protein expressed to be IFN-a2b. 
The mass spectrometry carried out on the solubilised inclusion body samples 
resulted in a Mowse score of 83 and above for IFN-a. This confirmed it was the 
correct protein as the cut off for significance is 67. 
Reduced forms of IFN-a2b 
This experiment aimed to determine whether there was dimer present in the IFN- 
a2b solubilised inclusion bodies or higher molecular weight contamination. It 
involved two methods of reduction. Reduction was achieved firstly using DTT 
and secondly using both 50 mM DTT and 5 mM lodoacetamide. lodoacetamide 
(chemical structure shown in figure 4.6) blocks the cysteine residues preventing 
the two disulphide bonds forming therefore highlighting any contamination. 
O 
NH2 \"-, 
A 
Figure 4.6: Chemical structure of lodoacetamide. lodoacetamide was used to block 
the four cysteine residues preventing disulphide bond formation. Drawn using 
Chemwindow® 6. 
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Lanes 
1. MWM 
2. Blank 
3. IFN-a2b Std 
4. Blank 
5. Soluble IFN-a2b 
6. Blank 
7. Soluble IFN-a2b + DTT 
8. Blank 
9. Soluble IFN-alb + lodoacetamide 
Figure 4.7: 12 % SDS-PAGE analysis of reduced IFN-a2b to illustrate the 
presence of any contamination. The dimer band has been reduced on addition of 
the reducing agents however there are still many high molecular weight contaminating 
bands present confirming the need fro further purification. IFN-a2b standard loaded to 
3 pug. 
Figure 4.7 shows IFN-a2b in two reduced forms one reduced by DTT, lane 7 and 
the second reduced by both DTT and iodoacetamide, lane 9. Lane 5 contains 
IFN-a2b as run previously illustrating the presence of possible dimer. This gel 
confirms the presence of both dimer and other high molecular weight multimeric 
species. The use of the iodoacetamide confirms this as all disulphide bonds are 
broken and as such IFN-a2b can only be present as monomer preventing the 
formation of any multimeric species, the monomer is represented by the two large 
bands in lanes 7 and 9 at approx 15 kDa. The presence of the other bands in 
lanes 7 and 9 suggest contamination and the requirement for further purification. 
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Reduced and oxidised forms of IFN-a2b 
As well as reduction of the IFN-a2b a sample was also oxidised in the presence 
of copper sulphate and phenanthroline to illustrate the formation of multimeric 
species 
12 
70 kDa 
50 kDa 
37kDaf 
25 kDa -p 
20 kDa- 
15 
-100. 
10 kDa 
Figure 4.8: 12 % SDS-PAGE analysis of IFN-a2b in its reduced and oxidised 
form. Lane 7 shows the shift of the IFN-a2b band to a higher molecular weight than 
the samples in lanes 3 and 5. Lane 9 illustrates the sample oxidised with copper 
sulphate and phenanthroline, the IFN-a2b band is faint as the sample has remained in 
the stacking gel due to the formation of oligomeric species. IFN-a2b standard loaded to 
3 pg. 
This gel in figure 4.8 shows the reduced IFN-a2b in lane 7 and the oxidised IFN- 
a2b in lane 9. The oxidised IFN-a2b has formed multimeric species which has 
resulted in a large proportion remaining in the stacking gel. This result would 
indicate the advantage of keeping IFN-a2b reduced during the purification stages 
to prevent the formation of oligomers and increase yields. A further observation 
from both figure 4.7 and 4.8 is that the reduced form of IFN-a2b runs at a higher 
molecular weight than the non-reduced form; something that could be used to 
decide whether the two disulphides have formed correctly. 
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Lanes 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
Faint IFN-a2b band 
MWM 
Blank 
IFN-a2b Std 
Blank 
Soluble IFN-a2b 
Blank 
Soluble IFN-a2b + DTT 
Blank 
Soluble IFN-alb + Copper Sulphate 
and Phenanthroline 
Differences in solubilisation with 6M guanidine-HCI and 8M urea with and 
without DTT 
This experiment was carried out to ensure that the 8M urea was effectively 
solubilising the IFN-a2b inclusion bodies. A comparison with 6M guanidine-HCI 
was incorporated. To solubilise the inclusion bodies 1g (wet weight) of inclusion 
bodies was solubilised in 10 ml of denaturant, the solubilisation was carried out 
overnight with agitation at room temperature. DTT was added to a final 
concentration of 5 mM. After centrifugation at 106255 xg (average speed) for 
1.5 h the supernatants were diluted 1 in 10 with SDS-PAGE sample buffer and 
0.01 g (wet weight) of the four pellets post centrifugation were resuspended in 
100 pl of SDS-PAGE loading buffer. 15 pi of the samples were loaded onto the 
gel. 
Lanes 
50 kDa 123456789 
30 kDa 
25 kDa 
20 kDa 
15 kDa 
10 kDa 
1. MWM 
2.6 M Guanidine-HCI Pellet 
3.6 M Guanidine-HCI SN 
4.6 M Guanidine-HCI 1 mM DTT Pellet 
5.6 M Guanidine-HCI 1 mM DTT SN 
6.8 M Urea Pellet 
7.8MureaSN 
8.8 M Urea 1 mM DTT Pellet 
9.8 M Urea 1 mM DTT SN 
Figure 4.9: A 17 % SDS-PAGE of the solubilised inclusion bodies after 
centrifugation using the four conditions; 6M guanidine-HCI, 6M guanidine-HCI 1 
mM DTT, 8M urea and 8M urea I mM DTT pH 8.0. Pellets are shown in lanes 2,4, 
6 and 8. Supernatants are shown in lanes 3,5,7 and 9. The small amount of IFN-a2b 
present in lanes 7 and 9 versus the large amount in lanes 6 and 8 illustrates the 
ineffectiveness of urea as the solubilisation agent. IFN-a2b standard loaded to 3 pg. 
Figure 4.9 shows that solubilisation with 6M guanidine-HCI is more effective than 
with 8M urea. This is shown by the large amount of IFN-a2b left in the pellet 
when 8M urea is used (lanes 6 and 8). Lanes 7 and 9 show very little soluble 
IFN-a2b. The presence of DTT does not seem to make a difference in the 
efficiency of the solubilisation in both cases. Both guanidine-HCI (Beldarrain et 
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a!., 2001) and urea (Srivastava et a!., 2005) have been used for the successful 
solubilisation of IFN-a2b inclusion bodies however it was Valente et al., (2006) 
who showed that guanidine-HCI had a much greater effect on the inclusion 
bodies solubilisation. Valente et al., (2006) found a difference in yield of IFN-a2b 
of 88 % when guanidine-HCI was used compared to 51 % using urea alongside 
DTT. 
4.2.4: Purification of the IFN-a2b solubilised inclusion bodies 
The SDS-PAGE analysis of the solubilised inclusion bodies highlighted the need 
for a purification step. This will ensure that only IFN-a2b is being refolded and 
not being affected by any contamination. 
Ion exchange 
In order to purify the inclusion bodies further ion exchange chromatography was 
chosen. The pl of IFN-a2b has been calculated to be 5.9 (Gasteiger E et al., 
2003). Anionic ion exchange media was chosen and run initially at pH 8.0, this 
was not successful. Further conditions tried can be seen in table 4.1. The 
elution was performed by an increasing concentration of sodium chloride 
concentrations up to 1 M. 
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Ion Exchange 
Run 
Buffer A pH Comments 
Dialysis into buffer A4 °C 
4M Urea, 50 mM Tris-HCI, 1 1 8.0 Linear Gradient 
mMDU 
Cloudy after dialysis 
PD10 column used for buffer exchange 4 M Urea, 50 mM Tns-HCI, 1 2 8.0 Step elution 250 mM, 500 mM, 750 mM and 
mM DTT 
1M NaCl. 
4M Urea, 50 mM Tris-HCI, 1 New PD10 column used for buffer exchange 3 8.0 
mM DTT Step elution 
4M Urea, 30 mM PD10 column used for buffer exchange 4 9.5 
Ethanolamine, 1 mM DTT Step elution 
8M Urea, 50 mM Tris-HCI, 1 Dialysis into buffer A4 °C 
5 8.0 
mM DTT Step elution 
Dialysis into buffer A4C 
8M Urea, 30 mM Urea came out of solution left for 3 hours at 6 9.5 
Ethanolamine, 1 mM DTT room temperature 
Step elution 
Dialysis into buffer A at room temperature 
8M Urea, 50 mM Tris-HCI, 1 
7 9.5 Step elution 
mM DU 
Dialysis into buffer A at room temperature 
8M Urea, 50 mM Tris-HCI, 1 
8 9.5 pH adjustment carried out with acetic acid 
mM DTT Step elution 
8M Urea, 0.1 M Citric acid, Dialysis into buffer A at room temperature 
9 4.0 
1 mM DTT Step elution 
After thoroughly cleaning the column. 
8M Urea, 20 mM Tris-HCI, 1 
10 8.0 Dialysis into buffer A , room temperature 
mM DU Step elution 
8M Urea, 1 mM DTT, 0.2 M Dialysis into buffer A at room temperature 
11 70 
Phosphate Step elution 
8 -M Urea, 1 mM DTT, 10 Dialysis into buffer A at room temperature 
12 70 
mM Bis Tris-HCI. Elution of 500 mM and 1 M. 
Table 4.1: All the different ion exchange conditions that were tried in order to 
purify the denatured IFN-a2b. None of these conditions were successful. 
From table 4.1 it can be seen the range of conditions tried and tested. None of 
the conditions proved successful as a purification technique. Examples of SDS- 
PAGE analysis of ion exchange runs 5 and 6 can be seen in figure 4.10. 
116 
A. (EX 4 
123456789 10 
70 kDa 
50 kDa f Lanes 37 kDa -º 1. MWM 25 kDa f 2. Std 
20 kDa 
15 kDa 3. Before filtration 
10 kDa f1 4. After filtration 
5. Flowthrough 
IFN-a2b 
B. I EX 5 6. Wash 
7. 250 mM Wash 
123456789 10 8. 500 mM Wash 
70 kDa f 9. 750 mM Wash 
5okDaf 10 1M Wash 37 kDa 9 . 
25 kDa 
20 kDa 
15 kDa 
10kDa4. 
IFN-a2b 
Figure 4.10: Examples of the SDS-PAGE analysis carried out after the ion 
exchange runs shown in table 4.1. A: Ion exchange run 4,8: ion exchange run 5, 
the two most successful ion exchange runs. It can be seen from these two gels the 
extent of protein loss during the ion exchange experiments, see lane 5. IFN-a2b 
standard loaded to 3 pg. 
The example gels from the ion exchange attempts shown in figure 4.10 highlight 
a great loss of protein in the flowthrough which is not pure IFN-a2b itself. Figure 
4.10B does show a small amount of IFN-a2b eluting in the 250 mM NaCl fraction 
however the yield is too low to consider this as an efficient purification technique 
at this stage. The results of the ion exchange confirm it to be an unproductive 
stage in purifying the inclusion bodies. This maybe because of the high 
concentrations of urea present interfering with the proteins access to the resin or 
the urea is producing cyanate which is causing carbamylation of the IFN-a2b. 
Ion exchange using Amberlite® treated buffers 
Urea has a tendency to break down producing cyanate which is able to 
carbamylate proteins. To eliminate the possibility of this happening to the IFN- 
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a2b, the urea buffers were treated with Amberlite®, a mixed-bed ion exchange 
media before the ion exchange run at pH 8.0.10 g of Amberlite® was added to 
100 ml of the running buffers and left stirring for 16 hours at room temperature (in 
accordance with manufacturer's instructions). The buffers were then 0.2 pm 
filtered and degassed under vacuum. 
Lanes 
1 
70 kDa -0.2 
3456789 10 1. MWM 
50 kDa f 2. Load 
37 kDa f 3. Flowthrough 
25 kDa f 
4. Wash 
20 kDa 
5.250 mM Elution 
f 6.500 mM Elution 
7.750 mM Elution 
15 kDa f 
8.1 M Elution 
9. Blank 
10. Blank 
Figure 4.11: SDS-PAGE analysis of the samples taken during the ion exchange at 
pH 8.0 using Amberlite® treated buffers. The gel shows that even when the buffers 
are treated with Amberlite® the protein still does not bind to the Q ion exchange resin. 
The ion exchange run using Amberlite® treated buffers does not result in 
improved purification, see figure 4.11. There is no indication of the sample 
binding to the column suggesting that the unsuccessful ion exchange is not due 
to breakdown products of the urea interfering with the binding of the IFN-a2b to 
the column. 
Isoelectric focusing analysis 
Isoelectic focusing (IEF) gels can be used to separate proteins according to their 
charge. The pH at which the protein has a net charge of zero is termed the pl 
and can be determined by IEF analysis. Once the pl is known the conditions of 
the ion exchange can be assessed and optimised. The running of an IEF gel 
should confirm the pl of IFN-a2b. 
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2. IFN-a2b Std 
3. New protein Sample 
4. Blank 
5. guanidine-HCI solubilised inclusion 
bodies dialysed into urea 
Figure 4.12: IEF gel of the IFN-alb standard and solubilised inclusion bodies. The 
calculated pl of IFN-a2b is 6 the IFN-a2b standard runs just above 6 but less than 6.9. 
The solubilised IFN-a2b inclusion bodies cannot be seen on the gel which was assumed 
to be due to the incompatibility of the solubilisation buffer with the running conditions. 
The solubilised inclusion body sample did not show up on the IEF gel shown in 
figure 4.12 which may be due to the high concentration of urea interfering with 
the efficient running of the gel. The IFN-a2b standard did confirm the pl as being 
just above 6, the calculated pl. This suggests that the pH at which the ion 
exchange is being carried out (above 6) is not the cause of the unsuccessful 
purification. These results conclude that maybe the high concentration of urea is 
reducing the IFN-a2b access to the resin preventing it from binding. 
Pure Inclusion bodies 
Due to the unsuccessful nature of the ion exchange purification the solubilised 
inclusion bodies were accepted as pure enough for the refolding to be carried out 
without the need for purification. The samples were treated with iodoacetamide 
(final concentration 5 mM) and analysed by SDS-PAGE. 
119 
!" Lanes 
12345678 
75 kDa 
50 kDa 1. MWM 
37 kDa 
2. IFN-a2b Standard 
3. Solubilised inclusion bodies heated to 95 
25 kDa °C only 
20 kDa 4. Solubilised inclusion bodies heated and 
15 kDa reduced with DTT 5. Solubilised inclusion bodies heated and 
10 kDa reduced with both DTT and lodoacetamide 
6. Lane 3 diluted 1 in 10 
7. Lane 4 diluted 1 in 10 
8. Lane 5 diluted 1 in 10 
Figure 4.13: 12 % SDS-PAGE analysis of the reduced solubilised inclusion 
bodies with DTT and lodoacetamide. This illustrates the relatively pure inclusion 
bodies due to the reduced level of contamination. IFN-a2b standard loaded to I pg. 
The gel shown in figure 4.13 shows the SDS-PAGE analysis carried out on the 
samples gained from the inclusion body solubilisation. The gel shows suitably 
pure inclusion bodies to have refolding studies started and will therefore not 
undergo further purification. 
4.2.5: Refolding without purification 
The following results are examples of the initial refolding experiments carried out 
on the solubilised IFN-a2b inclusion bodies without any purification after inclusion 
body preparation. 
Refolding at 4 °C and 24 °C 
The initial refolding experiments focused on finding an optimum temperature at 
which to carry out the refolding. The two temperatures chosen were 4 °C and 24 
°C (room temperature). Whether the protein refolded differently when solubilised 
in urea or guanidine-HCI was also investigated. This was thought to be important 
due to the differences in behaviour observed during the characterisation work 
and the differences in the extent of the solubilisation using the two denaturants. 
For details see chapter 2, section 2.11.1. 
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Refolding of IFN-a2b at 4 °C and 24 °C 
The initial refolding experiments were carried out at both 4 °C and 24 °C with 
inclusion body samples solubilised in both 8M urea and 6M guanidine-HCI, 20 
mM Tris-HCI, 1 mM DTT pH 8.0. The refold was as follows; 
91 in 10 dilution of the protein sample into 20 mM Tris-HCI, 1 mM DTT pH 
8.0,3 hour incubation. 
9 Addition of 0.1 mM oxidised glutathione, 4 hour incubation. 
" Dialysis into 20 mM Tris-HCI pH 8.0. 
The final samples under these four refold conditions; 
1. Refolded from urea at room temperature 
2. Refolded from urea at 4 °C 
3. Refolded from guanidine-HCI at room temperature 
4. Refolded from guanidine-HCI at 4 °C 
All were analysed by far UV CD, intrinsic fluorescence and SDS-PAGE. 
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Far UV CD analysis 
10 
8 
6\ 
4 
W21 
0 -- 
-2 
-4 
-6 
Refolded from 8M urea at room temperature 
Refolded from 6M guanidine-HCI at 4 °C 
- Refolded from 6M guanidine-HCI at room temperature 
Refolded from 8M urea at 4 °C 
Folded IFN-a2b standard 
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Figure 4.14: Far UV CD of the final samples from the refold carried out at both 24 
°C and 4 °C solubilised in both 6M guanidine-HCI and 8M urea. The only two with 
alpha helical structure are the two samples solubilised in guanidine-HCI (red and green 
lines). The samples showing alpha -helical structure are not as intense as the IFN-ar2b 
standard (black dotted line) confirming that they are not yet natively refolded. 
Initial Concentration for 
Final concentration 
Sample Concentration Yield(%) CD analysis 
(mg) 
(mg) (mg/ml) 
Guanidine-HCI refold at 4 °C 19.8 1.14 5,75 0.38 
Guanidine-HCI refold at 24 °C 19.8 0.75 3.78 0.22 
Urea refold at 4 °C 9.8 2.5 26 0.25 
Urea refold from 24 °C 10.5 3 28 0.3 
Table 4.2: Concentrations determined by A280 of the samples before and after the 
first refold attempt. The urea samples appear to give the greatest yields. The final 
samples were concentrated for far UV CD analysis. 
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Fluorescence analysis 
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Refolded at room temperature from 8M urea 
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Wavelength (nm) 
Figure 4.15: The fluorescence results of the final samples from the refold carried 
out at 4 °C and room temperature. Only the urea solubilised sample refolded at room 
temperature (red line) shows tryptophan fluorescence similar to that of the IFN-a2b 
standard. The other samples appear to be giving a mixture of tryptophan and tyrosine 
fluorescence not previously seen from the folded IFN-a2b standard. Sample 
concentrations determined by A280 were 0.1 mg/ml. 
The far UV CD of the final samples can be seen in figure 4.14. The only samples 
to give the correct alpha helical signal are the two samples solubilised in 6M 
guanidine-HCI especially when DTT is added. This may indicate that the protein 
is fully unfolded when DTT is used alongside guanidine-HCI for the solubilisation 
of the inclusion bodies but the refolding does not provide the correct conditions 
for fully folded IFN-a2b of the same intensity as the standard. Without the protein 
being fully denatured it is unable to refold correctly to its native conformation. The 
fluorescence results shown in figure 4.15 show the correct tryptophan emission 
from the inclusion bodies solubilised in 8M urea. The samples which had been 
solubilised in 6M guanidine-HCI gave a mixture of tyrosine and tryptophan 
fluorescence. This is the first indication of the different behaviour in refolding by 
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IFN-a2b starting from solubilisation in either urea or guanidine-HCI. A possible 
explanation for this is that the starting material in urea is not completely 
denatured and unfolded whereas it is with the guanidine-HCI. There are 5 
tyrosine residues present in IFN-a2b and 2 tryptophans and so tryptophan 
emission is expected. The tyrosine fluorescence has not been observed from the 
IFN-a2b standard during the characterisation work and so could be a difference 
in the proteins structure due to the mixture of tyrosine and tryptophan emission 
seen or a possible contaminant not removed during the washing of the inclusion 
bodies. 
SDS-PAGE analysis of the refolded samples 
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Figure 4.16: 12 % SDS-PAGE analysis of the final samples form the 4 °C and 24 °C 
refold from guanidine-HCI solubilised inclusion bodies. Lane 8 on both gels 
illustrates the loss of protein through precipitation during the 24 °C refold. The smearing 
effect is due to incomplete disulphide bond formation. IFN-cr2b standard loaded to 3 pg. 
The SDS-PAGE analysis shown in figure 4.16 shows the shift of the refolded IFN- 
a2b to a higher molecular weight, seen previously when the IFN-a2b standard 
samples have been reduced. There is no difference between the band position 
whether the samples are heated or not. The gels also illustrate the great loss of 
protein by precipitation during the refold at 24 °C. This is shown in lane 8 in both 
figure A and B. The refold at 24 °C shall not be used in future experiments due to 
this great loss. This loss in protein is however not reflected in the yields of the 
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refold shown in table 4.2. A much smaller yield would be expected from the 
guanidine-HCI refold carried out at 24 °C. There appears to be splitting of the 
IFN-a2b band, potentially indicating different combinations of disulphide 
formation. These bands run to the same molecular weight as the heated and 
reduced samples (lanes 5 and 6). In this experiment the results of the refolding 
are not successful but it does highlight the usefulness of SDS-PAGE in 
confirming the disulphides have formed and also that 24 °C is not a satisfactory 
temperature for the refold. 
Refold with longer oxidised glutathione incubation time 
The previous refold was carried out with an incubation time with oxidised 
glutathione of 3 hours, in this experiment the incubation time was increased to 16 
hours. Results were analysed by far UV CD and fluorescence. 
Far UV CD results 
10 
9 Refolded from guanidine-HCI 
8- Refolded from guanidine-HCI +DTT 
Refolded from urea 7 
6 Refolded from urea + DTT 
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Figure 4.17: The far UV CD results of the final samples of the refold involving a 16 
hour incubation time with oxidised glutathione. The only sample showing any alpha 
helical structure is the sample solubilised in 6M guanidine-HCI 1 mM DTT (red line). The 
remaining samples show signals of unfolded structure. 
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In figure 4.17 the only sample to give an alpha helical signal is the sample 
solubilised in 6M guanidine-HCI, 1 mM DTT. 
Intrinsic fluorescence analysis 
Refolded from 6M Guanidine-HCI 
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Figure 4.18: Fluorescence results of the refold at 4 °C from both urea and 
guanidine-HCI solubilised inclusion bodies with a 16 hour incubation time with 
oxidised glutathione. Tryptophan emission can be seen from the guanidine-HCI 
solubilised inclusion bodies (black and red lines) and tyrosine emission from the urea 
solubilised inclusion bodies (green and blue lines). Tyrosine emission is not expected 
from the refolded IFN-a2b. 
The fluorescence results in figure 4.18 show the correct tryptophan emission from 
the inclusion bodies solubilised in guanidine-HCI with or without DTT. The 
samples which had been solubilised in urea now give tyrosine fluorescence. It is 
however only the sample solubilised in 6M guanidine-HCI, 1 mM DTT which 
appears folded by far UV CD. The intensities of the fluorescence emissions are 
low and noisy even though their total protein concentrations are 0.1 mg/ml. This 
indicates that there is a contamination which is interfering with the absorbance 
measurements. 
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Conclusions from the refolding without purification 
The refolding without purification was carried out due to relatively pure inclusion 
bodies samples being obtained and the unsuccessful nature of the ion exchange 
as a purification method. The initial aim was to investigate a temperature at 
which the IFN-a2b could be refolded minimising the possibility of aggregation. 
The IFN-a2b seemed to undergo large precipitation when refolded at room 
temperature giving rise to small yields. The yields at 4 °C did not appear much 
better which was odd as the same level of precipitation had not been observed. 
It was the inclusion bodies solubilised in guanidine-HCI which resulted in alpha 
helical structure regardless of the temperature (figure 4.14). The urea samples 
showed signs of unfolded species due to the large negative intensities below 210 
nm. The intrinsic fluorescence from this study gave unexpected results. 
Although the guanidine-HCI solubilised samples were showing alpha helical 
structure they were displaying a mixture of tyrosine and tryptophan fluorescence 
something not seen from the IFN-a2b standard, see figure 4.15. The case was 
different for the urea solubilised inclusion bodies. The refold carried out at 24 °C 
gave tryptophan emission and the 4 °C refold gave tyrosine emission, again 
unexpected. There are 5 tyrosines and 2 tryptophans in IFN-a2b and usually 
only the tryptophan fluorescence is seen in a protein containing both when 
excited at 280 nm (Schmid, 1997). From this refold the conclusions were that the 
refold should be carried out at 4 °C to reduce the level of aggregation. The SDS- 
PAGE highlighted the extent of the aggregation when the refold is carried out at 
25 °C. A second function of the SDS-PAGE analysis is that they illustrate the 
formation of the disulphide bonds. In both gels the IFN-a2b band is more of a 
smear compared to the IFN-a2b standard and the reduced sample, see figure 
4.16. This suggests that the disulphides have not formed completely or maybe 
incorrectly. The next stage was to investigate the disulphide formation still using 
oxidised glutathione. 
The second refold was based on increasing the incubation time with oxidised 
glutathione from 3 to 16 hours, to improve disulphide bond formation. The 
inclusion bodies had now been solubilised in both urea and guanidine-HCI with 
and without DTT and so all four were refolded. The results from this second 
refold gave interesting results again. The only sample showing alpha helical 
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structure was from the inclusion bodies solubilised in guanidine-HCI with DTT, 
the remaining three showed strong characteristic unfolded signals below 210 nm 
(figure 4.17). The fluorescence results show strong tyrosine emission from the 
urea solubilised inclusion bodies and tryptophan emission from the guanidine-HCI 
solubilised inclusion bodies (figure 4.18). However inconsistent the results, both 
experiments highlight the differences in refolding of inclusion bodies solubilised in 
guanidine-HCI and urea; the guanidine-HCI solubilised samples can lead to an 
alpha helical structure whereas the urea solubilised samples do not. The 
fluorescence is odd as tyrosine emission is unexpected as not previously seen 
during the characterisation work in chapter 3, section 3.2.3. The tyrosine 
fluorescence must be seen in the IFN-a2b standard or the purification needs to 
be re-introduced. 
4.2.6: Standard Denaturation 
Repeated freeze thaw 
An aliquot of IFN-a2b standard at 0.01 mg/ml was freeze thawed for 5 days at -20 
°C and the fluorescence emission measured after excitation at 280 nm. 
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Figure 4.19: Fluorescence emission of continuous freeze thawing the IFN-a2b 
standard over a period of five days. There is no indication of the appearance of any 
tyrosine fluorescence due to freeze thawing. 
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The freeze thawing of the IFN-a2b standard shown in figure 4.19 did not result in 
tyrosine fluorescence. It did however show the decrease in intensity of the 
fluorescence emission over the five days which could indicate possible 
denaturation and in future freeze thawing of the IFN-a2b should be kept to a 
minimum. 
Denaturation with Guanidine-HCI, DTT and heat 
This second experiment was also designed to encourage tyrosine fluorescence 
from the IFN-a2b standard. A solution of the folded IFN-a2b standard was 
subjected to treatment with 6M guanidine-HCI, 50 mM DTT and heating to 95 °C. 
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Figure 4.20: The fluorescence emission of the IFN-a2b standard denatured using 
guanidine-HCI and heat. The fluorescence emission from treatment with guanidine- 
HCI, DTT and heat dose not result in tyrosine emission, tryptophan emission remains. 
The fluorescence results from the standard denaturation work did not present 
tyrosine fluorescence, see figure 4.20. Repeated freeze thawing indicated 
possible denaturation of the protein with the decrease in intensity. The deliberate 
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denaturation using guanidine-HCI and heat also illustrates denaturation but no 
tyrosine emission. 
The results indicate that a purification step is essential to gain more reliable and 
successful refold results especially with the urea solubilised samples. 
4.2.7: Purification using gel filtration 
As ion exchange had proved unsuccessful as a purification stage for IFN-a2b gel 
filtration was investigated as a possible alternative. Gel filtration would remove 
the need for dialysis of the guanidine-HCI solubilised inclusion bodies into urea in 
order to be purified allowing the two conditions to be investigated separately. A 
suitable gel filtration column would firstly have to be prepared as analytical 
columns available would be too small for this preparative work. 
Preparation of the gel filtration column 
A XK16 column (G. E. Healthcare, Amersham, UK) was packed with SuperdexTM 
75 media (G. E. Healthcare). The bed height was 11.5 cm giving a total column 
volume of 29 ml. To check the packing efficiency of the column NaCl was used. 
The column was equilibrated with 20 mM Tris-HCI pH 8.0, and when a stable 
baseline had been reached the column was spiked with 0.5 ml (approx 2% 
column volume) 1M NaCl. From the results the number of theoretical plates and 
the asymmetry can be calculated. The methods and equations used were taken 
from the Amersham Biosciences handbook on gel filtration 18-1022-18 edition Al 
(2002). 
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Figure 4.21: Chromatography spectrum of the XK16 packed to 29 ml with 
SuperdexTM 75 resin spiked with 1M NaCI. The peak was used to calculate the 
asymmetry and the number of theoretical plates. Ve is the peak elution volume, W112 is 
the peak width at half the peak height and L is the bed height (mm). 
The results of the NaCI spike in figure 4.21 enabled the number of theoretical 
plates to be calculated by the following equation 
N=5.54 (Ve/W1,2)2 X 1000/L (4.1) 
Where Ve is the peak elution volume, W1,2 is the peak width at half the peak 
height and L is the bed height (mm). 
The result gave a theoretical number of plates of 31452. The pre-packed 
SuperdexTM gel filtration columns from G. E. Healthcare are usually packed to 
30000 plates (Technical services at G. E. Healthcare) or as the Amersham gel 
filtration handbook (2002) recommends > 10000, indicating the packed column is 
sufficiently packed for this application. 
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The asymmetry was calculated by the following equation 
AS = B/A 
A= Leading half peak width at 10 % peak height 
B= Trailing half peak width at 10 % peak height 
(4.2) 
The result gave an asymmetry of 0.92 which indicates good asymmetry, for 
SuperdexTM media the asymmetry should lie between 0.7-1.3. 
As the column was well packed molecular weight markers were applied to the 
column to ensure the column was as effective with protein samples. The 
samples used were cytochrome C (12.5 kDa), carbonic anhydrase (29.5 kDa) 
and ß-amylase (200 kDa). The samples were applied to the column pre- 
equilibrated with 20 mM Tris-HCI, 0.15 M NaCl pH 8.0. The load volume was 0.5 
ml and the protein concentration was approx 1 mg/ml. Blue dextran (2000 kDa) 
was also used to elucidate the void volume. 
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Figure 4.22: Elution profiles of the molecular weight markers used to calibrate the 
SuperdexTM 75 column to be used for the purification of the IFN-a2b inclusion 
bodies. Carbonic anhydrase was added at a lower concentration due to availability. 
The peak elution volumes can be used to elucidate when the IFN-a2b should elute. 
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05 10 15 20 25 30 35 
Volume (ml) 
Sample 
Molecular weight 
(kDa) 
Elution volume 
(ml) 
Cytochrome C 12.5 17.45 
Carbonic anhydrase 29 15.29 
Beta amylase 200 10 
Blue dextran 2000 11.37 
IFN-a2b 19.5 13.4 
Table 4.3: Table of the molecular weight calibration markers along with their 
elution volumes. The Blue dextran and the beta amylase elute at similar volumes even 
though their molecular weights are different, this is probably due to them both eluting in 
the void volume as they are too large for separation by the SuperdexT""75. Unusually the 
IFN-a2b elutes before the carbonic anhydrase which is larger, this may be due to the 
loading concentration being different, the IFN-a2b was loaded to a much higher 
concentration. 
Table 4.3 and figure 4.22 shows the molecular weights and the elution volumes 
of the protein standards used to calibrate the gel filtration column. The calibration 
shows that the smaller proteins elute late and the large proteins elute early. Blue 
dextran and ß-amylase elute early in the void volume due to their large size. The 
IFN-a2b elutes around 13 ml, it would be expected that IFN-a2b would elute 
between cytochrome C and carbonic anhydrase however due to total protein 
concentration and load volume differences the elution may differ. 
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i_qure 4.23: 
1. MWM 
2. Urea solubilised inclusion bodies 
3. Urea solubilised inclusion bodies after gel 
filtration 
4. Guanidine-HCI solubilised inclusion bodies 
5. Guanidine-HCI solubilised inclusion bodies 
after gel filtration 
and after purification by gel filtration. The gel filtration appears to be purifying the 
guanidine-HCI solubilised inclusion bodies however there remains little difference 
between the urea solubilised inclusion bodies purity before and after gel filtration. 
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The SDS-PAGE analysis of the urea solubilised inclusion bodies before and after 
gel filtration shown in figure 4.23 confirms a similar amount of contamination 
present in each. The guanidine-HCI solubilised sample gives a better result after 
the gel filtration. There appears to be less high molecular weight contamination 
and reduced smearing of the sample. The apparent contamination may be 
aggregation during running of the gel. 
Gel filtration of solubilised inclusion bodies with and without the use of 
Triton X-100 
The following figure illustrates the difference in gel filtration profile with and 
without Triton X-100. 
Inclusion bodies solubilised in 6M guanidine-HCI 
Inclusion bodies solubilised in 6M quanidine-HCI washed with Triton X-100 
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Figure 4.24: Example of the differences in gel filtration of guanidine-HCI 
solubilised inclusion bodies with and without Triton X-100. The red line shows a 
large second peak after 20 ml indicating the removal of the Triton X- 100. The black line 
shows the separation of a sample having never come into contact with Triton X-100. 
The gel filtration profile of the guanidine-HCI solubilised inclusion bodies when 
Triton X-100 is used displays a large peak above 20 ml (figure 4.24). This peak 
is present in the samples where no Triton X-100 was used but at a much lower 
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concentration. The elution volume of the contamination suggests it is small in 
size and so may not be visible by SDS-PAGE; the fluorescence of this peak shall 
be investigated. 
Intrinsic fluorescence of the gel filtration of Triton X-100 washed inclusion 
bodies 
The two fractions were chosen from the centre of the two peaks and excited at 
280 nm. 
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Figure 4.25: Fluorescence spectra of two fractions taken during the gel filtration 
of guanidine-HCI solubilised inclusion bodies with Triton X-100 present in the 
wash buffer. The fraction taken at 14 ml shows tryptophan emission and the fraction 
taken at 25 ml shows tyrosine emission suggesting that the later fractions are not IFN- 
a2b. 
The fluorescence obtained from the two fractions revealed tyrosine fluorescence 
from the peak above 20 ml, see figure 4.25. It is possible that the tyrosine 
emission seen in the earlier refolds may have been caused by the Triton X-100. 
To confirm this, the fluorescence emission of pure Triton X-100 was compared to 
the emission of N-acetyl-L-tyrosinamide, a compound used to mimic tyrosine in a 
protein-like environment. Both the N-acetyl-L-tyrosinamide and the Triton X-100 
were diluted to approx 0.1 mM and the absorbance and the fluorescence 
emission measured after excitation at 280 nm. 
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Figure 4.26: Absorbance spectrum of N-acetyl-L-tyrosinamide and Triton X-100. 
Both scans show the peak at 275 nm followed by the shoulder at 280 nm characteristic 
of tyrosine absorption. The figure suggests the tyrosine fluorescence is a result of the 
Triton X-100. The compounds were diluted to approx 0.1 mM for fluorescence analysis. 
Chemical structures drawn using Chemwindow® 6. 
Both absorbance spectra in figure 4.26 show similar results with the shoulder at 
280 nm and a peak at 275 nm, a characteristic of tyrosine absorption. These 
samples were then subjected to excitation at 280 nm and their fluorescence 
emission measured. 
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Intrinsic fluorescence analysis of N-acetyl-L-tyrosinamide and Triton X-100. 
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Figure 4.27: Fluorescence emission of N-acetyl-L-tyrosinamide and Triton X-100. 
The barycentric mean of both samples show that they are very similar confirming Triton 
X-100 gives a strong tyrosine emission implicating it in the contamination of the IFN-a2b 
inclusion bodies. 
The fluorescence emission of N-acetyl-L-tyrosinamide and Triton X-100 give the 
expected tyrosine emission spectrum (figure 4.27). The barycentric mean, 
calculated between 286 and 337 nm for the N-acetyl-L-tyrosinamide is 308.4 nm 
and for the Triton X-100 is 307.8 nm indicating the cause of the "tyrosine" 
emission was the Triton X-100. 
The A280 spectrum shown in figure 4.26 illustrates the strong protein-like signal 
given by the Triton X-100. This suggests the total protein concentrations of the 
inclusion bodies and possibly the refolded samples displaying tyrosine 
fluorescence had been overestimated therefore explaining the unusual results 
obtained during the initial refolding. Removal of the Triton X-100 from the 
washing of the inclusion bodies will make total protein calculations more reliable. 
The gel filtration shall be kept even when Triton X-100 had not been used during 
the wash steps. This was due to there still being some small molecular weight 
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contamination between 20-30 ml but also due to the first peak not solely being of 
the correct IFN-a2b A280 spectrum. The fractions collected from the first peak 
were pooled on the basis of their A280 spectrum. The fractions pooled usually 
eluted between 14 and 18 ml (inclusive). Examples of the A280 spectra from a 
guanidine-HCI separation can be seen in figure 4.28. 
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Figure 4.28: Examples of the absorbance scans obtained of the guanidine-HCI 
fractions collected during the gel filtration. The fractions were pooled on the basis 
of their A280 profile. The red line indicates the possible contamination which absorbs 
around 260-280 nm and the black line indicates the IFN-a2b fractions pooled and taken 
through the refolding. 
The absorbance spectra shown in figure 4.28 shows the difference in absorbance 
of two fractions taken throughout the gel filtration where no Triton X-100 has 
been used. The spectra show the presence of either contamination that also 
absorbs around 260 nm, possibly DNA or mis-folded IFN-a2b. Due to these 
differences in the A280 spectra the BCA assay was introduced as a comparison to 
the A280 values. The BCA assay was used on the solubilised inclusion bodies 
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where Triton X-100 had been used to discover the correct total protein 
concentrations. The standard curves can be seen in figure 4.29. 
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Figure 4.29: Standard curves for BCA assay. The assay was carried out with the 
buffers 8M urea, 6M guanidine-HCI and 20 mM Tris-HCI and used to work out the total 
protein concentrations of subsequent samples (R values were 0.999,0.9992 and 0.9966 
respectively). 
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31 Expression Yields 
Cell Pellet 16.75 g 
Inclusion 
4.2 g bodies 
Weight of 
A280 BCA 
Triton X- Inclusion bodies Volume BCA Total 
(mg/ml) (mg/ml) 100 solubilised (g) (MI) mg 
Urea 0.5 0.78 0.58 20 11.6 
Urea DTT 0.5 0.53 0.29 20 5.8 
Guanidine-HCI 0.5 1.83 0.82 20 16.4 
Guanidine-HCI 
0.5 1.76 0.71 20 14.2 
DTT 
Without A280 BCA 
Volume BCA Total 
Triton X- (mg/ml) (mg/ml) 
(ml) mg 
100 
Urea 0.5 0.72 0.44 20 8.8 
Urea DTT 0.5 0.99 0.25 20 5 
Guanidine-HCI 0.5 1.23 1.22 20 24.4 
Guanidine-HCI 
0.5 1.26 1.3 20 26 
DTT 
Table 4.4: Concentrations of the washed IFN-a2b inclusion bodies with and 
without Triton X-100. The BCA assay tends to give lower protein concentrations when 
Triton X-100 has been added to the inclusion bodies indicating Triton X-100 interference 
with A280 readings. There is still a discrepancy between the urea solubilised inclusion 
bodies when Triton X-100 has not been used however the guanidine-HCI solubilised 
inclusion bodies give similar values. The guanidine-HCI solubilised inclusion bodies 
always give higher total protein concentrations indicating more solubilisation. 
The concentrations from the 31 expression of IFN-a2b can be seen in table 4.4. 
The inclusion bodies were split and half were treated with washing steps 
containing Triton X-100. There is a large amount of variability in the values for 
the total protein between the two methods used; A280 and the BCA assay when 
Triton X-100 is used during the washing. This highlights the problem with Triton 
X-100 contributing to the calculation of total protein concentration using A280. The 
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A280 is almost double the BCA value. The washing of the inclusion bodies without 
Triton X-100 provides much more consistent results between methods especially 
for the guanidine-HCI solubilised inclusion bodies, the urea solubilised inclusion 
bodies still have a degree of variability. The BCA assay was used to calculate 
the total amount of IFN-a2b in milligrams (mg); this showed in the highest case 
that from the guanidine-HCI solubilisation the amount of protein was almost three 
times the level from the urea solubilisation. 
Triton X-100 
Sample 
Solubilised inclusion 
bodies (mg) 
Pools after gel 
filtration (mg) 
Yield (%) 
A280 BCA A280 BCA A280 BCA 
Urea 7.8 5.8 0.19 0.38 2.4 6.6 
Urea DTT 5.3 2.9 0.26 0.24 4.9 8.3 
Guanidine-HCI 18.3 8.2 0.6 0.6 3.3 7.3 
Guanidine-HCI DTT 17.6 7.1 4.65 3.85 26.4 54.2 
Without Triton X-100 
Solubilised inclusion Pools after gel 
Sample Yield (%) 
bodies (mg) filtration (mg) 
A280 BCA A280 BCA A280 BCA 
Urea 0.72 0.44 0.11 0.095 15.3 21.6 
Urea DTT 1 0.99 1 2.5 1 0.225 1 0.75 1 22.7 1 30 
Guanidine-HCI 2.3 2.2 0.5 0.52 21.7 23.6 
Guanidine-HCI DTT 2.6 3 0.425 0.41 16.3 13.7 
Table 4.5: Concentrations from the 31 fermentation before and after purification 
by gel Filtration. Both the inclusion bodies treated with and with out Triton X-100 are 
shown. After the gel filtration the concentrations of the inclusion bodies treated with 
Triton X-100 give more consistent values between methods confirming the removal of 
the Triton X-100. 
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10 1 Fermentation Yields 
Cell Pellet = 52.46 g 
Inclusion bodies = 17.95 g 
Weight A280 BCA 
Volume Total using BCA (g) (mg/ml) (mg/ml) 
(ml) result (mg) 
Urea 1 2.3 2.2 20 44 
Urea DTT 1 2.9 2.2 20 44 
Guanidine-HCI 1 3.3 3.3 20 66 
Guanidine-HCI 
1 3.6 3.4 20 68 
DTT 
Table 4.6: Concentrations of washed IFN-a2b inclusion bodies from the 10 1 
fermentation. No Triton X-100 was used during the wash steps. The total protein 
concentrations between the guanidine-HCI solubilised inclusion bodies and urea do not 
vary to the same extent as the 3/ expression, see table 4.3. The solubilisation with 
guanidine-HCI still provides a higher total protein concentration. 
As with the 31 expression the concentrations of the solubilised inclusion bodies 
from the 10 1 fermentation were measured and investigated. No Triton X-100 was 
used during the washing of the 10 1 fermentation inclusion bodies and so only 
four conditions were analysed, see table 4.6. The concentration of the solubilised 
inclusion bodies did not differ to the same extent as the 31 expression. Gel 
filtration was also carried out on the 10 1 fermentation solubilised inclusion bodies 
and the total protein concentrations can be seen in tables 4.5 and 4.7. 
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10 1 fermentation yields from gel filtration 
Solubilised 
Pools after gel Sample inclusion Yield (%) 
filtration (mg) 
bodies (mg) 
A280 BCA A280 BCA A280 BCA 
23 22 6.4 6.05 28 27.5 
Urea 
Urea DTT 29 22 6.85 6.45 24 29 
33 33 12.1 11.65 37 35 
Guanidine-HCI 
36 34 13.4 12.9 37 38 
Guanidine-HCI DTT 
Table 4.7: Yields from the gel filtration run carried out on the inclusion bodies 
from the 10 1 fermentation. No Triton X-100 was used during the washing steps. As 
expected all the yields from the guanidine-HCI solubilisation are higher than the values 
for the urea solubilisation. 
The yields calculated in from both the 31 and 10 1 expressions show that the 
yields of IFN-a2b after gel filtration are lower when Triton X-100 has been used 
for the washing of the inclusion bodies washing. This demonstrates that the ion 
exchange has been successfully replaced with gel filtration and that the removal 
of Triton X-100 from the washing steps actually improves the yields of IFN-a2b. 
Refolding of the IFN-a2b solubilised inclusion bodies can now go ahead confident 
that contamination should not interfere. 
4.3: Conclusions 
This chapter has revealed some important characteristics of IFN-a2b. The 
differences in solubility of the IFN-a2b inclusion bodies is clear with guanidine- 
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HCI being the favoured denaturant as shown in figure 4.9 and previously by 
Valente et al., (2006). Urea however is the preferred denaturant for 
Biomanufacturing and thus was fully explored as a denaturant. The differences 
in the results gained from the refolding, depending on which denaturant has been 
used for the solubilisation was clear. Only the inclusion bodies solubilised in 
guanidine-HCI resulted in alpha helical secondary structure (figures 4.14 and 
4.17). However the intrinsic fluorescence results revealed "tyrosine" emission 
which had not been previously observed during the characterisation work in 
chapter 3, section 3.2.3, it is also known that in proteins containing a mixture of 
tryptophan and tyrosine residues it is the tryptophan residues which dominate 
(Lackowicz, 1983). Beldarrain et al., (2001) carried out detailed biophysical 
characterisation of folded IFN-a2b and there was no mention of tyrosine 
fluorescence. Therefore to ensure this tyrosine emission had been caused by the 
IFN-a2b, denaturation trials were carried out involving repeated freeze thawing 
(figure 4.19) along with denaturation with guanidine-HCI, DTT and heat (figure 
4.20). None however resulted in the IFN-a2b standard producing a mixture of 
both tyrosine and tryptophan fluorescence. 
The next stage was to investigate everything which had been added to the 
protein or used throughout the expression and treatment of the inclusion bodies. 
As Triton X-100 had been used during the wash steps and is known to absorb at 
around 280 nm it was investigated. Triton X-100 is a non-ionic detergent used 
extensively in the treatment of membrane proteins but also for its ability to 
breakdown lipids, a useful characteristic for washing away any contaminating 
lipids from inclusion bodies. Triton X-100 has been known to interfere with 
protein absorption spectra (Tiller, et al., 1984). The ability of detergents such as 
Triton X-1 00 to interact with membrane proteins has been investigated and is due 
to the binding of the detergent molecule to the protein's hydrophobic regions 
allowing it to remain soluble in aqueous solution (Moller and le Maire, 1993). 
This binding can take place whether the Triton X-100 is in the form of a monomer 
or as a micelle above its critical micelle concentration (CMC) (Clarke, 1975). The 
CMC is the concentration at which detergent molecules convert from monomers 
to micelles. The CMC of Triton X-100 is 0.2 mM as stated in the product 
literature. The solution used here was a1% (v/v) solution providing a final Triton 
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X-100 concentration of 15.5 mM. This suggests that the Triton X-100 was either 
binding to any exposed hydrophobic regions of the denatured IFN-a2b molecules 
or the concentration remaining after washing was high enough, due to such a 
high concentration being used initially, that the formed micelles were too large to 
pass through the dialysis tubing and be removed. 
The introduction of the gel filtration resulted in the Triton X-100 being removed 
from the solubilised inclusion body samples. The conclusion however that 
removal of Triton X-100 altogether did not have a negative effect on the yield of 
IFN-a2b allowed Triton X-100 to be removed completely. The gel filtration was 
kept even though no Triton X-100 was involved as a small peak late in the elution 
profile highlighted to continued need for a purification step, see figure 4.24. The 
next stage is to use this gel filtration step to purify the solubilised inclusion bodies 
and begin refolding this purified IFN-a2b using the same method of a1 in 10 
dilution followed by dialysis at 4 °C. 
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Chapter 5 
Chapter 5 
Refolding of IFN-a2b purified by gel filtration and investigation of 
the solubilised inclusion bodies 
5.1: Introduction 
The gel filtration proved successful in removing contamination from the IFN-a2b 
inclusion bodies. Refolding was therefore started. The refold method consisted 
of a dilution step followed by dialysis. The IFN-a2b was kept under reducing 
conditions by use of DTT until the final stage when it was removed using a 
second dialysis step. The addition of oxidised glutathione was investigated as 
the only additive. The refolding work detailed in this section concentrated on 
samples made up from pooled fractions from the gel filtration where no Triton X- 
100 has been used to wash the inclusion bodies. Once the refolding had been 
carried out the refolded material underwent functional analysis through an 
antiviral assay and a reporter gene assay. Alongside these experiments the 
refolded material was further purified to remove any mis-folded species and 
elucidate if ion exchange on IFN-a2b could be successful without the influence of 
urea. 
Due to the differences observed in chapter 3, section 3.2.4, in the unfolding of 
IFN-a2b along with the solubilisation of the inclusion bodies with urea and 
guanidine-HCI the solubilised inclusion bodies were investigated using the 
available techniques. Any differences in the starting material may have been the 
reason for such differences in the success of the refolding and so was 
investigated. The occurrence of secondary structure in unfolded proteins has 
been investigated by nuclear magnetic resonance (NMR) (Shortle and Ackerman, 
2001), small angle x-ray scattering (SAXS) (Lattman, 1994) and Fourier 
transform infrared spectroscopy (FTIR) (Ami et al., 2006). Here far and near UV 
CD, intrinsic fluorescence, ANS fluorescence, N-(1-pyrene) maleimide binding 
were investigated. These techniques are more widely available and may provide 
an insight into the difference observed during refolding. 
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5.2: Refolding 
5.2.1: Refold of a one step dialysis into 20 mM Tris pH 8.0 
The first refold experiment carried out was a short dialysis step of 1 ml sample of 
guanidine-HCI solubilised inclusion bodies dialysed into 1I of 20 mM Tris pH 8.0 
to investigate if the quick approach suits this protein. The refold was carried out 
at 24 °C as well as 4 °C and at this sample to buffer ratio all denaturant should be 
removed. 
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Figure 5.1: Fluorescence results of the final supernatants from the refold 
consisting of one dialysis step. Both samples (black and red lines) show tryptophan 
fluorescence but appear shifted to the longer wavelengths in comparison to the IFN-a2b 
standard (green line). 
Sample Barycentric Mean (nm) 
Folded IFN-a2b standard 341.6 
4C 343.2 
Room temperature 343.5 
Table 5.1: Barycentric mean of the samples refolded by one dialysis step at 4 °C 
and 24 °C. The results shows results similar to the IFN-ar2b standard suggesting some 
of the IFN-a2b has refolded 
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Starting Final 
Sample concentration concentration Yield (%) 
(mg/ml) (mg/ml) 
4 °C 1 0.084 8.4 
24 °C 1 0.0678 6.78 
Table 5.2: Concentrations and yields of the refolded samples after one dialysis 
step. The results show a large loss of protein indicating it is not an efficient method of 
refolding IFN-a2b. 
The refold of one dialysis step shown in figure 5.1 illustrates that IFN-a2b does 
refold to look similar to the IFN-a2b standard (table 5.1) however the yields listed 
in table 5.2 of 8.4 % and 6.78 % for 4 °C and 24 °C respectively suggest that it is 
not a suitable way of refolding IFN-a2b. 
5.2.2: Refolding under reducing conditions 
In this refold the protein underwent the following: 
91 in 10 dilution into 20 mM Tris, 1 mM DTT pH 8.0. 
" Dialysis into the same buffer to remove any denaturant. 
" Dialysis to remove the DTT. 
All steps were carried out at 4 °C. The end samples were concentrated for CD 
analysis using a Vivaspin 5000 MWCO concentrator. An aliquot of each of the 
guanidine-HCI pools was dialysed into 8M urea, 20 mM Tris pH 8.0 with and 
without DTT. This was to investigate, again whether the starting denaturant has 
an effect on the refolding now with the Triton X-100 removed. The 
concentrations were measured throughout the refold and can be seen in table 
5.3 
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Starting 
Sample Concentration Dilution Dialysis I Dialysis 2 (m /ml) 
BCA A280 BCA A280 BCA A280 BCA A280 
Urea 0.27 0.3 0.11 0.082 0.042 0.039 0.036 
Urea DTT 0.25 0.29 0.12 0.084 0.041 0.04 0.035 
Guanidine-HCI 1.3 2.4 0.19 0.12 0.15 0.22 0.14 
Guanidine-HCI 1 26 2 6 26 0 0 29 18 0 18 0 15 0 DTT . . . . . . . 
Guanidine-HCI 
dialysed into 0.88 2 0.23 0.24 0.15 0.21 0.17 
urea 
Guanidine-HCI 
DTT dialysed 0.98 1.9 0.21 0.13 0.15 0.21 0.13 
into urea DTT 
Yield (%) 
Sample BCA A280 
35 44 Urea 
33 42 Urea DTT 
Guanidine-HCI 116 117 
Guanidine-HCI 69 52 DTT 
Guanidine-HCI 
dialysed into 91 71 
urea 
Guanidine-HCI 
DTT dialysed 100 100 
into urea DTT 
Table 5.3: Concentrations of the samples taken throughout the refold under 
reducing conditions. The concentrations have been measured by both the BCA 
method and A280. The variation in sample concentration between methods highlights the 
difficulties experienced in measuring the concentrations throughout these experiments 
especially when the refold is unsuccessful. Throughout the refold a broad A280 spectrum 
does indicate the incorrect folding of the IFN-a2b. 
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The concentrations in table 5.3 highlight the variability between the two methods 
of protein concentration determination. Yields were calculated using the values 
from both assays and appear to give similar results. The greatest yields came 
from the samples where the inclusion bodies had been solubilised in guanidine- 
HCI. The samples solubilised in guanidine-HCI and then dialysed into urea give a 
yield of 100 %. A 100 % and above in refolding of proteins is unrealistic 
especially as there is loss of protein to precipitation throughout the refold. The 
values do however show the differences between refolding from urea and 
guanidine-HCI. 
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Figure 5.2: Intrinsic fluorescence results of the final samples of the refold. The 
results all show tryptophan fluorescence similar to that of the folded IFN-a2b standard 
(black dashed line). If not already at 0.1 mg/ml the samples were diluted to 0.1 mg/ml for 
fluorescence analysis using the A280nm value of the concentrated samples. From these 
curves the barycentric mean was calculated (table 5.4). 
The fluorescence results in figure 5.2 show tryptophan emission in all six 
samples. There is no indication of tyrosine fluorescence confirming the possible 
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cause of this was the Triton X-100. The Cobra reference standard can be seen 
as the purple line with the highest intensity. The other six samples can be seen 
to be lower in fluorescence intensity and more red shifted than the standard 
indicating that the tertiary structures are not quite as well folded as the standard. 
The barycentric means of the curves can be seen in table 5.4 measured between 
306 and 380 nm. 
Sample 
Barycentric Mean 
(nm) 
Guanidine start 349 
Guanidine end 344.2 
Guanidine DTT start 349 
Guanidine DTT end 343.7 
Urea Start 348 
Urea end 344.4 
Urea DT start 348 
Urea DTT end 346.7 
Guanidine dialysed into urea start 346 
Guanidine dialysed into urea end 344.5 
Guanidine DTT dialysed into urea DTT start 346 
Guanidine DTT dialysed into urea DTT end 343.1 
IFN-a2b standard 341.6 
Table 5.4: Barycentric means of the final samples of all six refolded samples. The 
closest samples to the folded IFN-a2b standard were the samples dialysed into urea 
DTT after being solubilised in guanidine-HCI and DTT. The start values represent the 
solubilised inclusion bodies and the end represents the values calculated from figure 5.2. 
The Barycentric mean was calculated between 306-380 nm. 
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The barycentric means in table 5.4 for all six samples support the results seen in 
figure 5.2 The samples are red shifted to the longer wavelengths in comparison 
the IFN-a2b standard indicating they are not quite as well folded as the IFN-a2b 
standard. 
ANS binding of the final samples from the refold 
The samples used for the intrinsic fluorescence analysis were also subjected to 
ANS binding. ANS was added to the sample to a final concentration of 0.1 mM, 
the samples were excited at 360 nm. 
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Figure 5.3: ANS binding of the final samples from the refold. The ANS binding of 
the final samples initially solubilised in guanidine-HCI (pink and royal blue lines) and the 
dialysed samples (green and red lines) show a larger emission than the IFN-a2b 
standard. The urea solubilised samples (brown and turquoise lines) show similar 
intensity of fluorescence but are blue shifted compared to the standard. 
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Sample Barycentric mean (nm) 
IFN-a2b standard 511.1 
Guanidine-HCI 502.7 
Guanidine-HCI DTT 497.8 
Urea 506.0 
Urea DTT 505.2 
Guanidine-HCI dialysed into urea 499.8 
Guanidine-HCI DTT dialysed into urea DTT 499.7 
Table 5.5: Table of the barycentric means of the final samples binding of ANS. 
Out of all six samples the closest to the IFN-a2b standard is the sample solubilised in 
urea. The samples appear to be blue shifted to the IFN-a2b standard. Barycentric mean 
measured between 420 -600 nm. 
The ANS binding of the final refolded samples shows that the samples are again 
not exactly the same as the IFN-a2b standard. The intensity of the guanidine- 
HCI solubilised samples and the samples dialysed into urea show a large 
increase in fluorescence intensity and a shift to the shorter wavelengths; see 
figure 5.3 and table 5.5. The large increase in intensity would suggest a more 
molten globule state than the fully native state. This supports the intrinsic 
fluorescence results as they also show indications of partially folded IFN-a2b. 
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Far and near UV analysis 
The samples were concentrated and far and near UV analysis carried out to gain 
information about secondary and tertiary structure. 
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Figure 5.4: Far UV CD to show the final samples of the refold. The far UV shows 
alpha helical structure in all six samples. The guanidine-HCI solubilised samples (brown 
and green lines) show alpha helical structure most similar to the IFN-a2b standard (black 
dashed line). 
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Figure 5.5: Near UV CD to show the final samples of the refold. The near UV shows 
tertiary structure similar to that of the standard in both the guanidine-HCI solubilised 
samples (red and green lines). The remaining samples do not give a near UV signal. 
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The far UV analysis in figure 5.4 shows alpha helical structure in all six samples. 
The closest secondary structure to the IFN-a2b standard comes from the two 
samples solubilised in 6M guanidine with or without DTT. The samples dialysed 
into urea then have the second best alpha helical structure and finally it is the 
urea samples with the least amount of secondary structure. The near UV (figure 
5.5) shows the same characteristics as the standard from both guanidine-HCI 
solubilised samples, indicating that the tertiary structure of the refolded samples 
is very similar to that of the IFN-a2b standard. The concentrations used for CD 
analysis can be seen in table 5.6. 
Sample A280 Concentration (mg/ml) 
Urea 0.11 
Urea DTT 0.11 
Guanidine-HCI 0.5 
Guanidine-HCI DTT 0.52 
Guanidine-HCI dialysed into urea 0.17 
Guanidine-HCI DTT dialysed into urea DTT 0.15 
Table 5.6: Table of concentrations used for far and near UV analysis. 
SDS-PAGE analysis of the refolded samples 
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Figure 5.6: SDS-PAGE analysis of the final samples of the retold. /he it-N-aZb 
shows a shift up the gel under reducing conditions (carried out by addition of DTT and 
lodoacetamide). The refolded samples also show a shift. The urea samples cannot be 
seen and may require a more sensitive staining procedure than the Coomassie blue 
used here. IFN-a2b standard loaded to 3 pg. 
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Figure 5.7: Thermal melt trace of the sample refolded from guanidine-HCI with 
DTT. This sample was the only sample which gave a trace to which a curve could be 
fitted to calculate a Tm. The Tm was found to be 59 °C. The IFN-a2b standard has a Tm 
of 70 °C. Curve fitted by Origin TM using a Boltzmann function. 
Conclusions from the refolding experiments 
Samples solubilised in guanidine-HCI 
The results show successful refolding from the two samples solubilised in 6M 
guanidine-HCI. The far UV CD for these two samples shows similar signals and 
intensities at 208 nm and 220 nm to that of the IFN-a2b standard. The barycentric 
means for both guanidine-HCI solubilised samples are not the same as the folded 
IFN-a2b standard indicating some incorrect folding therefore the sample may be 
a mixture of folded and mis-folded species and thus require further purification. 
The near UV shows tertiary structure in the solubilised guanidine-HCI sample 
supporting the intrinsic fluorescence as the barycentric mean is almost the same 
as the IFN-a2b standard. The SDS-PAGE analysis in figure 5.6 shows the shift 
of the band from the reduced sample to a higher molecular weight but it also 
156 
20 30 40 50 60 70 80 90 
highlights the presence of some aggregation. After each step of the refold the 
samples are centrifuged to remove any precipitation which may occur so this may 
be soluble oligomers which have formed. Figure 5.7 showing the thermal melt is 
poorly cooperative and gives a melting temperature of 59 °C whereas the IFN- 
a2b standard has a Tm of 70 °C. This result indicates the guanidine-HCI refolded 
samples are not as stable or as well folded as the IFN-a2b standard. 
Samples solubilised in guanidine-HCI and dialysed into urea 
The samples dialysed into urea after being solubilised into guanidine-HCI show 
far UV CD spectrum that does indicate alpha helical structure but is not as 
intense does as the signals from the folded IFN-a2b standard or the guanidine- 
HCI solubilised samples (figure 5.4). The intrinsic fluorescence does not shift to 
341.6 nm; the barycentric means for the samples are 346 nm (without DTT) and 
343 nm (with DTT) however the near UV does not show any native tertiary 
structure. 
Urea solubilised samples 
The inclusion bodies solubilised in urea were the least successful of all six 
samples. The starting concentrations are lower due to the poor solubilisation. 
Fluorescence analysis was carried out on both samples and tryptophan emission 
was observed however the barycentric means did not match the value from the 
IFN-a2b standard, table 5.5. The far UV CD also did not match the IFN-a2b 
standard, alpha helical signals were obtained but were not intense enough to 
confirm a structure equivalent to that of the IFN-a2b standards. 
5.2.3: Refold with 0.1 mM oxidised glutathione 
In order to ensure formation of the two disulphide bonds 0.1 mM oxidised 
glutathione was added after the first dialysis step in the hope the correct two 
disulphides would form, which may had been the reason the structure seen 
previously was not identical to that of the IFN-a2b standard. The oxidised 
glutathione was added at 0.1 mM and the incubation time was 1h at 4 °C. 
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Starting 
Sample Concentration Dilution Dialysis 1 Dialysis 2 (m /ml) 
BCA A280 BCA A280 BCA A280 BCA A280 
Urea 0.27 0.3 0.077 0.044 0.032 0.058 0.038 
Urea DTT 0.25 0.29 0.07 0.046 0.032 0.057 0.041 
Guanidine-HCI 1.3 2.4 0.17 0.19 0.13 0.16 0.12 
Guanidine-HCI 
DTT 1.26 2.6 0.16 0.2 0.12 0.15 0.11 
Guanidine-HCI 
dialysed into 0.88 2 0.61 0.23 0.2 0.22 0.17 
urea 
Guanidine-HCI 
DTT dialysed 0.98 1.9 0.6 0.29 0.21 0.22 0.18 
into urea DTT 
Yield 
Sample BCA A280 
75 86 Urea 
81 89 Urea DTT 
94 63 Guanidine-HCI 
Guanidine-HCI 94 55 DTT 
Guanidine-HCI 
dialysed into 36 74 
urea 
Guanidine-HCI 
DTT dialysed 37 62 
into urea DTT 
Table 5.7: Table of concentrations from the refold with 0.1 mM oxidised 
glutathione. The refolded samples from guanidine-HCI show the highest yield measure 
by the BCA assay however the urea solubilised and refolded inclusion bodies show the 
highest yield measured by A280, this confirms interference of contaminants which no 
longer include the Triton X-100. 
Table 5.7 details the protein concentrations measure throughout the refold for 
each condition. The highest yields can be seen to be gained from the refolded 
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guanidine-HCI solubilised inclusion bodies and the urea refolded are the least 
successful. 
Fluorescence analysis of the refold with 0.1 mM oxidised glutathione 
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Figure 5.8: Intrinsic fluorescence results of the refold using 0.1 mM oxidised 
glutathione. The results all show tryptophan fluorescence similar to that of the folded 
IFN-a2b standard however the fluorescence from the urea solubilised (green and blue 
lines) and refolded material have a lower emission intensity. 
The fluorescence results in figure 5.8 show tryptophan emission from all six 
samples. The urea solubilised samples give the lowest intensities suggesting 
less tertiary structure present compared to the other samples. The barycentric 
means of all six samples before the refold and after the refold can be seen in 
table 5.8. 
Solubilisatio 
buffers 
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Sample Barycentric Mean (nm) 
Guanidine start 349 
Guanidine end 341.6 
Guanidine DTT start 349 
Guanidine DTT end 341.6 
Urea Start 348 
Urea end 344 
Urea DTT start 348 
Urea DTT end 345 
Guanidine dialysed into urea start 346 
Guanidine dialysed into urea end 342.8 
Guanidine DTT dialysed into urea DTT start 346 
Guanidine DTT dialysed into urea DTT end 342.7 
IFN-a2b standard 341.6 
Table 5.8: Table to show the barycentric mean of the final samples of all six 
refolds before and after 0.1 mM oxidised glutathione was used. Both the refolded 
samples that were solubilised in guanidine-HCI with or without DTT have barycentric 
means the same as the folded IFN-a2b. 
The table shows that the inclusion bodies solubilised in guanidine-HCI with or 
without DTT give a barycentric mean the same as the IFN-a2b standard 
indicating the successful refolding of these samples has taken place. 
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ANS binding of the refolded samples 
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Figure 5.9: ANS binding of the final samples from the refold using 0.1 mM 
oxidised glutathione. The samples solubilised in guanidine-HCI ± DTT (maroon and 
red lines) and urea (green line) show similar fluorescent intensities as the IFN-a2b 
standard. 
Sample Barycentric mean (nm) 
IFN-a2b standard 511.13 
Guanidine-HCI 505.43 
Guanidine-HCI DTT 505.02 
Urea 508.57 
Urea DTT 517.35 
Guanidine-HCI dialysed into urea 497.17 
Guanidine-HCI DTT dialysed into urea DTT 500.60 
Table 5.9: Barycentric means of the ANS binding of the final samples of the refold 
with 0.1 mM oxidised glutathione. The closest to the IFN-a2b standard is the samples 
solubilised in urea. 
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The ANS results in figure 5.9 show the inclusion bodies solubilised in guanidine- 
HCI and then dialysed into urea give higher intensities than the IFN-a2b standard 
indicating molten globule structure present in these samples suggesting a less 
well folded structure. The barycentric means for the fluorescence analysis can 
be seen in table 5.9. 
Far and near UV CD analysis 
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Figure 5.10: Far UV CD to show the final samples of the refold using 0.1 mM 
oxidised glutathione. The far UV CD spectra show some alpha helical structure in all 
six samples. The samples which show alpha helical structure closest to the folded /FN- 
a2b standard are the samples solubilised in guanidine-HCI (yellow) and guanidine-HCI 
with 1 mM DTT (red). 
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Figure 5.11: Near UV CD to show the final samples of the refold using 0.1 mM 
oxidised glutathione. The near UV CD spectra shows tertiary structure similar to that 
of the standard in both the guanidine-HCI solubilised samples (pink and red lines), there 
is also a little tertiary structure in the dialysed samples (blue and green lines). The urea 
samples did not give a signal indicating any structure (data not shown). 
Sample 
A280nm Concentration 
(mg/ml) 
Urea 0.12 
Urea DTT 0.12 
Guanidine-HCI 0.31 
Guanidine-HCI DTT 0.32 
Guanidine-HCI dialysed into urea 0.17 
Guanidine-HCI DTT dialysed into urea 
DTT 
0.18 
Table 5.10: Sample concentrations for CD analysis. The concentrations shown here 
were used in the analysis of the far UV and near UV CD data shown in figures 5.10 and 
5.11 
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123456789 
Lanes 
50 kDa 1. MWM 
110 2. IFN-a2b standard reduced 
37 kDa01 3. Blank 
25 kDa-f 4. Guanidine-HCI final sample 
20 kDa_f reduced 
15 kDa 
5. Guanidine-HCI final sample 
6. Guanidine-HCI dialysed into 
10 kDaurea final sample reduced 
7. Guanidine-HCI dialysed into 
urea final sample 
8. Urea final sample reduced 
9. Urea final sample 
Figure 5.12: 17 % SDS-PAGE analysis of the final samples of the refold with 
0.1mM oxidised glutathione. The IFN-a2b shows a splitting of the in band in lane 2 
as both the reduced and non-reduced samples were applied to the same lane. The 
samples also show a shift. The urea samples cannot be seen once again, the gel was 
stained using the more sensitive SimplyBlueTM Safe stain. IFN-a2b standard loaded to 
1.5 pg. 
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Figure 5.13: Thermal denaturation of the final samples refolded with 0.1 mM 
oxidised glutathione from solubilisation in guanidine-HCI ± DTT. The Tm calculated 
of the two samples was 67 °C for the guanidine-HCI solubilised sample and 65 °C for the 
guanidine-HCI and DTT solubilised sample. The IFN-a2b standard has a Tm is 70 °C. 
Curve fitted by OriginTM using a Boltzmann function. 
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The results from this refold using 0.1 mM oxidised glutathione show good 
refolding of the IFN-a2b especially from the samples solubilised in guanidine-HCI. 
The far UV CD for these two guanidine-HCI samples show similar signals and 
intensities at 208 nm and 220 nm (figure 5.10). The barycentric mean for both 
guanidine-HCI solubilised samples are the same as the folded IFN-a2b standard, 
see table 5.9. The urea solubilised samples do not give the correct alpha helical 
structure in the far UV region. The intrinsic fluorescence does not shift to the 
wavelength 341.6 nm like with the guanidine-HCI solubilised samples. The 
concentration of the urea samples was too low to measure the near UV (figure 
5.11). All samples solubilised in guanidine-HCI even the samples dialysed into 
urea gave CD signals in the near UV region, the guanidine-HCI solubilised and 
refolded samples being the best. The samples dialysed into urea after being 
solubilise into guanidine-HCI show promising results, the far UV does not give as 
intense signals as the folded IFN-a2b standard however the shape is more 
correct than the urea solubilised samples. The barycentric mean from the 
dialysed samples are closer to the standard than the urea solubilised samples. 
The SDS-PAGE in figure 5.12 show a shift in molecular weight of the refolded 
samples from guanidine-HCI solubilised inclusion bodies. This shift is seen by 
the Cobra IFN-a2b reference standard, see chapter 3, figure 4.7. The thermal 
melts of the samples refolded from guanidine-HCI also give values similar to 
those of the Cobra IFN-a2b reference standard. Here in figure 5.13 the Tm 
values are 65 and 67 °C. The standard has a Tm of 70 °C, see chapter 3, figure 
3.24. 
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5.2.4: Addition of 1 mM oxidised glutathione 
In this experiment 1 mM oxidised glutathione was added to the refold instead of 
0.1 mM. All other steps were kept the same as in section 5.1.2. 
Far UV CD results of the refold with 1 mM oxidised glutathione 
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Figure 5.14: Far UV CD to show the final samples of the refold using 1 mM 
oxidised glutathione. The far UV shows no alpha helical structure in all six samples. 
The result in figure 5.14 indicates that the refolding of IFN-a2b is sensitive to the 
concentration of oxidised glutathione. The results in all six samples give an 
unfolded signal in the far UV region. The far UV CD results do however appear 
to separate into two distinct groups of differing signals. The urea solubilised and 
refolded samples give a positive signal between 220-230 nm. The characteristic 
signals of the poly pro (II) helix are a positive signal at 215 and 228 nm and a 
negative signal at 195 205 nm (Woody, 1992) whereas the remaining samples do 
not have the positive signal around 228 nm but do show a signal at 205 nm. The 
values for the poly proline II helix are for a poly proline peptide in aqueous 
solution and so here the values and positions may differ due to the differing 
environments, see figure 1.10 from Kelly et al., 2005 
investigated by SDS-PAGE. 
The samples were also 
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Figure 5.15: Example of the refolded material when 1 mM oxidised glutathione is 
added to the refold. The samples shown here were solubilised in guanidine-HCI 
usually the most successful condition. The band splitting indicates incomplete disulphide 
formation. 
The gel shown in figure 5.15 shows the incomplete formation of the disulphide 
bonds. There is splitting of the IFN-a2b band indicating that some of the IFN-a2b 
molecules either do not have any correctly formed disulphides or have partially 
formed disulphides. The first reaction is the formation of the mixed disulphide 
intermediate (figure 5.16) and the second an intramolecular step in which a 
second cysteine thiol displaces the mixed disulphide forming the proteins 
disulphide bond (Creighton, 1992). Oxidised glutathione is an intermolecular 
disulphide reagent and its concentration can affect the rate at which the protein 
reacts with the oxidised glutathione producing the mixed disulphide species (Goto 
and Hamaguchi, 1981). Protein disulphides are formed (and broken) by a two- 
step sequential thiol disulphide exchange reaction with the disulphide reagent. 
Work done by Goto and Hamaguchi in 1981 found that the constant fragment of 
the immunoglobulin light chain (CO which has one disulphide bond forms the 
disulphide much slower in the absence of urea as the protein adopts the folded 
conformation burying the cysteine residues. In the presence of urea the reaction 
was completed in 30 minutes whereas in the absence of urea it took several h 
however the effectiveness in the formation of the disulphide was better without 
urea. They also found that at lower concentrations of GSSG the formation of the 
disulphide increased compared to the accumulation of the mixed disulphide but 
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with high GSSG concentrations the mixed disulphide accumulated to a higher 
concentration than the complete disulphide form. They concluded that the 
formation of the mixed disulphide was dependent on the concentrations of GSSG 
but that disulphide formation was not. It could be suggested that in the case of 
the high GSSG concentration the IFN-a2b had been prevented from forming the 
disulphide. It is not the case that the cysteines are buried within the IFN-a2b 
structure, the two cysteines are said to be in region of high mobility 
(Radhaskrisnan et al., 1996). However the cysteines may still be as the mixed 
disulphide and the refolding was continued too early. 
SSG 
GSSG +- GSH 
SH 
SH 
Mixed disulphide intermediate 
Figure 5.16: Formation of the mixed disulphide intermediate when oxidised 
glutathione (GSSG) is used as the reagent. 
The step shown in figure 5.16 can result in both cysteine residues existing as the 
mixed disulphide which appears to be the case here with the IFN-a2b. The step 
which is important to protein folding is the second, the intramolecular step, where 
the protein disulphide is formed. If the disulphide is not formed two assumptions 
can be made either, the thiols are unreactive or the conformation of the molecule 
is keeping the cysteine residues apart (Creighton, 1992) both situations can 
occur also. If the intermediates accumulate then it is the incorrect conformation 
which is preventing disulphide formation. The alpha helical structure can be seen 
to be forming during the dilution step of the refold so conformation should not be 
the cause of the unsuccessful refold. 
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5.3: Activity assays 
These experiments were carried out to investigate any functional activity of the 
refolded samples. The samples used for these assays were the samples from 
the refold where no oxidised glutathione was added. An aliquot of each refolded 
sample was dialysed into PBS. The experiments were carried out at the National 
Institute of Biological Standards and Control (NIBSC), Herts, U. K. The IFN-a2b 
standard 95/566 was provided by NIBSC. 
5.3.1: Antiviral assay 
The first assay to be carried out was an antiviral assay based on the protection 
IFN-a2b gives to cells against the virus EMC. Two cell lines were investigated; 
2D9 glioblastoma cell line and the less sensitive A549 lung carcinoma cell line. 
The error bars shown in each activity assay are the standard deviations where n 
= 3. 
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Figure 5.17: Results of the antiviral assay using the samples in 20 mM Tris. All 
samples of IFN provide resistance to the virus EMC. The refolded samples from 
guanidine-HCI (green and navy lines) have activity closest to the IFN-a2b standard 
(black line) provided by NIBSC. The error bars shown are the standard deviations where 
n=3. 
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The IFN-a2b reference standard 95/566 shows a sigmoidal relationship between 
protein concentration and absorbance at 610 nm, see figure 5.17. The majority 
of the samples show this relationship also which is a good indication that the 
expressed and refolded IFN-a2b is acting correctly as is the IFN-a2b reference 
standard. The IFN-a2b standard does not give a complete sigmoidal curve due 
to lack of data. 
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Figure 5.18: Antiviral assay using 2D9 cell line and PBS refolded samples. All 
samples of IFN provide resistance to the virus EMC activity. The samples refolded from 
guanidine-HCI (green and navy lines) have activity similar to the NIBSC standard (black 
line) and the urea refolded samples (turquoise and pink lines) have the least amount of 
activity. The error bars shown are the standard deviations where n=3. 
The samples in 20 mM Tris give data which fits a sigmoidal curve better than the 
samples dialysed into PBS (figure 5.18 and 5.17) 
choice for these experiments. 
PBS is usually the buffer of 
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Results of the PBS refolded samples using the A549 cell line. 
For the cell line A549 only the PBS samples were tested. 
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Figure 5.19: Data to show the effects of the IFN-a2b on the cell line A549 on 
infection with EMC virus. All samples provide resistance from the EMC virus on the 
less sensitive cell line. The urea refolded samples (turquoise and pink lines) have the 
least amount of activity and the guanidine-HCI samples (green and navy lines) have the 
most activity. The error bars shown are the standard deviations where n=3. 
Figure 5.19 show the results from the antiviral assay using the cell line A549, the 
less sensitive cell line shows good sigmoidal shaped curves similar to the IFN- 
a2b reference standard 95/599. 
5.3.2: Reporter gene assay 
The second assay to test IFN-a2b function was a reporter gene assay based on a 
transfected HEK 293 cell line harbouring the secreted alkaline phosphatase 
cDNA linked to the IFN stimulated response element (IRSE) promotor. This 
experiment was also only carried out on the PBS samples and as it is a less 
sensitive assay compared to the antiviral assay the initial dilutions were smaller. 
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Figure 5.20: Reporter gene assay results of the PBS samples. All samples induce 
expression of alkaline phosphatise leading to some level of substrate breakdown.. The 
sample refolded from guanidine-HCI once dialysed into urea (navy line) shows activity 
closest to the NIBSC standard (black line). Surprisingly the Cobra standard (red line) is 
one of the least active samples. The error bars shown are the standard deviations where 
n=3. 
The reporter gene assay gave good data for the refolded samples along with the 
antiviral assay even with the reporter gene assay being less sensitive, figure 
5.20. The results from these two assays can be used to calculate specific activity 
of all the samples relative to the IFN-a2b standard 95/566. 
The 95/566 standard has an assigned potency of 70,000 IU/ml. The estimated 
IFN-a2b protein concentration is 500 ng/ml. Therefore the calculated specific 
activity is 140 IU/ng or 1.4 x 108 I U/mg. 
A 
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A549 
Specific Activity 
(IU/mg) 
Sample Tris PBS 
Cobra standard 3.3 x 10 
Guanidine-HCI DTT 6.4 x 10 
Guanidine-HCI dialysed 
into urea 
3.1 x 10' 
Urea 105 2.4x10 
UreaDTT 1.2x10 2.5x10 
Unfolded 8.5 x 106 9.6 x 10 
2D9 
Sample Specific Activity (IU/mg) 
Tris PBS 
Reporter gene 
assay 
Cobra standard 2.11 x 10 2.05 x 10 1.08 x 10 
Guanidine-HCI DTT 1.46 x 10 4.8 x 10 1.8 x10 
Guanidine-HCI dialysed 
into urea 
7 10x10 7 4.8x10 7 1.7x10 
Urea 2.33x10 3.96x10 2.2x10 
Urea DTT 5.2x10 2.5x10 7.8x10 
Unfolded 15.5 x 106 10 x 10 
Table 5.11: Specific activities for the refolded samples from the antiviral assay 
and the reporter gene assay. The Cobra standard and the guanidine-HCI refolded 
material give activities good enough for fully folded active IFN-a2b. 
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The specific activities calculated from the activity assays can be seen in table 
5.11. The values generated for the Cobra standard and the guanidine-HCI 
solubilised samples are what would be expected for properly folded fully active 
IFN-a2b. There is some variation but that is a reflection on the fact that there is 
only data from a couple of assays. Manufacturers usually perform at least 5 
independent assays (personal communication A. Meager). There is however 
consistent differences in activity between the guanidine-HCI and urea samples. 
The fact that the unfolded samples gave activity could be due to the high dilutions 
the samples undergo as part of the assay which may have lead to some 
refolding. Examples of values published for the activity of folded and purified 
IFN-a2b can be seen in table 5.12. These are consistent with the results shown 
in table 5.12 from the guanidine-HCI solubilised inclusion bodies. 
Activity (IU/mg) Reference 
1x 10 Beldarrain et al., 2001 
3x 10 Srivastava et al., 2001 
2.7 x 10 Cao et al., 2006 
2x 10 Rabhi-Essati et al., 2007 
1.9 x 10 Shi et al., 2007 
Table 5.12: Specific activities recorded for different methods of purifying and 
refolding IFN-a2b. These values are similar to those achieved from the guanidine-HCI 
refolded samples and also the Cobra standard. 
5.4: Ion exchange of the refolded IFN-a2b 
Ion exchange was used as a final purification step following the refold. It was 
clear from the SDS-PAGE analysis that either there was contamination of a 
higher molecular weight or oligomerisation of the IFN-a2b. But also in the case of 
the refold where no oxidised glutathione was added the fluorescence of the 
guanidine-HCI solubilised samples differed from the IFN-a2b standard but the far 
UV CD gave a very successful result. In order to obtain pure refolded material 
especially from the refolds from guanidine-HCI ion exchange at pH 8.0 was used. 
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Ion exchange of the guanidine-HCI solubilised and refolded IFN-a2b 
Ion exchange was used to purify the IFN-a2b from the refold without oxidised 
glutathione from guanidine-HCI solubilised inclusion bodies. The concentrations 
before and after the ion exchange can be seen in table 5.13. 
Sample Concentration (mg/ml) 
Starting concentration post refold 0.14 
Pool post ion exchange 0.025 
Pool post ion exchange concentrated 0.075 
Table 5.13: Concentrations of the pools before and after the ion exchange from a 
guanidine-HCI solubilised and purified inclusion bodies. 
40 
30 
20 
cv 
O 
10 
0 
Volume (ml) 
Figure 5.21: Ion exchange profile of guanidine-HCI solubilised sample refolded 
and then purified at pH 8.0. The spectrum shows some loss of protein in the 
flowthrough. The elution profile shows a prominent peak at 26 ml (Na CI concentration of 
-300 mM NaCl), followed by a second peak at 32 ml. The peaks were analysed by 
fluorescence and far UV CD. 
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The ion exchange of the final sample from the refold can be seen in figure 5.21. 
The ion exchange was carried out a pH 8.0. The fractions collected from 20-40 
ml were analysed by absorbance at 280 nm and pooled on the basis of their 
profile as with the initial gel filtration. The samples were too dilute to be analysed 
by SDS-PAGE. Once the pools had been made they were concentrated using a 
Vivaspin 5 kDa MWCO concentrator. The fractions used for the pool of the 
folded protein were made up of fractions taken at 25-29 ml (inclusive). 
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Figure 5.22: Absorbance spectra of the fractions collected during the ion 
exchange purification of the guanidine-HCI refolded IFN-a2b. The fractions 
collected between 25 and 29 ml show similar absorbance spectra to the IFN-a2b 
standard. The fractions collected later around 30 ml and the flowthrough do not show 
absorbance spectra similar to the standard indicating purification of a further 
contaminant. 
The fractions collected from the ion exchange at pH 8.0 of the guanidine-HCI 
refolded IFN-a2b were pooled on the basis of their A280 spectra (figure 5.22). The 
absorbance spectra also highlight the similarities between the material which did 
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not bind to the resin and was lost in the flowthrough and the material which did 
bind but eluted later. The differences observed between the fractions at 26 ml 
and 30 ml indicate that the IFN-a2b has some residual contamination present 
and/or mis-folded IFN-a2b. Usually a polishing step would be incorporated in an 
industrial setting and the results here confirm the need for this further purification 
post refolding. 
Intrinsic fluorescence analysis of the refolded and purified IFN-a2b from 
guanidine-HCI solubilised inclusion bodies. 
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Figure 5.23: Fluorescence results of the ion purified IFN-a2b by ion exchange at 
pH 8.0, solubilised with guanidine-HCI and refolded. The barycentric mean results in 
the same wavelength as the IFN-a2b standard. 
Sample Barycentric Mean (nm) 
Refolded and purified IFN-a2b from guanidine-HCI 341.43 
IFN-a2b standard 341.62 
Table 5.14: Barycentric mean of the refolded and purified IFN-a2b from 
guanidine-HCI solubilised inclusion bodies. 
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The fluorescence emission in figure 5.23 shows tryptophan fluorescence and a 
barycentric mean which now matches the IFN-a2b standard, see table 5.14. 
Far UV CD analysis of the refolded and purified IFN-a2b from guanidine-HCI 
solubilised inclusion bodies. 
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Figure 5.24: Far UV CD of the guanidine-HCI solubilised, refolded and purified IFN- 
alb. The sample exhibits alpha helical structure similar to that of the IFN-a2b standard 
suggesting the further purification of the IFN-a2b after refolding was successful. 
The far UV CD in figure 5.24 shows alpha helical structure from the guanidine- 
HCI solubilised, refolded and purified by ion exchange IFN-a2b. The result is not 
an exact match as with the fluorescence but both show promising and successful 
purification of the IFN-a2b after refolding. The purification of the IFN-a2b 
solubilised inclusion bodies at high concentrations of urea by ion exchange was 
not particularly successful as the IFN-a2b did not appear to bind. This result 
shows that IFN-a2b does bind to the Q SepharoseTM resin at pH 8.0 providing yet 
more evidence that the high urea concentrations were the problem during the 
178 
initial purification of the IFN-a2b solubilised inclusion bodies, chapter 4, section 
4.2.4. 
To optimise conditions two further pH values were tested to investigate whether 
the ion exchange could be improved, possible eliminating any loss of IFN-a2b 
during in the flowthrough or improvement to the separation. These were carried 
out at pH 8.4 and 8.6. Once the refolding had ended the samples were dialysed 
into the appropriate buffers. 
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Figure 5.25: Ion exchange of refolded guanidine-HCI samples at pH 8.4 and pH 8.6. 
The separation is not as efficient as the ion exchange at pH 8.0. It also shows more 
unfolded IFN-a2b contaminating the IFN-a2b which elutes at a lower NaCl concentration. 
The ion exchange at pH 8.4 and 8.6 shown in figure 5.25 confirm pH 8.0 to be the 
best condition in which to purify IFN-a2b after refolding. The purification does not 
result in a clear separation but also increases the amount of protein lost in the 
flowthrough. 
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Urea ion exchange 
As the ion exchange had been successful in purifying the guanidine -HCI 
solubilised and refolded inclusion bodies, the urea solubilised material was 
investigated also. 
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Figure 5.26: Ion exchange profile of a refolded sample from urea solubilised 
inclusion bodies. The peak at 26 ml is present as with the guanidine-HCI solubilised 
and refolded IFN-a2b however the more dominant peak is at -33 ml, also the separation 
of the two species is poor. 
The ion exchange results of the urea solubilised and refolded IFN-a2b in figure 
5.26 shows a similar separation to the guanidine-HCI solubilised and refolded 
IFN-a2b however the largest peak comes from the material which elutes later (33 
ml). There is protein eluting around 26 ml which was where the correctly refolded 
IFN-a2b eluted from the guanidine-HCI material. This suggests that the material 
which elutes above 30 ml is mis-folded IFN-a2b and due to it being refolded from 
urea there is more mis-folded. The IFN-a2b was purified in the same ways as the 
guanidine-HCI refolded and purified IFN-a2b. 
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Figure 5.27: Fluorescence analysis of the ion exchange carried out on the urea 
refolded material. The fractions collected have a red shifted barycentric mean 
compared to the IFN-a2b standard whereas the flowthrough has a barycentric mean 
more blue shifted than the IFN-a2b standard. 
Sample Barycentric Mean (nm) 
Fractions 20-26 ml 346 
Fractions 30-37 ml 345 
Flowthrough 338 
IFN-a2b standard 341 
Table 5.15: Barycentric mean of the urea solubilised inclusion bodies post 
refolding and purification by ion exchange. 
The results from the ion exchange from urea solubilised material shows IFN-a2b 
which does not match the IFN-a2b standard. The fractions collected during the 
NaCl elution have barycentric means more red shifted than the standard (table 
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5.15) whereas the flowthrough appears to be blue shifted, see figure 5.27). This 
suggests the presence of both contamination and mis-folded IFN-a2b. The 
positive result is that the contamination does appear to be separated form the 
IFN-a2b in the flowthrough and even the partially and/or mis-folded species 
appear to elute later. 
Conclusions from the ion exchange 
The ion exchange of both the guanidine-HCI and urea solubilised and refolded 
material show a need for a purification step once the refold has ended. They 
both show some degree of contamination which luckily does not bind to the 
column and is lost in the flowthrough. Both purifications also show the separation 
of folded and mis-folded IFN-a2b. The guanidine-HCI purification shows that the 
first peak gives a fluorescence spectrum similar to that of the IFN-a2b standard 
and an equivalent far UV CD signal. The urea has the same two peaks but the 
second peak, the one deemed the mis-folded protein from the guanidine-HCI run, 
is larger indicating more mis-folded species. The first elution peak from the urea 
run does not give a barycentric mean of the same wavelength to the IFN-a2b 
standard and is red shifted compared to its original value without ion exchange. 
However the mis-folded peak gives a very blue shifted barycentric mean which 
could have influenced the initial measurement before ion exchange and so the 
value of 346 nm is a more true value for the urea folded IFN-a2b. In order to 
improve on the separation (especially the urea) from the ion exchange instead of 
changing the pH of the running buffers the gradient could be optimised. Due to 
time restrictions this was not carried out. 
5.5: Investigation of the denatured state of IFN-a2b in solubilised inclusion 
bodies 
Due to large differences seen in the refolding of the urea and guanidine-HCI 
solubilised inclusion bodies, their analysis was further investigated. The 
guanidine-HCI solubilised inclusion bodies which were dialysed into urea were 
also investigated as they resulted in much better results than the urea solubilised 
inclusion bodies. The techniques used to analyse the inclusion bodies are ones 
which are widely available instead of the specialised methods such as NMR and 
182 
small angle X-ray scattering which are currently the most commonly used 
techniques to investigate the presence of structure in denatured proteins. 
Far and near UV CD analysis of the solubilised and purified inclusion 
bodies 
The far and near UV CD of the solubilised and purified inclusion bodies was 
investigated. The high concentrations of guanidine-HCI and urea may affect the 
far UV analysis but was investigated nonetheless. 
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Figure 5.28: Far UV analysis of the inclusion bodies after solubilisation and 
purification by gel filtration. The dialysed samples were initially solubilised in 6M 
guanidine-HCI and then dialysed into 8M urea with or without DTT. Both the dialysed 
samples (turquoise and pink lines) and the urea solubilised samples (green and blue 
lines) show some secondary structure which appears very different to the unfolded 
guanidine-HCI solubilised samples. Data ends before 200 nm due to 600 volts being 
exceeded due to the absorptive properties of guanidine-HCI and urea. 
The far UV of the solubilised and purified inclusion bodies can be seen in figure 
5.28. The far UV shows that there is a difference in the secondary structure of 
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the IFN-a2b under differing denaturant conditions. The most secondary structure 
appears to be in the samples solubilised in guanidine-HCI and then dialysed into 
urea. The solubilised urea samples also show some secondary structure, 
however the guanidine-HCI solubilised samples do not show any secondary 
structure. 
Near UV CD of the solubilised and purified inclusion bodies 
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Figure 5.29: Near UV analysis of the inclusion bodies after solubilisation and 
purification by gel filtration. The dialysed samples were initially solubilised in 6M 
guanidine-HCI and then dialysed into 8M urea with or without DTT. Both urea 
solubilised samples show some structure which appears very different to the unfolded 
guanidine-HCI solubilised samples and the dialysed samples. 
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Protein concentrations for CD analysis 
Sample A280 Concentration (mg/ml) 
Urea 0.32 
Urea DTT 0.3 
Guanidine-HCI 2.4 
Guanidine-HCI DTT 3.8 
Guanidine-HCI dialysed into urea 2.2 
Guanidine-HCI DTT dialysed into urea DTT 2 
Table 5.16: Total protein concentrations of the samples used for far UV CD 
analysis. 
The near UV CD shown in figure 5.29 does not indicate any native-like tertiary 
structure in any of the six samples. The two urea solubilised samples do give a 
large positive signal between 260-290 nm however this is not characteristic of the 
native IFN-a2b near UV spectrum or the unfolded spectrum seen in figure 3.2. 
The protein concentrations at which the CD analysis was carried out are shown in 
table 5.16. 
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Intrinsic fluorescence analysis 
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Figure 5.30: Intrinsic fluorescence results of the solubilised inclusion bodies. The 
results show the difference the denaturant used for solubilisation causes to the 
fluorescence emission. The most denatured signal comes from the sample solubilised in 
guanidine-HCI with 1 mM DTT (red line). The sample solubilised in guanidine-HCI and 
then dialysed into urea (turquoise line) shows the most structure; being the most blue 
shifted of the samples. 
Protein concentrations for fluorescence analysis 
Sample A280 Concentration (mg/ml) 
Urea 0.1 
Urea DTT 0.11 
Guanidine-HCI 0.11 
Guanidine-HCI DTT 0.11 
Guanidine-HCI dialysed into urea 0.093 
Guanidine-HCI DTT dialysed into urea DTT 0.093 
Table 5.17: Concentrations of the solubilised inclusion bodies used for 
fluorescence analysis. 
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Barycentric mean analysis of the intrinsic fluorescence 
Sample 
Barycentric Mean 
(nm) 306-380 nm 
Urea 348 
Urea DTT 348 
Guanidine-HCI 349 
Guanidine-HCI DTT 349 
Guanidine-HCI dialysed into urea 346 
Guanidine-HCI DTT dialysed into urea DTT 347 
Table 5.18: Barycentric means of the solubilised inclusion bodies from intrinsic 
fluorescence analysis. The barycentric means confirms the guanidine-HCI solubilised 
samples dialysed into urea as showing the most structure. 
The fluorescence results in figure 5.30 of the solubilised inclusion bodies all show 
tryptophan emission. The values for the barycentric means (table 5.18) are all 
similar to each to other ranging from 346-349 nm. The most blue shifted are the 
guanidine-HCI solubilised inclusion bodies dialysed into urea and the most red 
shifted are the guanidine-HCI solubilised samples. The concentrations at which 
the fluorescence analysis was carried out can be seen in table 5.17. 
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Results of the ANS binding to the solubilised inclusion bodies 
The ANS was added to the above samples at a final concentration of 0.1 mM. 
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Figure 5.31: ANS fluorescence results of the solubilised inclusion bodies under 
six different conditions. The results show the difference the denaturant used for 
solubilisation causes to the fluorescence emission when bound to ANS. The sample 
with the smallest effect on ANS binding is the samples solubilised in guanidine-HCI, I 
mM DTT. The samples which give the most ANS binding are the two samples that were 
solubilised initially in guanidine-HCI with or with out DTT and then dialysed into urea with 
or without DTT (turquoise and pink lines), indicating the presence of a molten globule 
type structure. 
The ANS results in figure 5.31 indicated the presence of some structure in the 
inclusion body samples solubilised in guanidine-HCI and then dialysed into urea. 
Both the urea and guanidine-HCI solubilised inclusion bodies show similar 
binding and therefore structure even though there are great differences in their 
success at refolding. ANS binding results is similar shifts in wavelength (same as 
tryptophan) in that a blue shift indicates a more hydrophobic environment (Wang 
and Geng, 2006b). 
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N-(1-pyrene)maleimide labelling of IFN-a2b's four cysteines. 
N-(1-pyrene)maleimide is a fluorescent probe exhibiting monomer emission 
peaks at 375 nm and 395 nm when excited at -345 nm, see figure 5.32. When 
the pyrene molecules are brought into close proximity, and are excited, they form 
excited state dimers (excimers) that emit at longer wavelengths usually around 
470 nm (Betcher-Lange and Lehrer, 1978). 
r) 
I 
r"y 
4 benzene ring Pyrene molecule 
Figure 5.32: Chemical structure of N-(1-pyrene)maleimide. The four benzene rings 
are the pyrene moiety. Drawn using Chemwindow® 6. 
Binding of the N-(1-pyrene)maleimide may give more indication of any structure 
present in the solubilised inclusion bodies. The N-(1-pyrene)maleimide binds to 
the cysteine residues elucidating if the structure is compact enough to bring 
together the cysteine residues therefore forming excimers. 
The IFN-a2b samples were reduced using 10 mM TCEP. The N-(1- 
pyrene)maleimide was added to a 10 fold molar excess and the samples left for 
16 h with agitation at room temperature. The excess N-(1-pyrene)maleimide was 
removed by PD-10 purification using buffers still containing TCEP (Sahoo et al., 
2002, Drury and Narayanaswami, 2005). The resulting samples were analysed 
for their absorbance and fluorescence spectra. 
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Figure 5.33: Absorbance spectrum of the N-(1-pyrene)maleimide stock solution 
and the labelled solubilised inclusion bodies. The amount of labelling was 
calculated from these absorbance spectra. 
The absorbance spectra shown in figure 5.33 was used to calculate the extent of 
the N-(1-pyrene)maleimide labelling. This was calculated by using the ratio of the 
peaks at 278 nm and 344 nm of the stock solution and the extinction coefficient of 
N-(1-pyrene)maleimide at 344 nm of 40 000 M-1 cm-' (Drury and Narayanaswami, 
2005). 
190 
Fluorescence analysis of the N-(1-pyrene)maleimide binding 
The labelled samples were analysed by fluorescence to investigate the possibility 
of excimer fluorescence from the N-(1-pyrene)maleimide. The samples were 
excited at 338 nm and normalised due to concentration differences at 375 nm. 
Pyrene Maleimide stock solution 
Folded IFN-a2b standard 
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Figure 5.34: Fluorescence emission of the N-(1-pyrene)maleimide labelling of the 
solubilised inclusion bodies. The samples were excited at 338 nm. The IFN-a2b 
standard shows excimer fluorescence at 490 nm. The samples solubilised in guanidine- 
HCI show signs of some excimer emission but it is not as prominent as the IFN-a2b 
standard. 
There is a slight increase in the emission by the guanidine-HCI solubilised 
inclusion bodies along with the guanidine-HCI solubilised inclusion bodies 
dialysed into urea indicating that there may be some structure present, but is not 
sufficient enough to bring the cysteines together causing excimer emission as 
large as the IFN-a2b standard, see figure 5.34. Thus the partially folded or 
molten globule states observed are not native like. 
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SDS-PAGE analysis of the N-(1-pyrene)maleimide labelled samples 
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Figure 5.35: SDS-PAGE analysis of the labelled inclusion bodies with N-(1- 
pyrene)maleimide. Figure A: The fluorescently labelled IFN-a2b proteins can be 
seen in lanes 3,5,7 and 9. The molecular weights at 25 and 35 kDa fluoresce also. 
Figure B: The safe stained SDS-PAGE highlighting the IFN-a2b bands but also shows 
some dimerisation in all four samples. IFN-a2b standard loaded to 3 Ng. 
The SDS-PAGE shown in figure 5.35 confirms that all the samples were labelled 
with the N-(1-pyrene)maleimide. 
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Figure 5.36: N-(1-pyrene)maleimide fluorescence analysis of the labelled IFN-a2b 
standard subjected to 6M guanidine-HCI. The excimer peak seen from the IFN-a2b 
standard around 490 nm appears to shift to the shorter wavelengths. 
Figure 5.36 shows the disruption of the IFN-a2b molecule on addition of 
guanidine-HCI. This disruption can be seen by the change in pyrene emission 
indicating the cysteine residues are no longer in proximity to one another. 
Second derivative analysis of the IFN-a2b solubilised inclusion bodies 
Second derivative analysis was introduced to calculate the exposure of the 
tyrosine residues in the solubilised inclusion bodies. For this, the absorbance 
spectra of the solubilised inclusion bodies can be used. This technique has the 
ability to take the overlapping regions of the aromatic residues which bring about 
the absorbance spectra and separate them into their individual contributions 
(Ragone et al., 1984). 
For the calculation the absorbance spectrum of each sample was measured at 
similar concentrations, figure 5.37. 
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Figure 5.37: Absorbance spectra of the solubilised inclusion bodies used for 
second derivative analysis. All the samples have the same shape however the 
solubilised inclusion bodies (black, red and green lines) are shifted the shorter 
wavelengths in comparison to the folded standard (blue line). 
The absorbance spectra were converted to their second order derivatives using 
OriginTM 7 software, the results can be seen in figure 5.38. 
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Figure 5.38: Second derivative spectra of the solubilised inclusion bodies. All 
samples give peaks between 287 - 283 nm and 295 - 290.5 nm 
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The calculation of the percentage of accessible tyrosine residues (a) was 
calculated as described by Ragone et al. (1984) using the following equation 5.1. 
r,, - ra 
a= (5.1) 
rn - ra 
Where r= the ratio between the peak to peak distance of 287 - 283 nm 
and 295 - 290.5 nm. 
rn = ratio for the native IFN-a2b standard 
r,, = ratio for the sample being investigated 
ra = ratio calculated from the Tyr/Trp ratio using the coefficient 
relative to ethylene glycol given by Ragone et al. (1984). 
ra for IFN-a2b was calculated to be 0.21. 
Sample A (%) 
IFN-a2b 39 
Urea solubilised inclusion bodies 100 
Guanidine-HCI solubilised inclusion bodies 
dialysed into urea 
100 
Table 5.19: Values for the exposure (a) of the tyrosine residues in the solubilised 
inclusion bodies. Both urea and guanidine samples show complete exposure of their 
tyrosine residues. 
The exposure (a) of the IFN-a2b standard was calculated to be 39 %, see table 
5.19. The exposure of the urea and guanidine-HCI solubilised inclusion bodies 
solubilised in urea were over 100 %. These are based on the assumption that 
the tyrosine residues are completely exposed in the guanidine-HCI denatured 
sample. There appears to be a large difference between the samples and the 
IFN-a2b standard, highlighted in both figure 5.37 and 5.38. The IFN-a2b 
standard shown in figure 5.38 appears to be shifted to the longer wavelengths 
compared to the samples, which can also be seen in figure 5.33 of the N-(1- 
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pyrene)maleimide experiment, possibly indicating an environmental factor. The 
consequence of this is that the IFN-a2b is shifted in figure 5.38. This may affect 
the calculation of exposure as the ratios are based on the peaks which from 
figure 5.38 are not all in the identical position. 
Conclusion from the analysis of the solubilised inclusion bodies 
The CD results showed some secondary structure present in the inclusion bodies 
solubilised in guanidine-HCI followed by dialysis into urea; this was confirmed by 
the intrinsic fluorescence and the ANS binding. These two samples (with and 
without DTT) showed fluorescence emission of a shorter wavelength than the 
other four samples solubilised in guanidine-HCI and urea only. This apparent 
structure may be due to some refolding of the IFN-a2b taking place when 
transferred into the urea by dialysis. Dialysis is a slow process so the partial 
refolding of the IFN-a2b may have taken place. The urea solubilised inclusion 
bodies do not appear to show any structure which was unexpected due to the 
large differences in the success of the refolding compared to the guanidine-HCI 
solubilised inclusion bodies. A possible explanation is that the urea solubilised 
inclusion bodies are locked in a specific unfolded structure which results in a 
pathway for unsuccessful refolding. The samples solubilised in guanidine-HCI 
and then dialysed into urea give better refolding results than the urea but not as 
successful as the inclusion bodies solely solubilised inclusion bodies in 
guanidine-HCI. The inclusion bodies solubilised in guanidine-HCI are assumed to 
be completely unfolded and are therefore able to refold successfully, the inclusion 
bodies then dialysed into urea may have started to refold during the dialysis and 
are also able to refold better than the urea solubilised inclusion bodies. 
The N-(1-pyrene)maleimide results do not confirm any native like structure in any 
of the solubilised inclusion body samples. The samples do not appear to have 
the cysteines in close enough proximity to allow excimer emission, the pyrene 
molecules must be within 10 A of each other (Sahoo et al., 2002). N-(1- 
pyrene)maleimide labelling has been used to investigate the inter- and 
intramolecular interactions of apolipoprotein E (apoE4), a lipopoprotein (Drury 
and Naravanaswami. 2005). The protein was investiaated as lipid free and lipid 
bound. by labellina of mutated residues for cvsteines within specific domains of 
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the protein. Other proteins investigated include Apolipophorin III (Sahoo et al., 
2002) and apomyoglobin (Wang and Geng, 2006b). N (1-pyrene)maleimide is 
also used to investigate synthetic polymers due to the excimers long lifetime 
under non-polar conditions (Gelir et al., 2006), under these highly hydrophobic 
conditions the ratio of pyrenes emission peaks at 383 and 373 nm increase with 
increasing hydrophobicity (Gelir et al., 2006; Wang and Geng, 2006b). 
The ANS binding showed emission from the guanidine-HCI dialysed into urea 
samples that may have molten globule-like structure due to the emission being 
blue shifted compared to the two samples solubilised in guanidine-HCI and urea. 
Molten globule structures are said to still contain a hydrophobic core but just not 
as closely packed as the native protein (Ptitsyn, 1992). The lack of definite 
secondary structure may indicate further that the partial structure formed is again 
not native. 
Second derivative analysis has been used previously to characterise the partially 
unfolded states of ß-lactoglobulin and interferon alpha-2a (Kumar et a!., 2005). 
Instead of absorbance however the tryptophan fluorescence was investigated 
highlighting changes in the tertiary structure of folding intermediates. From these 
results the tryptophan residues in the urea solubilised inclusion bodies were 
calculated to be exposed however, this is based on the assumption that the 
tryptophan residues present in the guanidine-HCI solubilised inclusion bodies are 
also completely exposed to the solvent. The results here are inconclusive due to 
the shifting of the wavelength peaks however previous use of second derivative 
spectroscopy provides an efficient method of measuring small differences within 
samples without the need for high concentrations. IFN-a2b has been 
investigated for the presence of structure as inclusion bodies (Ami et a!., 2006). 
To do this FTIR was used on IFN-a2b expressed using two different levels of 
expression, high and low. The high producer resulted in more aggregation 
however both producers showed signs of some native-like secondary structure 
around 1653 cm-1 however both were shifted to a higher wavenumber compared 
to the native. The suggestion for this is the possibility of shorter alpha helical 
segments and/or more flexibility (Ami et a!., 2006). 
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The analysis carried out on the solubilised inclusion bodies highlighted 
differences between the inclusion bodies solubilised in different denaturants. The 
implication of structure in these chemically denatured states may explain the 
differences observed in the refolding. Dill and Shortie, (1991) state that the 
characterisation of the denatured state is fundamentally important for 
understanding the proteins stability and folding. The denatured state has been 
investigated by various techniques; CD (Goto et al., 1990), DSC (Privalov, 1990), 
NMR (Jonas et al., 1998), small angle x-ray scattering (SAXS) (Konno et al., 
1995; Kataoka et al., 1997) and FTIR (From and Bowler, 1998). Ding et al., 
(2005) devised a computational method to investigate thermally denatured 
proteins by molecular dynamics simulations. These experiments however tend to 
be investigating proteins which are not chemically denatured but in pH extremes 
or heat/cold treated, the chemical denaturants such as guanidine-HCI and urea 
are usually used as the control for the most unfolded state. The limitation of such 
techniques is the interference of the denaturants with the analysis due to their 
own absorptive properties. In order to obtain data for the unfolded sates of 
proteins from CD the increase in use of synchrotron radiation CD measurements 
has been introduced allowing data collection at wavelengths of 140 nm being 
achieved (Matsuo et al., 2007) however still carried out on non-chemically treated 
proteins. 
The random coil was defined by Creighton (1993) as being the conformation of 
each part of the polypeptide chain which is assumed to be independent of the 
conformation of the remainder of the polypeptide and by Shortle in 1996 as being 
a well defined reference state in which no side chain interactions occur. The 
exploitation of the torsion angles of the peptide backbone has lead to calculation 
of all the possible conformations of the peptide, see figure 5.39. 
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Figure 5.39: Schematic diagram of a polypeptide chain illustrating the torsion 
angles 0 and W. These angles determine the main chain conformations, taken from 
Smith et al., 1996a. 
In a folded protein the torsion angles have a single conformation and in an 
unfolded protein they have a distribution for each amino acid residue allowing 
many conformations (Smith et al., 1996a). The assumption is that the 0 and W of 
a random coil are independent of the other residues resulting in no non-local 
interactions. The values for the 4) and W torsion angles for each residue has 
been calculated based on synthetic peptides (Smith et al., 1996a) and are used 
for the calculation of the torsion angles in specific polypeptides when analysed by 
methods such as NMR (Smith et al., 1996b) and SAXS (Lattman, 1994). For 
these types of experiments the need for the two reference states is essential, the 
native state is required along with the unfolded. These calculations provide a 
model for the assumed random coil for the specific polypeptide to which the 
experimental data can be compared. NMR is used to elucidate local 
characteristics and SAXS is used for more global properties. 
Residual structure has however been observed by Bu et al., (2001) using 
quasielastic neutron scattering (QENS) of a-lactalbumin in 9M urea. NMR has 
been used to elucidate structure of the 434-repressor in 7M urea (Neri et al., 
1992) and in 6M guanidine-HCI GED, the assembly domain of dynamin has 
largely beta-structure measured by multidimensional NMR (Chugh et al., 2007). 
The occurrence of native like hydrophobic character of staphylococcal nuclease 
in 8M urea has been detailed by Shortle and Ackerman, 2001 again using NMR. 
The resulting structure seen in these cases is not fully stable conformations but 
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residual structure of a dynamic nature. The techniques used however are 
specialised and not easily interpreted, the aim here was to use the techniques 
widely available which do not require high protein concentrations and long 
periods of time to run and analyse to gain some insight into whether structure is 
present in the assumed unfolded solubilised inclusion bodies. In this case there 
may indeed be some small amount of structure present but not necessarily 
native. 
The second aspect influencing this unfolding is also the interaction of the 
denaturant with the peptide. The large difference observed during the refolding 
may be structure related and caused by the denaturant itself. Figure 1.5 shows 
the chemical structure of both urea and guanidine; they are very similar and yet 
result in very different refolding and unfolding yields of IFN-a2b. The interaction 
and efficiency of guanidine-HCI is usually focused on the salt effect caused by 
the HCI group. Urea however poses a different debate. One opinion is that urea 
interacts favourably with the nonpolar side chains (Nozaki and Tanford, 1963) 
and the second is that urea interacts with the peptide backbone (Auton et al., 
2007; O'Brien et al., 2007). Both could also play a part. 
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Chapter 6 
Chapter 6 
Conclusions and Future Work 
6.2: Conclusions 
The unfolding of IFN-a2b carried out in chapter 3 gave an interesting insight 
into the behaviour of IFN-a2b in solution. The far and near UV CD was 
consistent with structural data (Radhakrishnan et at, 1996) but also with the 
similar study carried out by Beldarrain et at, (2001) who quote maximum 
stability of IFN-a2b between 0.3-0.5 M phosphate pH 7.0 giving a Tm of 65 °C 
whereas here the Tr, was found to be 70 °C at 0.2 M phosphate pH 7.0. On 
reduction of IFN-a2b's two disulphide bonds the protein remained intact, less 
stable, but still alpha helical, see figure 3.5. A change in pH from pH 7.0 to 9 
and 5 shown in figure 3.23 also resulted in very little change in secondary 
structure. All these results confirmed the stability of IFN-a2b's structure as a 
whole. It was however the denaturation of IFN-a2b which lead to unexpected 
results. The denaturation was carried out with increasing concentrations of 
guanidine-HCI and urea giving the first insight into the differing behaviour of 
IFN-a2b during unfolding. The denaturant curves in section 3.2.4 from 
guanidine-HCI unfolding resulted in cooperative unfolding and the addition of 
DTT having a destabilising effect on the IFN-a2b molecule. It was the results 
from the urea denaturation which led to unsuccessful non-cooperative 
unfolding of IFN-a2b. The data gained from urea unfolding could not 
therefore be used for any stability determination IFN-a2b. 
Once the expression of the IFN-a2b had been initiated and was working 
efficiently, the solubilisation of the inclusion bodies with both urea and 
guanidine-HCI was investigated. This was a consequence of the observed 
differences in unfolding of the IFN-a2b standard, by these two denaturants. 
As with the unfolding experiments urea was found to be the poorest 
denaturant, this was shown by the SDS-PAGE analysis in figure 4.9. The 
resulting solubilised inclusion bodies in guanidine-HCI were however dialysed 
into urea for anionic ion exchange purification. This purification detailed in 
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table 4.1 was unsuccessful and the high concentrations of urea, keeping the 
IFN-a2b soluble was to blame. The consequent refolding from these 
solubilisation studies were carried through a refold protocol which resulted in 
little success due to the interference of Triton X-100 used during the washing 
of the inclusion bodies. A different method of purification was introduced in 
section 4.24; gel filtration. This enabled the guanidine-HCI solubilised 
inclusion bodies to be purified without coming into contact with urea. The 
refolding from this step was successful and resulted in folded IFN-a2b with a 
functional activity similar to NIBSC provided WHO international biological 
reference standard of IFN-a2b (95/566), see section 5.3. The refolding, 
however successful was only true of the guanidine-HCI solubilised inclusion 
bodies, the urea solubilised inclusion bodies resulted in activities which were 
lower than the guanidine-HCI solubilised and both Cobra Biomanufacturing 
provided standard and the NIBSC reference material. 
The differences between the refolding success of the guanidine-HCI and urea 
solubilised samples led to the investigation of the IFN-a2b solubilised 
inclusion bodies in both urea and guanidine-HCI, section 5.5. The techniques 
used were widely available and did not require the high protein concentrations 
need for techniques such as NMR. The results implicated structure in the 
urea solubilised samples but not necessarily native. The inclusion bodies 
which were solubilised in guanidine-HCI and then dialysed into urea showed 
the most structure out of all the variants, giving both high intensity and blue 
shifted fluorescence emissions (5.30) but also signal in the far UV region 
(figure 5.29). 
The overall aim of this project was to devise a successful and robust refolding 
method of IFN-a2b. The refolding of IFN-a2b was successful when the 
inclusion bodies had been solubilised in guanidine-HCI not urea. The 
solubilisation of IFN-a2b inclusion bodies with urea is common (Srivastava et 
al., 2005), this solubilisation is usually followed by ion exchange purification 
which requires urea rather than guanidine-HCI. However in chapter 4, section 
4.2.4 it was found that ion exchange was not successful with urea and so gel 
filtration became the preferred method of purification. The refold itself was 
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kept simple using a dilution step followed by two dialysis stages; the first 
removing the denaturant and the second removing the reducing agent. 
Valente et a!., (2006) also refolded IFN-a2b using a simple two step dialysis, 
this however was carried out over 9 days. The refold here was carried out 
over 2 days. In conclusion the refolding method devised was successful and 
the information gained during the structural analysis of both the folded IFN- 
a2b (chapter 3, section 3.2.1) and the solubilised inclusion bodies (chapter 5, 
section 5.5) enabled conclusions to be drawn as to why the refolding had not 
been successful from urea solubilised inclusion bodies 
6.2: Future Work 
The unfolding analysis carried out on the IFN-a2b standard was sufficient 
enough to provide guidelines for a refolding protocol to be formed. The 
refolding carried out supported the idea of primarily refolding the majority of 
both the secondary and tertiary structure under reducing conditions and 
forming the disulphides during the late stages. For Biomanufacturing the 
issues of scale up are of great importance and have hopefully been 
addressed here. The dialysis stages can be replaced with diafiltration 
coupled with a concentration step. This would reduce both incubation times 
and volumes however the temperature of 4 °C for this to be carried out may 
be problematic. The 1 in 10 dilution may also be difficult to overcome but 
could possibly be achieved by a diafiltration step using a buffer containing low 
concentrations of denaturant. 
The use of guanidine-HCI is not favoured widely by biomanufacturing due to 
the use of stainless steel tanks during manufacturing, these being susceptible 
to corrosion by the chloride ions. The washing of the inclusion bodies should 
therefore be investigated. There is potentially a case for urea to be used 
during the washing stages due to it having a negative effect on the 
solubilisation of the IFN-a2b. Pressure could also be investigated as it does 
not always require urea or guanidine-HCI. 
Following the successful refold a polishing step by ion exchange was briefly 
investigated, firstly to confirm whether the high levels of urea had interfered 
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with the previous runs but also to further purify the IFN-a2b. This appeared to 
be successful at pH 8.0 resulting in impurities being lost in the flowthrough 
and either impurities or mis-folded IFN-a2b eluting later than the correctly 
folded. This step could be further investigated by increasing the length of the 
gradient or even incorporating a step elution. With more material the results 
could be analysed by SDS-PAGE confirming the nature of the impurities but 
also the purification of the correctly folded IFN-a2b. 
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Appendices 
Appendix 1. Reagents 
Reagent 
Acetic acid 
Acrylamide 
Agar bacteriological 
Amberlite® MB-1 
Manufacturer Lot / Batch 
Number 
Product/Catalogue 
Number 
BDH 
National diagnostics 
Oxoid 
Sigma 
Ammonium persulphate Sigma 
8-Anilino-1- 
naphthalenesulphonate (ANS) Sigma 
Lot: K36922116 702 
Lot: 09-04-17 
Lot: 62810502.2 
Lot: 37H0572 
Lot: 88H2629 
27013BV 
EC-852 
X587B 
A5710 
A-3678 
A-5144 
Bicinochoninic Acid Sigma Lot: 34K9800 BCA-1 
Protein Assay (BCA) 
Bromophenol blue BDH Lot: L825539 320 200173J 
CHAPS Melford Batch no. 18380 B2006 
Citric acid BDH Lot: F1275138 406 277814N 
Copper Sulphate BDH Lot: 995038OF 10091 
Coomassie brilliant blue Fisher scientific Batch: 4880 BPE100-25 
Disodium hydrogen BDH Lot: K91248180 433 301586N 
orthophosphate 
(Na2HPO4.2H20) 
DNase I Roche Lot 13498000 10 104 159 001 
DTT Melford Batch no. 17708 MB1015 
EDTA BDH Lot: K26458264 100935 
Guanidine-HCI Melford Batch no. 17812 MB2002 
Guanidine thyocyanate Melford Batch no. 16603 MB1010 
Glycine Melford Batch no. 17651 G0709 
lodoacetamide Sigma Lot: 21 F-5045 1-6125 
Isopropanol BDH Lot: 1508556 15252 
Kanamycin Sigma Lot: 95H0734 K-4000 
Molecular weight marker BioRad Lot: 310001729 161-0374 
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Phenanthroline Sigma Lot: 61 K1565 P-9375 
Pyrene Maleimide Sigma Lot: 056K2614 P7908 
RNase A Roche Lot: 93271221 10 109 134 001 
Sigma antifoam 289 Sigma Lot: 28H8641 A-8436 
SDS Melford Batch no. 18332 B2008 
Sodium Borate Sigma Lot: 93H0576 S-9640 
Sodium Chloride BDH Lot: K33210432 420 3012375 
Sodium dihydrogen BDH Lot: K91551420 142 301324Q 
orthophosphate 
(NaH2PO4. H2O) 
SuperdexTM 75 gel filtration GE Health care Lot 288694 17 1044 01 
media 
TCEP Sigma Lot: 046K1287 C4706-2G 
TEMED Sigma Lot: 062K1054 T-8138 
Tris-Base Melford Batch no. 18198 B2005-06-13 
Triton X-100 BDH Lot: 9402580D 30632 
Tryptone Duchefa Biochemie Lot: 001744.02 T1332.0500 
Urea Sigma Lot: 052KO0441 U-S128 
Yeast extract Duchefa Biochemie Lot 000946.04 Y1333 
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Appendix 2. Equipment 
Dialysis tubing MWCO 3500 Da 
BCA Assay Kit 
Fluorimeter 
CD spectropolarimeter 
Fermenter 
Spectrophotometer 
Spectrum laboratories 
Sigma Lot: 34K980 
Cary eclipse fluorometer (Varian, Victoria, 
Australia). 
JASCO J-810, JASCO Corp. 
Bioflo 3000 Barch/continuous Bioreactor. 
(New Brunswick scientific Edison, N. J., USA). 
Cary 4E UV-Visible absorbance 
spectrophotometer (Varian, Victoria, Australia) 
230 
